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Poliomyelitis is a highly infectious disease caused by the poliovirus, a human enterovirus 
belonging to the Picornaviridae family. The poliovirus is a small (30 nm) non-enveloped, 
positive strand RNA virion with a protein shell called a capsid. There are three serotypes of 
wild poliovirus (type 1, type 2 and type 3), each with a slightly different capsid protein. The 
virus is most often spread by fecal-oral route; it enters through the mouth and multiplies in the 
intestine. Most polio infections are asymptomatic or lead to mild symptoms causing minor 
illness. In less than 1% of the cases, the poliovirus can invade the central nervous system, 
which may cause irreversible paralysis and even death in case breathing muscles become 
affected. Polio-infected individuals shed poliovirus into the environment for several weeks, 
where it can spread rapidly through the population, especially in lower developed areas with 
poor sanitation. Polio can strike at any age, but mainly affects young children. Since there is 
no cure for poliomyelitis, the only way to combat polio is by prevention through vaccination. 
Polio vaccines
The first vaccine against polio was developed in the 1950s by Jonas Salk. This inactivated 
polio vaccine (IPV) consists of formalin-inactivated (killed) poliovirus strains of all three 
serotypes (type 1, Mahoney or Brunhilde; type 2, MEF-1; and type 3, Saukett strains). The 
vaccine is given via intramuscular or intradermal injection and confers protection against 
disease via the induction of serotype-specific antibodies in the blood. In the 1960s, Albert 
Sabin developed the oral poliovirus vaccine (OPV), a trivalent vaccine based on attenuated 
poliovirus (Sabin) strains. Major advantage of this orally administered vaccine is the induction 
of antibodies both in the blood and, like in natural infection, locally in the gut. Since the live-
attenuated OPV is able to replicate in the intestine, it is able to elicit effective immunity at 
the primary site of poliovirus entry. Moreover, in areas of poor hygiene and sanitation, OPV 
vaccination can result in unintentional transfer of the vaccine to people who have not been 
vaccinated. Therefore, the use of OPV can rapidly stop person-to-person transmission and 
interrupt further spreading of the (wildtype) poliovirus through the whole community.
Both vaccines, OPV and IPV, are considered as safe, but in extremely rare cases the live-
attenuated vaccine-virus in OPV might cause paralysis, the so-called vaccine-associated 
paralytic polio (VAPP). Moreover, also very rarely, when there is insufficient coverage in the 
community, the vaccine-virus may be able to circulate and might revert in a form with similar 
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transmissibility and neurovirulence as wild polioviruses. These circulating vaccine-derived 
polioviruses (cVDPVs) can cause new polio outbreaks. A major advantage of OPV is its 
affordability for low- and middle-income countries. Since IPV is not a live vaccine, it has no 
risk of VAPP, but IPV is more than five times more expensive than OPV. Thereby, conventional 
intramuscular vaccine administration using needle and syringes requires trained health 
workers, as well as sterile injection equipment and procedures to avoid re-use of needles or 
needle-stick injuries. Advantages and disadvantages of both OPV and IPV are listed in table 
1.
Polio eradication
Since the introduction of the Global Polio Eradication Initiative (GPEI) in 1988, the 
incidence of polio has decreased by more than 99.9%. In the late 1980s, polio paralyzed 
more than 1000 children every day, whereas only 22 cases of wildtype and 91 cases of 
vaccine-derived polioviruses were reported last year (2017) (Figure 1). However, polio 
remains endemic in three countries that have never stopped polio transmission: Afghanistan, 
Nigeria and Pakistan. 
Of the three wildtype polioviruses, two of them are eradicated. The last case of type 
2 was reported in 1999 and the most recent case of wildtype poliovirus type 3 dates to 
November 2012. However, stopping the last polio cases to reach global polio eradication 
proved to be challenging due to conflicts, political instability, hard-to-reach populations, 
and poor infrastructure. Therefore, in 2013 the GPEI launched a comprehensive strategic 
polio endgame plan that describes several steps to reach and maintain a polio-free world. 
The first objective of the plan is to discontinue the transmission of all wildtype poliovirus, 
but also to rapidly stop new outbreaks due to circulating VDPVs. This should be reached 
Table 1 Pros and cons of both polio vaccines: the live-attenuated oral polio vaccine (OPV) versus 




Mucosal immunity (intestinal sIgA)
Safe (no risk of VAPP1)
Relatively stable
High efficacy (1-2 dose)
Cons Risk of VAPP1




Trained health personnel needed to administer
1 VAPP – vaccine-associated paralytic polio
2 VDPV – vaccine-derived polioviruses
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by enhancing global polio surveillance, improving the quality of OPV campaigns in the 
remaining endemic countries and ensuring rapid outbreak response. The second objective 
includes strengthening of immunization programs and the phased withdrawal of OPV in order 
to hasten the interruption of all poliovirus transmission. As wildtype poliovirus type 2 was 
eradicated since 1999 and main cause of VDPV outbreaks is currently the type 2 component 
of OPV (91 VDPV type 2 cases reported), every country using trivalent OPV switched to 
bivalent OPV to reduce the risks of new circulating VDPVs. Thereby, the introduction of at 
least one dose of trivalent IPV into all routine immunization programs is part of the plan to 
strengthen immunization systems, especially in areas of highest risk. All these efforts resulted 
in the current situation with fewer cases reported from fewer areas in fewer countries than 
ever before (Figure 1). 
Another aim of the Polio Eradication & Endgame Strategic Plan encompasses the 
certification of all regions to be polio-free and the guarantee that all poliovirus stocks are safely 
contained. Strict requirements for safe handling and biocontainment of polioviruses, retained 
Figure 1 Geographical distribution of polio cases reported in 2017. Both wildtype polioviruses (WPV, 




at only a small number of facilities, are essential to minimize the risk of reintroduction of the 
poliovirus in the post-eradication era. Currently, the GPEI is developing a post-certification 
strategy to ensure maintenance of a polio-free world after complete eradication. Polio legacy 
planning, as fourth objective of the endgame plan, and its subsequent implementation into 
public health programs should ensure that the world learns from all investments made in 
polio eradication for future health care. 
While the program had many successes, eradication goals were not reached yet due to 
both external (e.g., growing conflict areas) and internal factors (e.g., suboptimal management, 
inappropriate surveillance, tight IPV supply). As the virus’ prevalence is declined to very 
limited parts of the world, the eradication of polio depends on the success of health workers 
to identify and vaccinate every high-risk child, even living in dense urban environment, in 
extremely remote and hard-to-reach area, or being on the move.
Towards and beyond polio eradication
The inclusion of IPV into all global routine immunization programs and the possible 
eradication of polio spur the need for improved and affordable IPV formulations. Important 
variables for the development of new IPV formulations are the route of administration, 
the selection of adjuvants, the vaccine formulation, and the use of (non-invasive) delivery 
methods. Ideally, a new generation of IPV have the benefits of OPV and should therefore be 
easy to administer, provide mucosal immunity, and be affordable for low-income countries. 
IPV formulations with improved thermostability that can be kept outside the cold chain may 
simplify logistics and increase vaccine availability in remote areas. Furthermore, the ideal polio 
vaccine should be safe to manufacture and have a long shelf-life with both characteristics 
being even more critical in the period after polio eradication, respectively to reach biosafety 
goals and for stockpiling purposes.
Towards polio eradication and also in the period thereafter, there will be a market for 
better IPV formulations. Besides, it is important to build up stocks of a polio vaccine that can 
be used as outbreak intervention in case of reemergence of poliovirus in the post-eradication 
era and even in the period post-vaccination.
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THESIS SCOPE AND OUTLINE
The aim of this thesis was to develop improved formulations and novel delivery strategies 
for polio vaccination using IPV as staring point. In chapter 2, the current status of alternative 
polio vaccine delivery strategies is provided. The feasibility of these strategies is discussed 
by highlighting challenges, hurdles to overcome, and formulation issues relevant for optimal 
vaccine delivery. 
Chapter 3 describes the development of a dried IPV having minimal loss during the 
lyophilization process and improved stability when compared with the conventional liquid 
IPV. A certain thermostable vaccine formulation should allow distribution and storage at 
unrefrigerated conditions, at least long enough for their transport to remote areas. In chapter 
4 the potency of lyophilized IPV was evaluated. Moreover, an approach to obtain a hexavalent 
vaccine by reconstituting lyophilized IPV with liquid pentavalent vaccine, which contains 
diphtheria toxoid, tetanus toxoid, whole cell pertussis, Haemophilius influenza type B and 
hepatitis B (DTwP-Hib-HepB), is described.
The potential of the Bioneedle-technology as syringe-free alternative delivery system for 
polio vaccination is described in chapter 5. Bioneedles are small biodegradable mini-implants 
that can be filled with antigen followed by a lyophilization process. After subcutaneous 
delivery, the implant dissolves and the antigen releases. Antigenicity of IPV when formulated 
in Bioneedles was assessed, both directly upon preparation and after elevated stability 
testing. Further, we evaluated the immunogenicity of IPV-filled Bioneedles in rats and the 
residence time at the site of administration.
Mucosal tissues are attractive administration and target sites for vaccination due to 
their large surface and immunological competence. In chapter 6, the characteristics of and 
approaches for sublingual and buccal vaccine delivery are described and compared with other 
mucosal vaccine delivery routes. Besides, this chapter highlights promising developments in 
the search for vaccine formulations, including adjuvants and suitable dosage forms, which 
are likely critical for the design of a successful sublingual or buccal vaccine. 
Chapter 7 describes the potential of polio vaccination via mucosal surfaces using IPV 
based on the attenuated Sabin strains. It was investigated whether intranasal or sublingual 
vaccination with sIPV is able to elicit functional systemic immunity (serum) as well as local 
immune responses at different mucosal sites. The need of an adjuvant for polio vaccination 
via mucosal routes was examined as well by testing sIPV in combination with the mucosal 
14
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adjuvant cholera toxin. For the induction of protective immunity upon sIPV vaccination under 
the tongue, the development of novel oral dosage forms that facilitate antigen uptake by 
the oral mucosa may be required. In chapter 8 the possibility to make polymer-based films 
containing trivalent sIPV suitable for oromucosal vaccination was evaluated. Different film 
forming polymers were selected from literature and tested in combination with excipients 
that stabilize the antigen during the drying process in order to obtain a sIPV-containing oral 
film formulation with minimal loss of antigenicity.
Chapter 9 summarizes the results and conclusions of this thesis. Moreover, all different 
aspects of this thesis are discussed and perspectives of improved formulations and 
alternative delivery strategies for polio vaccination are given. 
1
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CHAPTER 2
Global polio eradication is closer than ever. Replacement of the live attenuated oral 
poliovirus vaccine (OPV) by inactivated poliovirus vaccine (IPV) is recommended 
to achieve complete eradication. Limited global production capacity and relatively 
high IPV costs compared to OPV, spur the need for improved polio vaccines. The 
target product profile of these vaccines includes not only dose sparing but also 
high stability,  which is important for stockpiling, and easy application important 
for (emergency) vaccination campaigns. 
In this review, the current status of alternative polio vaccine delivery strategies is 
given. Furthermore, we discuss the feasibility of these strategies by highlighting 
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INTRODUCTION
Poliomyelitis is an infectious disease caused by poliovirus, an enterovirus belonging to 
the Picornaviridae family. After infection by one of the three serotypes, the virus multiplies in 
the intestine from where it can invade the nervous system and cause paralysis. 
The only way to combat poliomyelitis is by prevention through vaccination. Most 
industrialized countries use trivalent inactivated poliovirus vaccine (IPV, based on the wild 
polio ‘Salk’ strains) in their pediatric vaccination programs. IPV may be formulated as a 
combination vaccine with other antigens, such as diphtheria/tetanus/(acellular) pertussis 
(DTP), Haemophilus influenzae type B (Hib) and hepatitis B surface antigen. In developing 
countries, the live attenuated oral poliovirus vaccine (OPV, based on Sabin strains) has been 
the vaccine of choice because of a number of advantages as compared to IPV. These include 
the induction of stronger mucosal immunity, ability to interrupt wild poliovirus circulation in 
areas of intense fecal-oral transmission, immunization of close contacts through secondary 
spread, affordability and ease of administration. However, the use of OPV comes with a 
rare, but serious adverse effects, i.e. reversion to virulence resulting in vaccine-associated 
paralytic polio (VAPP). Circulating reverted vaccine viruses (circulating vaccine-derived 
polioviruses, cVDPV), may have similar transmissibility and neurovirulence as wild poliovirus 
and can cause new polio outbreaks. 
The eradication of polio is one of the top global health priorities. Efforts to eradicate polio 
should focus on both wild polioviruses as well as vaccine-derived viruses. Therefore, the 
Global Polio Eradication Initiative (GPEI) has defined an endgame strategy that includes a 
phased withdrawal of OPV and the worldwide inclusion of IPV into all routine immunization 
programs [1]. Besides the short term changes in current immunization procedures, more 
affordable, more effective and safer forms of the existing polio vaccines are needed [2]. The 
target product profile of the ideal polio vaccine may differ depending on the eradication 
phase (Table 1). In the development of new polio vaccine delivery systems, the intended use 
is an important consideration.In the short term, the worldwide switch to injected IPV at the 
expense of OPV will occur, which brings some challenges: 
1. IPV is injected and so has the disadvantages of needles and syringes, like risk of needle 
stick injuries, potential re-use of needles and, as a result, complicated waste management. 
2. IPV is, compared to OPV, considerably more expensive. The downstream processing 
is more complex since the parenteral version is extensively purified. Besides, unlike 
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OPV, the inactivated virus is not able to replicate in the host. The dose needed to confer 
protection is about ten times higher. 
3. In general, IPV does not induce mucosal intestinal immunity (polio-specific secretory IgA 
antibodies), which is crucial to provoke a strong herd immunity effect and to interrupt 
poliovirus transmission in developing countries. Although IPV can prevent poliovirus 
outbreaks and provide herd protection to some extent, IPV is probably less effective to 
stop transmission of poliovirus. 
A disadvantage of both OPV and IPV is that they need a cold-chain for their storage 
and logistics. For use in emergency vaccinations or post-eradication stockpiling this 
is undesirable. Stockpiling after eradication and cessation of routine polio vaccination is 
important in case of re-emergence of the virus.
The GPEI is pursuing some priority approaches to make IPV more affordable for low-
income countries, like dose-sparing strategies using adjuvants and the introduction of 
IPV based on Sabin strains, instead of wild type poliovirus (Salk) strains [2]. An overview 
of different approaches that are currently under development, including their strengths and 
weaknesses, is given in figure 1. 
Table 1 The ideal polio vaccine is not able to revert to virulence, is stable during storage, affordable and 
easy to produce, and induces sterilizing immunity (i.e., interrupts virus transmission). .
The relevance of this ideal target product profile depends on the polio status worldwide (i.e., current 
phase with OPV/IPV in use, after complete OPV cessation, post-eradication or, eventually, without 
routine polio vaccination), but also on the aim (i.e., routine immunization program versus outbreak 
control campaigns) 



























No reversion to virulence - - + + ++ ++ ++
Transmission interrupting 0 ++ 0 + - ++ ++
Stable 0 + + + + ++ ++
Affordable + 0 ++ 0 ++ 0 0
Easy to administer 0 ++ 0 ++ ++ + +
Easy to produce - - - - - ++ ++
Safe to produce + + + + ++ ++ ++
- less important; 0 neutral; + important; ++ very important
IPV: inactivated poliovirus vaccine; OPV: oral poliovirus vaccine
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The current review will focus on IPV delivery approaches by highlighting recent 
developments of alternative administration methods for IPV. The use of dermal delivery 
of polio vaccines, like jet injection and microneedle approaches, are discussed. Mucosal 
delivery and the potential of new mucosal delivery routes for IPV are described. Finally, future 
perspectives, including the potential of improved vaccine formulations, the use of adjuvants 
and promising delivery technologies, are given.
NOVEL INTRAMUSCULAR AND 
SUBCUTANEOUS ADMINISTRATION
Most of high-income countries use Salk IPV, which is administered intramuscularly, in 
their routine vaccination programs, often in combination with other antigens. Alternative 
delivery approaches are developed for polio vaccination. These vaccine delivery strategies 
could address issues, like safety, needle phobia and vaccine stability.
Figure 1 An overview of different approaches, which are currenlty under development, to make 
inactivated poliovirus vaccine (IPV) more affordable for low-income countries. 
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Needle-free (intramuscular/subcutaneous) jet injection
An option to facilitate intramuscular (IM) or subcutaneous (SC) delivery is the use of needle-
free jet injectors. Jet injectors use high-pressure to inject the fluid into or through the skin, 
either subcutaneously or intramuscularly. Injection depth depends on nozzle design, pressure 
and pressure profile during injection. Initial studies aimed at demonstrating non-inferiority or 
superiority of intramuscular jet-injections over the needle-based intramuscular vaccinations. 
The study of Lipson et al. demonstrated that IPV vaccinations using the press-o-jet [3] induced 
similar responses in children as the needle approach [4]. In general, the use of jet injectors 
could provide a solution for safety issues accompanied with needles, reduces the amount of 
waste, and increase the immunization speed. However, after the introduction of the devices 
concerns about blood-borne infection were raised. The use of multi-dose systems with the 
same nozzle, occasionally lead to transmission of for example Hepatitis B between recipients. 
Studies demonstrated the infectious potential of several jet injectors [5,6]. Today, safe jet 
injection systems are available using disposable parts facing the vaccine recipient. Current 
systems in use for IM and SC administration of vaccines are the Biojector2000 (Bioject Medical 
Technologies Inc, Tigard, OR, United States), ZetaJet (Bioject Medical Technologies Inc, Tigard, 
OR, United States) and PharmaJet (PharmaJet, Golden, CO, United States). 
Soonawala et al. compared the PharmaJet with conventional needle-injection (one IPV dose) 
in healthy adults in a phase 1 study [7]. Vaccination with the jet injector was less painful (87% no 
pain) than vaccination with needle and syringe (60% no pain), but caused more adverse effects 
at the site of administration, like transient erythema and swelling. Moreover, IM jet injector 
vaccination resulted in similar geometric mean virus-neutralizing antibody titers as induced 
after IM injection using needle and syringe. These data demonstrated that the technique itself 
could help to improve acceptability by reducing the pain sensation [7]. Intradermal jet-injection 
further reduced pain and increased immunogenicity as further described in section 3.2. Since 
subjects had background immunity against polio in this phase 1 study, further clinical testing 
(phase 2 and 3) is needed to assess immunogenicity.
A recently completed trial in a large cohort of infants in Gambia addresses safety and 
immunogenicity of IPV given concomitantly with other vaccines (Measles, Rubella and Yellow 
Fever) (study nr. NCT01847872). One of the aims of this trial was to compare the performance of 
a jet injector with that of needle and syringe for IM and intradermal (ID) delivery. Seroconversion 
levels, adverse events, cellular immune responses and virus shedding after OPV ‘challenge’ 
are measured to quantify the type of response induced and the potential presence of mucosal 
immunity. The results have not been published yet. 
2
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Bioneedles
Bioneedles are dissolvable implants (12 mm) made from biodegradable polymers that can 
be filled with antigen and are injected subcutaneously by air pressure. The included vaccine 
formulation is in a solid state. Using a solid formulation could diminish the dependence on 
the cold-chain. Furthermore, the Bioneedles could eliminate needle-stick accidents and do 
not create sharp waste. 
IPV formulated in Bioneedles showed improved thermostability compared with liquid IPV 
[8]. Storage of the IPV-filled Bioneedles at 45°C for one week led to a reduction of antigenicity 
between 20-50% for the different serotypes compared to 80 to 100% antigen loss for the 
standard liquid form. Storage of the liquid vaccine at 60°C for one hour did lead to complete 
loss of antigen compared to 20-30% reduction for the antigen in Bioneedles. Furthermore, 
vaccination of rats with IPV Bioneedles induced comparable levels of virus-neutralizing 
antibodies to the IM administered conventional IPV vaccine. These data demonstrate that 
the Bioneedle polio vaccine has similar immunogenic properties and better resistance to 
higher temperatures compared to current liquid IPV. The implementation of the thermostable 
vaccine in biodegradable needles could help to stimulate the expansion of IPV usage to 
developing countries, because of its improved thermostability, which is required in remote 
areas, and potential to vaccinate relatively fast. 
24
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Table 2 Preclinical assessment of other administration routes than conventional intramuscular (IM) or 
subcutaneous (SC) injection for polio vaccination 





Novel IM/SC delivery 
Bioneedle 2.7;0.6;2.1 PagLa Rats Inferior VN titers for type 3 after prime 
immunization for Bioneedle-group. 




ID injection (unclear) CAF01b Mice Similar (type 1 and 3) or superior VN 
titers after ID vaccination plus adjuvant 
and superior IgG titers compared to IM 
injection. 
No mucosal IgA (feces)
[39]
ID injection 1-10; 
1-10; 
1-10
dmLT Mice Similar VN titers and superior polio-
specific IgG titers compared to IM 
vaccination.  
Prolonged systemic immunity (VN)





5/15;NA;NA NA Rats Polio-specific IgG and VN titers similar 










NA Rats Superior VN titers for 40% ID with 40% 
IM and when comparing 40% ID with 




47;9;38 NA Monkeys VN titers similar to IM injection for type 




45;NA;NA TMC Rats Inferior polio-specific systemic IgG titers 







dmLT Mice No immune responses detected without 
adjuvant. Inferior VN titers or systemic 
Ig titers compared to IM injection.
Superior mucosal IgA titers (feces, 
saliva) for SL vaccination (+adjuvant) 
compared to IM injection
[60]
Abbreviations used:
DU: D-antigen unit; dmLT: double mutant heat-labile toxin; ID: intradermal; IM: intramuscular; IPV: inactivated poliovirus 
vaccine; NA: not applicated; SL: sublingual; T1/2/3: serotype 1/2/3; TMC: trimethyl chitosan; VN: virus-neutralizing
a PagL LPS is a LPS-derivate obtained through expression of the Bordetella bronchiseptica PagL gene in Neisseria 
meningitides LPS.
b CAF01 is an adjuvant composed of cationic liposomes DDA (dimethyldioctadecylammonium) and TDB (trehalose 
6,6′-dibehenate).
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.DERMAL IMMUNIZATION
The dermis and epidermis of the human skin are rich in antigen-presenting cells (APC) 
and therefore are attractive sites for vaccine delivery. The skin’s structural and cellular 
composition enables it to function as a physical and immunological barrier, suggesting that 
delivery of vaccines to the dermal layers, rather than IM or SC vaccine delivery, could be 
more efficient and induce protective immune responses with smaller amounts of vaccine 
antigen [9]. 
Dendritic cells (DCs) are APCs that serve to efficiently amplify innate and adaptive immune 
responses. In the normal human skin two distinct populations of immature DCs are found, 
each within a specific layer, i.e., Langerhans cells (LCs) in the epidermis, and dermal DCs 
in the deeper skin layers [10]. However, the skin is equipped with an impressive barrier, the 
stratum corneum, which makes it almost impossible to induce an immune response through 
dermal vaccination without disrupting this first defense line. Therefore, effective, safe, and 
convenient methods to achieve disruption of the stratum corneum are needed [11]. 
The intradermal (ID) delivery methods that are currently available can be roughly 
classified into three categories: administration by (i) needle and syringe; (ii) jet injectors; and (iii) 
microneedles [12]. An overview of these different ID delivery methods tested in combination 
with IPV is given in table 2 (preclinical) and table 3 (clinical).  
Traditional needle-based dermal vaccination
The traditional needle-based ID vaccines rely on a single needle inserted shallow into 
the skin (the ‘Mantoux’ technique, originally used as diagnostic for tuberculosis) or needle(s) 
especially designed to penetrate only into the dermis (i.e., bifurcated needles, multipuncture 
systems). They have been used extensively in the past for various vaccination programs, like 
those for smallpox, and some are studied for the use in the polio immunization programs. 
However, ID injection methods using needles and syringes require considerable expertise 
and are, therefore, not ideal for routine vaccinations.
Although IPV is given intramuscularly, the initial experiments of Jonas Salk anticipated its 
use via the ID route. In 1953, Salk demonstrated the immunogenicity of IPV administrated 
both intramuscularly and intradermally [13]. Despite these and more promising results in the 
mid-1950s [13-16], the ID route was only in Denmark the most used route for IPV vaccination 
at that time [16,17]. 
26
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With the purpose of developing a more affordable IPV for the lower-income countries and 
increase its use in the post-eradication era, different studies investigated ID polio vaccination 
[18]. After development and licensure of the enhanced-potency IPV, which was responsible 
for highly improved seroconversion rates for all three serotypes due to its higher content of 
poliovirus antigen [19], three trials using ID administration of the IPV have been conducted in 
India since the early 1990s. Those proof-of-concept studies established the immunogenicity 
of a fractional (one-fifth) IPV dose delivered ID (via Mantoux injection) in subjects who had 
been previously immunized [20], or had never been immunized against polio [21]. The trial 
among 69 Indian infants demonstrated that two or three fractional doses ID were equivalent 
in terms of seroconversion to two full doses of IPV delivered IM or five doses of OPV (based 
on historical data). All infants who had no pre-existing maternal antibodies seroconverted to 
all serotypes [22]. In none of these studies, however, a comparator IM group was included. 
Therefore, a randomized controlled trial was conducted in the Philippines, to compare the 
primary and booster immunogenicity of IPV by ID injection (one-fifth dose) with the IM route 
(full dose). These data demonstrated non-inferiority of fractional dosing by the ID route, and 
thus confirmed the validity of this IPV vaccination strategy [23]. 
The bifurcated needle and multipuncture system were introduced to improve ID delivery 
of vaccines by limiting the penetration depth, which ensures dermal delivery. The bifurcated 
needle consists of a needle that branches out into two solid needle points. Formulations are 
administered via multiple punctures at a local area. To our knowledge, no research has been 
conducted with this type of needle administering IPV. 
The multipuncture system was deployed for Bacillus Calmette-Guerin (anti-tuberculosis) 
vaccines. The vaccine administration is a two-step process. First, the skin is penetrated using 
a device with multiple needles. Secondly, the vaccine is applied evenly on the punctured area. 
A large clinical trial conducted in Cuba included the multipuncture system as a control in a 
comparative study for three needle-free delivery devices for polio vaccination. In this study, 
inferior immune responses (defined as seroconversion and increase in virus-neutralizing 
titers) following fractional-IPV dose administered via the ID route compared with full-dose 
IPV administered IM were reported [24]. 
Considered together, the trials in the Philippines (Mantoux injection) [23] and Cuba 
(multipuncture system) [24] provided inconclusive results after ID delivery of IPV. Moreover, 
a problem for traditional needle-based methods is their inaccuracy, the need of well-trained 
personal for administration and low patient compliance. To be able to completely use the 
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potential of the skin as a vaccination site, less invasive systems are examined in animal and 
human trials. 
Jet injector
While several studies confirm the observations of Salk about the potential of dose sparing 
by ID injection, usage of needle ID injections on a large scale is not foreseeable given that 
the need for skilled personnel, which is a major limitation for large-scale campaigns, and 
the safety and disposal concerns related to the use of needles remain. To overcome these 
problems and increase the affordability of IPV, needle-free devices for ID injection, which can 
be manually reset and used by volunteers if necessary, have been developed [25]. 
Needle-free jet injector systems are used for IM and SC administration (see section 
Needle-free jet injection), but are also studied as ID delivery devices (e.g., Biojector 2000, 
PharmaJet). Furthermore, the ID Pen injector (Bioject Medical Technologies Inc., Tigard, 
OR, United States) and the PharmaJet Tropis (PharmaJet, Golden, CO, United States) are 
especially designed for the ID delivery of vaccines. Several clinical trials with polio vaccines 
are already conducted to compare the different injector systems to IM (conventional) 
hypodermic needles or to each other (Table 3). 
The Biojector 2000, a disposable syringe jet injector for ID delivery, has been evaluated by 
WHO sponsored studies in Cuba and Oman, and compared to IM delivery using conventional 
syringe and needle. Two different IPV vaccines and two different immunization schedules were 
evaluated. Target groups were infants in both studies. The primary objective of these trials 
was to demonstrate non-inferiority of fractional (one-fifth) dose in terms of seroconversion 
for the ID route compared to the full dose via the IM route. Non-inferiority could not be 
demonstrated in the Cuban study; significantly lower seroconversion rates (ID: 52.9%, 85.0%, 
and 69.0% versus IM: 89.3%, 95.5%, and 98.9% for serotypes 1, 2, and 3, respectively) and 
significant lower median antibody titers were induced in the ID arm after three doses of IPV 
[26]. In the Omani study, similar levels of seroconversion for serotypes 1 and 3 were after ID 
delivery of fractional doses and after IM vaccination of the full dose were detected. Serotype 
2 showed a statistically significant different, although small, reduction in seroconversion 
rate after ID delivery (ID: 95.7% vs. IM: 100%). For all serotypes, the median antibody titers 
were significantly lower in the fractional dose group [27], but it remains unclear whether 
the differences have practical implications since any detectable titer of neutralizing antibody 
against poliovirus would be expected to prevent against paralytic disease [28]. Maternal 
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antibodies may interfere with IPV vaccination at very young age [29,30], Administration of 
fractional doses of IPV is unlikely to serve as an optimal antigen-sparing strategy when given 
at the standard ages of 6, 10, and 14 weeks, rather than a schedule in which the first dose is 
administered at 2 months of age [26,27]. 
Dermal IPV vaccination with the PharmaJet device has been evaluated in clinical trials in 
India and The Netherlands [7,27]. The study in The Netherlands was performed administering 
vaccine to young adults, whereas the study in India was conducted with infants. For the Indian 
study, the ID administered fractional dose was less effective than full-dose IM administration 
in seroconverting seronegative infants and in increasing antibody titers in seropositive 
children. This result is in contrast with the very small differences found between fractional 
and full-dose in a three-dose schedule conducted in Oman (as described above) [27], which 
might be related to the device and/or geographic differences.  Unfortunately, as with most 
studies mainly aiming at non-inferiority of ID fractional dose IPV delivery, the study was not 
designed to evaluate the impact of ID-administration solely, e.g., by including a group that 
receives fractional dose by IM injection as performed in the Dutch study [7].
More recently, in another WHO-sponsored clinical trial in Cuba the performance of three 
jet injectors, i.e., Biojector2000, Bioject ID Pen injector and PharmaJet Tropis, was evaluated 
and the immune response induced by a ID administered fractional dose with that induced 
by full-dose IPV given via the IM route [24]. Children between 12 and 20 months of age, who 
had previously received two doses of OPV, received a single dose of IPV either full-dose IPV 
via IM injection or fractional dose given via the ID route using one of the jet injectors or via 
‘Mantoux’ needle and syringe. Whereas the Indian study reported excellent immunogenicity 
of fractional IPV when administered in a three-dose schedule with appropriate age and 
interval between doses [27], the results from recent Cuban study were more comparable 
with to those from the boosting study in India were fractional IPV also induced significantly 
lower immune responses than full-dose IPV [24]. Nevertheless, at the end of the study, the 
seropositivity rates were similar for both ID jet injector, ‘Mantoux’ needle and syringe (ID), and 
conventional IM-injection groups [24]. 
The fractional dose strategy might be suitable as a substitute to full-dose IPV when given 
at the correct interval. The newly developed jet injector (Tropis Needle-Free Injector from 
PharmaJet) would facilitate the administration of a fractional dose when given ID [24]. The 
use of jet injectors may solve two existing problems of IPV by being safer to administer and 
decreasing costs by using less antigen. In addition, it has been hypothesized that ID delivery 
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could improve protection against infection in the gut, since it may stimulate IgA mucosal 
immunity [31]. However, further investigations are needed to assess whether the lower 
immunogenicity of fractional IPV is sufficient to provide adequate protection and whether 
potential loss of immunogenicity is worth the cost savings. 
Microneedle approaches 
Another approach for ID vaccine delivery makes use of microneedle arrays that can 
penetrate the stratum corneum. These arrays are designed to disrupt the stratum corneum 
and target Langerhans cells in the epidermis, but are minimally invasive, since the nerves in 
the underlying tissue are not reached, and therefore caused no pain and only minimal irritation 
[32]. Different microneedle strategies are being exploited, i.e., the straightforward methods by 
pre-treating the skin with solid microneedles followed by application of a vaccine containing 
patch on the pretreated skin surface or using hollow microneedles to inject the vaccine into 
the epidermis. More recent strategies include the use of dissolvable microneedles or antigen-
coated microneedle arrays. Microneedle technologies are in preclinical or early clinical 
development and the optimal microneedle strategy (material, shape) to deliver a vaccine into 
the skin has not yet been established [33]. 
Since ID administration of IPV has been shown to have potential, a microneedle approach 
appears to be a useful delivery method for IPV vaccination. To guarantee the stability and 
immunogenicity of a dermal polio vaccine by using coated or dissolvable microneedles, the 
development of a solid IPV formulation is required, which is a major hurdle to overcome. The 
problem of the often low loading capacity of microneedle arrays may be solved by adjuvants 
(see section Intradermal adjuvants). 
A preclinical study focusing on the production and usage of a single hollow microneedle for 
IPV has been performed by Van der Maaden et al. [34]. Immunization of rats with 5 D-antigen 
units (DU) of IPV serotype 1 at a depth of 300µm led to similar systemic IgG levels and virus 
neutralization titers as compared to intramuscular and needle-based intradermal injections 
[34]. One other micro-injector system has been used for IPV vaccination: the MicronJet600 
(NanoPass Technologies Ltd., Rehovot, Israel). The performance of the MicronJet600 in rats 
dosed with a different fraction of the human IPV dose was studied by Kouiavskaia et al. 
[35]. The response rate of animals immunized with 20 or 40% of the human dose at 35 
days was equal for IM and ID injections. The 5% dose ID led to almost double the response 
rate compared to intramuscular injections. In addition, the neutralizing virus titer for type 
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1 and 3 after 35 days and 40% of the full-dose was higher than full -dose administered 
intramuscularly. These results confirmed the potential of using fractional doses during ID 
vaccination programs. To study the performance of the MicronJet600 in humans, a large 
cohort of infants in Bangladesh was vaccinated with a fractional IPV-dose. No adverse events 
were reported among participants within 30 minutes after vaccine administration. None of 
the adverse events reported during follow-up were attributed to the MicronJet600-device. 
When compared with full-dose IPV given via IM injection, the fractional IPV dose given ID 
by microneedles failed the non-inferiority test for all serotypes for seroconversion observed 
with 1 or 2 doses [36]. In this study, the assessment of the microneedle device was limited 
to safety and injection quality. Therefore, the comparison of immune responses induced by 
IPV administered by MicronJet600 with standard needle and syringe for ID administration 
was not possible. 
Apart from hollow microneedles, also solid needles for skin pretreatment, biodegradable 
needles and coated needles [37] are under development (Table 2). The usage and action of 
both the solid and hollow needle arrays are similar to the single microneedle system. First 
of all, they require the use of a delivery device like a pressure-based applicator to actually 
puncture the skin. Secondly, the vaccine is introduced from an external source, via a syringe 
into the hollow needle or with a patch applying the vaccine onto the punctured skin. The 
biodegradable and coated needles are manufactured with the vaccine in or on top of the 
needles and forced into the skin followed by release of their content. Van der Maaden et al. 
developed a protocol for the production of alternating layers of IPV and N-trimethyl chitosan 
on microneedle arrays. Using a one-layer coating technique, Edens et al. were able to create 
an IPV-coated microneedle array that induced comparable neutralizing antibody titers as IM 
injections [38].
Intradermal adjuvants
The necessity of adjuvants to stimulate systemic as well as mucosal immunity has been 
reported in the preclinical dermal immunization studies for Hepatitis B, HIV, Diphtheria, 
Cholera and ETEC diarrheal antigens. Two adjuvants have been studied in combination with 
ID administration of IPV; CAF01 and dmLT (Table 2).
CAF01 is a liposomal formulation composed of the cationic lipid DDA 
(dimethyldioctadecylammonium) and TDB (trehalose-6,6-dibehenate). Dietrich et al. 
reported that IPV mixed with CAF01 and administered to mice via ID injection, was able to 
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induce superior polio-specific serum IgG levels and virus-neutralizing titers compared to 
the non-adjuvated vaccine [39]. No mucosal immunity (IgA in feces) was detected after ID 
administration alone. However, simultaneous priming of CAF01 adjuvated IPV at an ID and 
IM site followed by IM boosting induced significant levels of fecal IgA, without compromising 
serum virus-neutralizing titers [39]. 
Another study investigated the use of genetically detoxified E. coli heat-labile toxin (dmLT) 
as adjuvant for IPV administered via IM or ID injection in mice [40]. Intradermal vaccination 
with a fractional IPV-dose combined with dmLT as adjuvant, elicited serum virus-neutralizing 
antibody titers similar to those obtained by non-adjuvated IPV given via IM injection leading 
to a five-fold dose sparing. The duration of the systemic antibody responses was prolonged 
for the mice vaccinated with IPV adjuvated with dmLT either via IM or ID delivery. Moreover, 
dmLT enhanced mucosal immunity as defined by fecal and intestinal polio-specific IgA 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Efficacy of mucosal vaccination
Although parenteral vaccination in some instances can provide protection against 
mucosal infections, in most cases and especially in naïve subjects, e.g., newborns and young 
infants, a mucosal vaccine delivery route is needed for effective immunization [41]. Despite 
the practical advantages of mucosal vaccine delivery over injectable vaccines, only relatively 
few vaccines for human use are licensed: oral vaccine against cholera, typhoid, rotavirus, and 
polio, and a nasal vaccine against influenza [42]. With the exception of the cholera vaccines, 
which have a very strong intrinsic immuno-potentiating capacity [43], all these vaccines are 
live attenuated vaccines. They effectively induce both systemic (serum) and local mucosal 
immune responses, superior protection against re-infection, persistence of immunological 
memory, better herd immunity (because of secondary spread and mucosal immunity) and 
are easy to administer [44]. For vaccination against polio, polio-specific mucosal immunity 
in the gut is a powerful protecting and transmission inhibiting mechanism as we know from 
OPV. To date marketed mucosal vaccines are administered via the mucosa where protection 
is required. This is in contrast to vaccination strategies that are under development in order 
to generate mucosal immunity at distant effector sites.
OPV
The only marketed needle-free polio vaccine is the live attenuated oral vaccine, OPV. The 
success of the live-attenuated OPV is attributed to the capability of the virus to replicate in 
the intestine, and thus generate an increasing antigen load that elicits both strong systemic 
(serum IgG) and mucosal (local secretory IgA (sIgA)) antibody responses [45,46] and long-
term persistence of neutralizing antibodies against poliovirus [47,48]. The mucosal sIgA 
confers protection from poliovirus entry and multiplication in the intestine [49]. 
Although OPV is the most effective vaccine in endemic and high-risk areas to interrupt 
wild poliovirus transmission, the estimated number of polio cases caused by OPV now likely 
exceeds those related to wild polioviruses [50]. Wild type 2 poliovirus has not been detected 
since 1999 and the last case of wild type 3 was reported in November 2012. For that reason, 
the Endgame Strategy aims for global cessation of type 2 OPV by switching from trivalent 
to bivalent OPV in routine immunization programs [50]. Such bivalent vaccines (type 1 and 
3) are more immunogenic than trivalent OPV [51] and nearly as effective as the monovalent 
OPV formulations, especially in young children receiving their first polio immunization [52-
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55]. However, the risks of VAPP and VDPVs by reversion of the Sabin strains to a pathogenic 
strain still remain, and thus the global eradication of polio by using these OPVs is impossible. 
As a result, OPV cessation and replacement by IPV is highly recommended and supported 
by the GPEI. Substitution of OPV by a similar (low) dose oral inactivated poliovirus vaccine is 
unlikely to succeed. Instead, the development of live poliovirus strains with stable attenuation 
properties seems more feasible [56-58]. It is expected that some of these approaches will be 
clinically tested in the coming years. 
Novel oral mucosal vaccine delivery – sublingual and 
buccal route
Sublingual vaccine delivery has gained significant attention during the past few years, as 
shown by the numerous preclinical studies published in the last decade [59].  
The use of the sublingual administration route for IPV has been studied preclinically 
by White et al. [60]. They compared the IM administration with sublingual administration 
using a thermoresponsive gel (TRG) delivery system. These TRG systems are liquid at room 
temperatures and become solid in warmer environments, like the mouth [61,62]. The solid 
gel has high mucosal adhesion properties and ensures slow release and potentially minimal 
loss because of swallowing. The effect of dmLT as oral mucosal adjuvant was investigated 
in this study as well. Sublingual administration of IPV without dmLT or as liquid (instead of 
the TRG delivery system) was not able to induce any immune response in mice. Sublingual 
administered IPV as TRG in combination with dmLT led to serum virus-neutralizing titers and 
systemic Ig levels, nevertheless significantly lower than when IPV alone is administered via 
the IM route. However, the TRG-formulation containing IPV plus dmLT induced systemic and 
mucosal IgA production not seen via IM vaccination. The mucosal immunity as measured by 
IgA in salivary samples, improved with an increasing IPV dose [60].
To our knowledge the buccal route has not yet been studied with IPV. Whether OPV 
administration leads to some sublingual or buccal delivery or even replication is not known. 
In order to achieve successful vaccination via the sublingual or buccal route, enhanced 
vaccine formulations are essential to target these mucosal inductive sites. It is expected that 




Nasal vaccination and other novel mucosal vaccination 
routes
Intranasal vaccination can avoid degradation of vaccine antigen by digestive enzymes, 
low pH and strong dilution. As a result nasal vaccination may require smaller doses of 
antigen when compared to oral immunization [64]. However, for nasal vaccination also to 
date no vaccine is on the market on the basis of inactivated pathogens or subunits/proteins. 
A risk of intranasal immunization is the possible deposition of antigen or adjuvant in the 
central nervous system through the olfactory bulbs and olfactory nerves, which can cause 
adverse effects like temporary facial paralysis (Bell´s palsy) [65,66]. This has been seen with a 
marketed virosomal influenza vaccine that was adjuvated by heat labile enterotoxin of E.Coli 
(LT) and has been withdrawn from the market due to this side effect. Also, wheezing may 
occur in young children after intranasal vaccination. To date no efforts have been published 
that address nasal vaccination with polio vaccine formulations since this administration 
route induces mucosal immune responses mainly in the respiratory and reproductive tract 
mucosae. Moreover, immunization via the nose is often efficient for inducing systemic 
immune responses, but not for eliciting intestinal immunity in humans [67].
Other routes that are investigated for mucosal vaccination against infectious diseases 
include pulmonary, vaginal and rectal routes [11]. However, like nasal vaccination these 
routes are not yet explored and/or disclosed for use in polio vaccination. Amongst others, 
this might be related to the fact that these routes are not first choice because of ease of 
accessibility, acceptance by the public or technical challenges.
Mucosal adjuvants
The necessity of adjuvants to stimulate has been reported in the preclinical mucosal 
immunization studies for several antigens as reported elsewhere. In contrast to OPV and 
its potentially live virus successors, mucosal polio vaccination based on IPV is expected 
to require adjuvants in order to induce sufficient systemic as well as mucosal immunity. 
Although there is a broad preclinical experience on adjuvants for several antigens as reported 
elsewhere [11], only limited studies have shown the use of adjuvants for mucosal IPV delivery 
(Table 2). Current experience is limited to the use of dmLT in combination with TRG as 
described above.
2
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EXPERT COMMENTARY
Due to the cessation of OPV and the possible eradication of polio there is a need for 
better and affordable IPV. Ideally, a new generation of IPV should be administered through 
alternative (needle-free) delivery routes, provide mucosal immunity, be safe to manufacture, 
have a long shelf-life, be stable outside the cold-chain, and be affordable for low-income 
countries. 
Important variables for the development of improved IPV are the route of administration, 
the selection of adjuvants, the vaccine formulation and the use of (non-invasive) delivery 
methods [11]. The use of jet injectors is probably the fastest way to introduce needle-free IPV 
vaccines, but apart from injection safety it may not lead to dose sparing. Another promising 
and relatively short-term solution in the context of parenteral IPV vaccination is probably 
the replacement of the needle and syringe with a biodegradable implant as vaccine carrier. 
Biodegradable implants could both reduce the safety risks related to conventional injection 
and carries the vaccine in the (more thermostable) solid form, which might minimize the 
dependence on the cold-chain. 
Mucosal vaccine delivery, like the sublingual and buccal routes, has the potential to elicit 
local immune responses at the point of virus entry, but often induces in the absence of 
an adjuvant tolerance or low-to-undetectable immune responses [68]. Therefore, efforts on 
mucosal vaccine design should focus on (i) overcoming physiological barriers at mucosal 
routes, (ii) targeting local APCs for appropriate processing of the antigens that lead to specific 
T and B cell activation, and (iii) controlling the kinetics of antigen and adjuvant presentation to 
promote long-lived, protective adaptive immune memory responses [44]. 
Different adjuvants have already proven their potential for (Sabin) IPV though via the 
parenteral route. However, limited data is available on preclinical evaluation of adjuvants 
for mucosal vaccination. The E. coli heat labile toxin with 2 mutant (dmLT) has proven its 
potential for IPV delivery via the mucosal route (sublingual) preclinically and an ongoing clinical 
phase 1 study in healthy subjects should proof its safety via the sublingual route (study no. 
NCT02052934). This could be therefore an interesting adjuvant for further development for 
polio vaccination via the oral mucosa. 
Special attention should be given to restrictions related to the final target population 
for polio vaccination: infants. The delivery method and the delivery device and formulation 
should be suitable for application in infants. For example sublingual tablets are not suitable 
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for infants since they may give risk of choking. Improved ways of delivery to the buccal and/
or sublingual mucosa are under way. These include sticking formulations, like fluids that 
jellify upon contact with the mucosa (temperature) or thin films that can be applied below 
the tongue. Advantage of these formulations is that they prolong the contact time with the 
mucosa and thereby may decrease the dose needed for induction of immunity.
Dermal delivery might be a more suitable alternative for vaccination of infants. A 
disadvantage of dermal delivery is that in general no mucosal immunity is elicited by this 
route. However, for certain vaccine adjuvant, like dmLT, combinations there is evidence 
that ID vaccination may also have the potential of inducing mucosal immunity [69-72]. New 
approaches, such as biodegradable or coated microneedles, hold promise for dermal delivery 
since they also may contribute to the stability of the vaccine.
FIVE-YEAR VIEW
In the next five years, the phased withdrawal of OPV and inclusion of IPV into all global 
routine immunization programs will create a market for non-invasive delivery of polio vaccines, 
although it is not clear how large this market will be since IPV demand in the post-eradication 
era is uncertain. However, several new approaches for IPV delivery are underway. In addition, 
potentially safer OPV vaccines may be introduced to have a role during polio outbreaks.
Since more research groups have access to (Sabin) IPV via support from organizations, 
such as BMGF and/or (new) sIPV producers, more efforts to develop alternative administration 
methods for IPV are expected the coming years. This will result in an increase of preclinical 
studies evaluating use of new ways of delivery, which in five years may reach the clinical 
development phase.
Furthermore, it is expected that other novel approaches, such as heterogeneous prime-
boost schedules, e.g., priming with OPV and follow-up vaccinations with intramuscular or 
dermal administered IPV will get attention the coming years. IPV has been shown to boost 
mucosal immunity among recipients who have earlier received OPV [73,74]. Further clinical 
studies on heterogeneous prime-boost vaccination schedules, but also of other administration 
strategies, mucosal immunity will be more and better addressed by modern techniques [75]. 
Finally, the design of administration methods that have the potential to give improved 
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thermostability of the vaccine will evolve, such as solid dosage forms for sublingual delivery 
[59], dissolvable microneedle patches and biodegradable mini-implants (e.g., Bioneedles). 
These approaches would be favorable to reach remote areas in developing countries for 
which proper logistics are not available.
One of the main challenges for future introduction of newly administered IPV vaccines is 
the acceptance by the (final) stakeholders, which include (local) governments shaping their 
immunization programs, global vaccine procurement organizations like UNICEF, but also key 
opinion leaders, vaccine producers and vaccine recipients. To this extent, BMGF, PATH and 
WHO are working as part of the Global Vaccine Action Plan (GVAP) on a method to address 
total system cost-effectiveness [76]. A total system cost-effectiveness evaluation is a holistic 
evaluation of trade-offs between price and deliverability that potentially can guide target 
product profiles and incentive structures that are most representative of what countries 
need to efficiently achieve maximum immunization coverage [76]. For instance, this involves 
improved effectiveness of the vaccine for example by mucosal immunity, advantages of 
logistics without use a cold-chain, but also use of less trained health-care personal and the 
costs of the vaccine. These types of approaches may on the long term yield insights that for 
example a thermostable IPV delivered by sublingual patches may come out favorable for 





•  To date the potential of alternative IPV delivery has not been explored comprehensively. 
Emphasis is on dermal delivery and jet injection without the use of adjuvants.
•  IPV has been shown to boost mucosal immunity among recipients who have earlier 
received oral poliovirus vaccine (OPV), indicating that heterologous vaccination strategies 
hold promise including those with new(ly developed) delivery methods.
•  Ideally, the new generation of IPV vaccines after global OPV cessation, should induce 
mucosal immunity already after prime immunization in order to stop the transmission of 
polioviruses in high-risk areas.
•  Future (pre)clinical studies have to evaluate mucosal immunity more extensively. 
•  Costs for novel ways of IPV delivery have to be approached comprehensively in order to 
calculate cost-effectiveness and warrant the product cost price, which are required for 
market introduction.
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CHAPTER 2
The aim of the current study was to develop a dried inactivated polio vaccine 
(IPV) formulation with minimal loss during the drying process and improved 
stability when compared with the conventional liquid IPV. 
Extensive excipient screening was combined with the use of a Design of 
Experiment (DoE) approach in order to achieve optimal results with high 
probability. Although it was shown earlier that the lyophilization of a trivalent 
IPV while conserving its antigenicity is challenging, we were able to develop a 
formulation that showed minimal loss of potency during drying and subsequent 
storage at higher temperatures.
This study showed the potential of a highly stable and safe lyophilized polio 
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INTRODUCTION
Poliomyelitis is a highly infectious disease, which mainly affects young children. The 
disease, caused by any one of three serotypes of poliovirus (type 1, type 2 or type 3) has no 
specific treatment, but can be prevented through vaccination.
Currently, the live attenuated oral poliomyelitis vaccine (Sabin OPV) is the vaccine of 
choice to prevent polio outbreaks and stop transmission of wild polioviruses, especially in 
the remaining endemic countries. However, a major concern is the ability of OPV to revert to 
a form that can cause paralysis, so-called vaccine-associated paralytic poliomyelitis (VAPP). 
Permanent use of OPV would continue to generate circulating vaccine-derived polioviruses 
(cVDPVs) that will inevitably lead to new outbreaks [1]. Therefore, the new endgame strategy 
of the Global Polio Eradication Initiative (GPEI) includes the introduction of an inactivated 
polio vaccine (IPV) into all routine immunization programs followed by phased withdrawal 
of OPV [2]. In most of the high-income countries, IPV based on Salk strains is already the 
present preferred way to eliminate the risk of VAPP and cVDPVs. 
To achieve global polio eradication, an (improved) IPV must be efficacious, inexpensive, 
safe to manufacture, and easy to administer [3]. The feasibility of current IPV in developing 
countries is limited, because IPV is more expensive than OPV and is administered through 
injections only. In order to extent the availability of IPV, the World Health Organization (WHO) 
and the Institute for Translational Vaccinology (Intravacc) in the Netherlands have developed 
a non-commercial IPV for technology transfer to developing countries [4]. Because the 
containment of the wild-type Salk poliovirus during production might be an issue, especially 
in developing countries, the new vaccine will be based on the traditional Sabin OPV strains 
(sIPV). For reduction in costs, Intravacc is developing sIPV formulations that show dose 
sparing by using an adjuvant [5] and/or other immunization routes [6, 7].
Vaccine delivery encompasses both administration of the vaccine formulation to specific 
sites and delivery of the antigen to and activation of relevant cells of the immune system [8]. 
Since alternative delivery methods and improved vaccine formulations have the potential to 
make vaccine delivery easier and safer [9, 10], several alternative vaccine delivery methods 
are currently being developed. However, the focus in vaccine development has been on 
optimization of the immunological properties, while stability issues are minimally addressed. 
Most vaccines, IPV included, are insufficiently stable to allow them to be purified, transported 
and stored at unrefrigerated conditions [11, 12]. 
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One way to improve the storage stability of (s)IPV might be conversion into the dry state as 
is known to improve the stability of biopharmaceuticals [13]. An increased shelf life is not only 
of use for the final product for use within three months to two years, but also for stockpiling (1-
10 or more years of storage). Particularly after polio eradication, a stockpile of polio vaccines 
is required to anticipate the potential risk of new polio outbreaks caused by circulating VDPV 
(even after OPV cessation) [14, 15] or bioterrorism attacks. In order to achieve an optimal 
vaccine stockpile, various issues need to be considered. The shelf life is paramount, because 
a delayed expiration time will reduce the stockpile costs [16]. Moreover, storage of dried 
materials at ambient temperature, including concomitant costs (e.g., reformulation costs), is 
cost effective compared with storage options at low temperatures. In addition, the ability to 
develop solid antigen formulations is crucial for new vaccine delivery routes including dermal 
delivery by coated or dissolving microneedles, parenteral delivery by powders or dissolvable 
needles, and pulmonary delivery of powders [8]. Technologies for producing dried biologicals 
include vacuum drying, air-drying, coating, spray (freeze-)drying and foam-drying [17-19]. 
One of the oldest and commonly used techniques is freeze-drying, also called lyophilization. 
However, during the lyophilization process the proteinaceous vaccine is subjected to 
freezing and drying stress by which its activity can be lost. Therefore, cryoprotective and 
lyoprotective agents are required. Many compounds, such as sugars, polymers, amino acids 
and surfactants, have been shown to improve the stability of biopharmaceuticals during 
lyophilization and subsequent storage [20].  
Aim of the current study is to design IPV in the dry state with maintenance of the potency. 
A potency indicating parameter is D-antigenicity, which can be determined in ELISA using 
specific antibodies as stated in the European Pharmacopeia. Lyophilization of polio vaccines 
has been shown to be challenging since earlier studies failed to obtain a stable product 
with preservation of all three serotypes [21-23]. We describe the development of an IPV 
formulation by selecting excipients that i) minimize potency loss upon drying and subsequent 
reconstitution, and ii) increase the stability of IPV at elevated temperatures. Extensive excipient 
screening was combined with the use of a Design of Experiments (DoE) approach in order to 
achieve optimal results with high probability.
3




Trivalent IPV, containing the inactivated Mahoney strain for type 1, MEF for type 2 and 
Saukett for type 3, was obtained from the process development department of Intravacc 
(Bilthoven, The Netherlands). The ten times concentrated trivalent bulk used in this study was 
determined at a nominal concentration of 400-80-320 DU/mL by ELISA as described [24]. 
The excipients sucrose, D-sorbitol, D-trehalose dihydrate, mannitol, L-glutamic 
monosodium salt monohydrate (MSG), glycine, myo-inositol, magnesiumchloride 
hexahydrate, lithium chloride and ovalbumin were all purchased from Sigma (St. Louis, MO). 
Peptone (vegetable) and dextran (6 kDa, from Leuconostoc ssp) were from Fluka (Buchs, 
Switzerland) and sodium chloride was from Merck (Darmstadt, Germany). To prepare 10 mM 
McIlvaine buffer, 10 mM citric acid (Sigma-Aldrich, St. Louis, MO) was added to 10 mM 
disodium hydrogen phosphate dehydrate (Na2HPO4) (Fluka, Buchs, Switzerland) in a ratio of 
1:6 resulting in a pH-value of 7.0. All excipients used were of reagent quality or higher grade.
Methods
Dialysis
Unless otherwise indicated, the trivalent IPV bulk material was dialyzed against 10 mM 
McIlvaine buffer (pH 7.0) using a 10 kDa molecular weight cut-off, low-binding regenerated 
cellulose membrane dialysis cassette (Slide-A-Lyzer®, Pierce, Thermo Scientific, Rockford, 
IL) to replace the buffer components of the IPV bulk (M199 medium).
Formulations
All excipients were dissolved in McIlvaine buffer at a double concentration of the 
indicated end concentration. The dialyzed IPV was mixed 1:1 by volume with the formulation 
to be tested. Subsequently, 2 mL neutral glass injection vials (Müller + Müller, Holzminden, 
Germany) were filled with 0.2 mL of the IPV-excipient mixtures and half-closed with 13 mm 





The filled (0.2 mL/vial) and half-stopped vials were loaded into a pilot freeze dryer (freeze-
drying unit sublimator 2-3-3, Zirbus) at a shelf temperature of -50°C, or at a shelf of 4°C and 
subsequently frozen to  -50°C by reducing the shelf temperature at a rate of 1°C/min. These 
different processes will be denoted as fast and slow freezing, respectively. The vials were kept 
at a temperature of -50°C for two hours. For the primary drying phase, the shelf temperature 
was increased at a rate of 0.2°C/h to -45°C (while decreasing the chamber pressure to 0.045 
mbar) followed by drying for 3h. The secondary drying phase was performed by further 
increasing the shelf temperature at 0.02°C/min to 25°C while decreasing the chamber 
pressure to 0.01 mbar, followed by 24h drying at 25°C. At the end of the cycle, the vials were 
closed under vacuum, sealed with alu-caps and kept at 4°C until analysis. 
In literature, different vacuum drying processes are described [25-27]. The vacuum drying 
process used in current study was slightly adapted, due to the characteristics of IPV. Briefly, 
the vials were loaded at shelves of 15°C and kept at that temperature for 10 minutes. The 
chamber pressure was reduced to 1 mbar in different ramping steps of 15 minutes and 
starting at a 25 mbar chamber pressure. The temperature was decreased to -10°C for one 
hour at 0.05 mbar and for one hour at 0.03 mbar so that freezing of the formulations was 
prevented since product temperature was kept above the ice-nucleation temperature of the 
formulations. Subsequently, shelf temperature was increased at 0.05°C/min to 30°C. At the 
end of the cycle, the vials were closed under vacuum, sealed with alu-caps and kept at 4°C 
until analysis.
Design of Experiments (DoE)
The Design of Experiments models for D-antigen recoveries measured by ELISA were 
evaluated in Modde 9.1 software (Umetrics AB, Umea, Sweden) to establish the stability 
profiles of the lyophilized IPV. In a first pilot experiment, the effect of common used stabilizers, 
i.e., sucrose (0-20% w/v), trehalose (0-20% w/v), mannitol (0-10% w/v), dextran (0-10% w/v) 
and NaCl (0-63 mM), was determined using a D-optimal design containing of 22 different 
formulations and three replicates of the center point (supplemental data, table S1). For the 
screening of some excipients, a full factorial DoE was performed around sorbitol, MgCl2, 
monosodium glutamate (MSG) and mannitol, all within the concentration range from 0 to 
10% w/v. In this full factorial design 24 formulations were tested and three replicates of the 
center point (Table 2). For the optimization experiment a central composite circumscribed 
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(CCC) design was used around sorbitol (8 to 12% w/v), MgCl2 (5 to 12% w/v) and MSG (5 to 
12% w/v). The CCC design consisted of eight corner experiments, six axial experiments and 
three replicated center points (Table 3). The models were fitted using partial least squares 
(PLS) regression and subsequent optimized by deleting non-significant terms leading to a 
model with the best model performance parameters, i.e., goodness of fit (R2), goodness of 
prediction (Q2), model validity and reproducibility.
D-antigen ELISA 
A sandwich enzyme-linked immunosorbent assay (ELISA) was used to quantify D-antigen 
units (DU) of the lyophilized polio vaccine formulations as described by Ten Have et al. 
(2012) [28]. Briefly, microtiter plates were coated with serotype-specific bovine anti-polio 
serum (Bilthoven Biologicals, Bilthoven, The Netherlands). After washing dilutions of IPV-
formulations were added (in duplicate). After a 30 minutes incubation at 37°C under gentle 
shaking, plates were washed and a mixture of serotype-specific anti-poliovirus monoclonal 
antibody (mab 3-4-E4 (type 1), 3-14-4 (type 2), 1-12-9 (type 3); all from Intravacc, Bilthoven, 
The Netherlands) and HRP-labeled anti-mouse IgG (GE Healthcare, Buckinghamshire, UK) 
was added and incubated for 30 minutes at 37°C while shaking. Subsequently, plates were 
washed followed by addition of ELISA HighLight signal reagent (ZomerBloemen BV, Zeist, The 
Netherlands). Chemiluminescence was measured for 10-15 minutes by using a luminometer 
(Berthold Centro LB960). The signal at maximum intensity was used to calculate D-antigen 
content relative to the reference standard. Unless otherwise indicated, D-antigen recovery 
values were shown as normalized values for liquid formulations prior to lyophilization. 
Dynamic Light Scattering (DLS)
Particle size measurements were performed using a Zetasizer Nano-ZS system (Malvern 
Instruments, Malvern, UK). DLS measurements were done in triplicate with 0.5 mL liquid 
(undialyzed) IPV bulk at an operating temperature of 25ºC. Homogeneity of the size distribution 
was reflected in the polydispersity index (PdI), which ranges between 0.0 (fully homogeneous 
size distribution) and 1.0 (random size distribution).
Moisture content analysis
The water content was determined using a Karl Fischer coulometric titrimeter (Model CA-
06 Moisture meter, Mitsubishi). The samples were weighted, subsequently reconstituted in 
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the Karl-Fischer reagent, Hydrana Coulomat A (Fluka, Buchs, Switzerland), and injected into 
the titration vessel. Each vial was measured in triplicate. The empty vials were weighted and 
the water content was calculated based on the water content measured by the titrimeter, the 
weight of the lyophilized product in the vial, the reconstitution volume of the reagent, titration 
volume and the water content of the blank titration.
Differential Scanning Calorimetry (DSC)
The thermodynamic behavior of the formulations was determined by differential scanning 
calorimetry (DSC). Aluminum DSC pans were filled with the liquid formulations and subjected 
to a controlled temperature program in a differential scanning calorimeter (DSC Q100, TA 
Instruments). The samples were cooled to -70°C at a rate of 10°C/min, kept isothermal for 
2 min, and subsequent heated from 0°C to 20°C at a heating rate of 10°C/min. The sample 
chamber was purged with nitrogen gas (50 mL/min). The glass transition temperatures (Tg’) 
were determined as the midpoint of the discontinuities in the heat flow curves using thermal 
analysis software (Universal Analysis 2000, TA Instruments).
RESULTS & DISCUSSION
Common lyoprotectants
The first design of experiment approach was based on the most commonly used 
lyoprotectants, i.e., sucrose, trehalose and mannitol, in combination with dextran, with 
and without NaCl (Table S1, supplemental data). These excipients are known to provide 
physical and biochemical stabilization as well as appropriate structural properties to the cake 
structure, during and after lyophilization [29-32]. 
A partial least squares (PLS) regression model was fitted and optimized per serotype, 
which resulted in valid models to predict the D-antigen recoveries directly after lyophilization 
according to the model performance parameters. For serotype 1, 2 and 3, the Q2 values were, 
respectively, 0.650, 0.592 and 0.671, while the R2 values were 0.905, 0.873 and 0.929. The 
effects of the different stabilizers, after optimization (excluding non-significant parameters) 
on the D-antigen recovery after lyophilization are presented in figure 1A. 
Without the addition of stabilizers, D-antigen recoveries of type 1, 2 and 3 after lyophilization 
were 9, 11 and 2%, respectively (Table S1, supplemental data). Both sucrose and mannitol 
are able to stabilize all serotypes to a certain extent during the lyophilization process (Figure 
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1A). Dextran has a negative effect on type 1 and 3 during the lyophilization process, whereas 
the addition of NaCl has no significant effect on the D-antigen recovery, independent of 
serotype (Figure 1A). Best results, with recoveries of approximately 55%, 85% and 50% for 
serotype 1, 2 and 3 respectively, were obtained with formulations containing sucrose and/
or trehalose in combination with mannitol (Figure 1B). Among the three serotypes, type 2 
was the least affected during lyophilization, resulting in a maximum recovery of 85% after 













































































Figure 1 Stabilizing potential of the excipients sucrose (SUC), trehalose (TRE), mannitol (MAN), dextran 
(DEX) and NaCl on D-antigen recovery directly after lyophilization. Main and interaction effects that 
contribute (per serotype) to the best model, according to the model performance parameters (Q2=0.650, 
R2=0.905 (type 1); Q2=0.592, R2=0.873 (type 2); Q2=0.671, R2=0.929 (type 3)), are depicted in coefficient 
plots (A). Surface response plots of the D-antigen recovery for each serotype based on formulations 
containing sucrose and trehalose in combination with 10% mannitol (without dextran or NaCl) (B).
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This first experiment illustrated the complexity of lyophilizing a trivalent polio vaccine 
retaining its antigenicity and displayed that each serotype may behave different within 
the same formulations. It has been reported earlier that lyophilization of polio vaccines is 
challenging. For example, Nagel et al. revealed that with the excipients sorbitol and peptone 
relative potencies of 70% for type 1 and 50% for type 2 could be obtained after lyophilization 
of IPV, while all activity of type 3 was destroyed [22]. In addition, Pollard et al. exhibited that 
lyophilization of the wild type poliovirus resulted in almost complete inactivation, although it 
was not determined whether D-antigenicity was also negatively affected [34].
Drying methods
Literature indicates that vacuum-drying, a drying process without a freezing step, can be 
used to stabilize IPV [35]. With the use of disaccharides sucrose and trehalose as stabilizing 
agents, it is feasible to obtain a dried (or highly viscous) polio vaccine by vacuum-drying 
without affecting its potency. As a result, we decided to investigate the impact of different 
drying processes on the integrity of IPV. Trehalose and sucrose based IPV formulations were 
vacuum dried and compared with the same formulations that underwent different lyophilization 
processes. One lyophilization process starting with a slow freezing step (cooling of shelves 
from 4°C to -50°C, at 1°C/min) and one with a fast freezing step (shelves pre-cooled to -50°C 
























type 1 type 2 type 3
negative control 10% sucrose 10% trehalose
Figure 2 D-antigen recovery of dried IPV using different drying methods, i.e., vacuum drying (V) or 
lyophilization with low (FD-low) or high freezing rate (FD-high). Common used stabilizing sugars sucrose 
(10% w/v) and trehalose (10% w/v) were compared with the formulation without additives (negative 
control). Mean values (n=3) and SD are shown.
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any additives, showed recoveries <15% for all serotypes after vacuum drying or lyophilization 
(Figure 2). The vacuum drying process yielded highly viscous IPV formulations with a water 
content of respectively 9% or 12% for the formulations containing sucrose or trehalose, 
whereas lyophilization yielded formulations with a water content of <1%. While more than 
55% of the antigen is intact after vacuum drying of IPV containing 10% trehalose, both 
lyophilization processes resulted in almost complete loss of D-antigenicity. These results 
depict both one of the main disadvantages of vacuum drying as well as the opportunity to dry 
without freezing stresses. The high moisture content is caused by the relatively low specific 
surface area during vacuum drying, which results in an extremely slow secondary drying 
when compared to lyophilization. As a result, the risk of sugar crystallization and/or phase 
Table 1 Formulations tested in an excipient screening experiment (S). D-antigen recoveries were 
determined directly after lyophilization. 
Sugars Polyols Amino acids Proteins Other D-antigen 
recovery (%)
T1 T2 T3
S0 - - - - - 12 17 2




7% ovalbumin - 66 89 73




7% ovalbumin 10 mM EDTA 66 81 77








- - 3% ovalbumin - 27 58 12


































S11 * - 5% sorbitol - 5% peptone 2% MgCl2 80 79 75
S12 * - 5% sorbitol - 5% peptone 1% LiCl 86 100 87
S13 5% sucrose
5% trehalose
- - 5% peptone - 29 62 26
* Formulation selected for stability testing (as shown in figure 3)
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separation in the rubbery state exists [13]. 
The poor recoveries depicted in figure 2 suggest that neither trehalose nor sucrose alone 
was able to protect IPV against both the freezing and drying stresses during lyophilization. 
Although the different freezing rates of the lyophilization processes did not show significant 
differences in D-antigenicity, particle size measurements after freeze thawing revealed 
differences in IPV particle size that were dependent on freezing rate. Slowly frozen IPV had a 
size of 44.7 ± 2.1 nm with a PdI of 0.485 ± 0.062, whereas fast frozen IPV remains at a particle 
size of 38.7 ± 1.1 nm with a PdI of 0.166 ± 0.009 (similar to IPV bulk prior to freeze thawing). 
Thus, IPV appeared to be most resistant to freeze thawing when a fast freezing rate was 
applied, which induced less aggregation than slow freezing. For that reason, a fast freezing 
step was selected for optimization of the IPV formulation for lyophilization.
Extensive excipient screening
In order to obtain an IPV formulation that is suitable for lyophilization we performed a 
more extensive excipient screening. The selection of excipients for the screening (Table 1) 
was based on findings from literature [20, 22, 36-40] and earlier unpublished data.
In general, the formulations containing sorbitol showed high recoveries directly after 
lyophilization. Especially formulations containing sorbitol, mannitol and monosodium 
glutamate (MSG) stabilized the IPV during the process of freezing and subsequent dehydration 
with D-antigen recoveries of >65% for all serotypes (Table 1; S1-S3, S6). Another notable 
formulation is the combination of sorbitol, peptone and the salts LiCl or MgCl2 (Table 1; 
S11 and S12) indicating that this combination of excipients is able to protect the IPV during 
lyophilization. The best formulations, which showed D-antigen recoveries of >60% directly 
after lyophilization for all serotypes, were selected and subsequently tested for stability 
(Figure 3). In general, the tested formulations so far showed disastrous recoveries after 
incubation at higher temperatures (Figure 3B-C) and even after incubation for a month at 
ambient temperature, a large drop in antigenicity was observed (Figure 3D).
The appropriate performance of sorbitol combined with mannitol and MSG indicates that 
the presence of polyols in combination with MSG stabilizes the IPV during lyophilization in 
a similar way as the disaccharides sucrose and/or trehalose (combined with mannitol) did 
as shown in the pilot study. In earlier lyophilization studies, sorbitol was used as excipient 
in combination with peptone [22], which showed again to be a valuable combination 
in this experiment, whether or not in the presence of a salt like MgCl2 or LiCl. Peptone-
3















































































Figure 3 D-antigen recoveries of the best formulations from the screening experiment based on 
recoveries directly after lyophilization (>60% for all serotypes). Panel A shows the D-antigen recoveries 
directly after lyophilization. Panel B, C and D show the recoveries after incubation for one week at 45°C, 




containing lyophilized IPV formulations, however, showed limited storage stability at elevated 
temperatures (Figure 3B-C). Furthermore, peptone is poorly defined and heterogeneous in 
composition; therefore, it was chosen to exclude peptone further in the formulation design. 
MgCl2’s stabilizing potential has been described for fluid oral polio vaccine. As a result, a 
number of manufacturers use MgCl2 to stabilize their OPV (39). Thus, MgCl2 could also be a 
critical additive in a dried IPV formulation.
 
Table 2 Excipients sorbitol, magnesium chloride (MgCl2), monosodium glutamate (MSG) and mannitol 
(all 0-10% w/v) examined in a full factorial design (D). Glass transition temperature (Tg’) of the liquid 
formulation before lyophilization and residual moisture content (RMC) of the dried cake were determined.




D1 - - - - n.d. 0.2
D2 10% - - - -43.4 2.4
D3 - 10% - - n.d. 45.9
D4 10% 10% - - n.d. 20.6
D5 - - 10% - -47.0 7.4
D6 10% - 10% - -41.2 1.8
D7 - 10% 10% - -58.6 4.0
D8 10% 10% 10% - -49.6 7.6
D9 - - - 10% -34.6 1.1
D10 10% - - 10% -40.5 0.3
D11 - 10% - 10% n.d. 16.1
D12 10% 10% - 10% -51.6 17.1
D13 - - 10% 10% -41.0 2.8
D14 10% - 10% 10% -39.7 2.3
D15 - 10% 10% 10% -51.2 8.2
D16 10% 10% 10% 10% -48.2 9.7
D17 5% 5% 5% 5% -48.1 5.8
D18 5% 5% 5% 5% -47.7 17.7
D19 5% 5% 5% 5% -47.7 9.7
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Design of experiments – full factorial design
Based on the results of our study so far, we selected the most promising excipients to 
screen them further using a DoE approach and get more insight in the IPV stabilizing potential 
of these additives. Therefore, a full factorial design was performed around the excipients 
sorbitol, MSG, MgCl2 and mannitol (all in the concentration range of 0-10% w/v) (Table 2). 
The mixture of sorbitol, mannitol and MSG has already shown its capacity to provide valuable 
protection during the lyophilization process. In addition, mannitol was selected as a common 
bulking agent due to its excellent cake-forming property and the option to apply annealing 
when needed [41, 42]. As mentioned above, MgCl2 is already a proven stabilizer for OPV and 
therefore we examined its contribution in a dried IPV formulation as well.
Figure 4A shows that sorbitol seemed to be an important excipient for the stabilization of 
both type 1 and 2 during lyophilization with recoveries up to 89% (Formulation D2 and D8). 





































Type 1 Type 2 Type 3
A
B
Figure 4 The stabilizing effect of sorbitol, magnesium chloride (MgCl2), monosodium glutamate (MSG) 
and mannitol was investigated in a screening experiment using a DOE approach. Mean D-antigen 
recoveries and standard deviations (n=3) directly after lyophilization (A) and after incubation for one 
week at 45°C (B) are shown. 
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sorbitol, as well as MgCl2 and MSG in the formulation (Figure 4A, formulation D8). Regression 
models (R2>0.65 and Q2>0.5) of these data confirm the findings that are described above. 
The stabilizing effects of the excipients on D-antigen recovery directly after lyophilization 
are depicted per serotype in coefficient plots after model optimization (Figure 5A). For all 
serotypes, there is a main effect of sorbitol, whereas MSG showed to be significant beneficial 
for the D-antigen recovery of type 1 and 3. However, sorbitol showed an interaction with 
mannitol that negatively affected IPV recovery after lyophilization, implying that the addition 




































































Figure 5 Stabilizing potential of the excipients sorbitol (SOR), MgCl2, monosodium glutamate (MSG) 
and mannitol (MAN) on the D-antigen recovery directly after lyophilization. Main and interaction effects 
that contribute (per serotype) to the best fitted model, according to their model performance parameters 
(Q2=0.685, R2=0.923 (type 1); Q2=0.577, R2=0.877 (type 2); Q2=0.575, R2=0.824 (type 3)) are shown 
in coefficient plots (A). Surface response plots of the D-antigen recovery for each serotype based on 
formulations containing MSG and MgCl2 in combination with 10% sorbitol (without mannitol) (B).
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testing revealed that MgCl2 and MSG are important stabilizers for all serotypes, indicated 
by significant main effects and interaction between these excipients. This means that the 
addition of MgCl2 or MSG (10% w/v) results in an increase of 7-13% in D-antigen recovery, 
while the combination of these excipients would boost the D-antigenicity with 6-10%. The 
inclusion of MgCl2 to the IPV formulation increases the residual water content (Table 2) after 
lyophilization significantly. This excipient is also responsible for reducing the glass transition 
temperatures (Tg’) of the formulation before drying. The sorbitol and MSG interaction factor 
is able to increase the Tg’ significantly (data not shown). As such, formulations might be 
optimized for Tg’ by increasing the sorbitol-MSG content in order to be capable to lyophilize 
at higher temperatures resulting in shorter process time.
Again, it was observed that there are some divergences between the serotypes regarding 
their preference for stabilizers during lyophilization, whereas all serotypes seemed to prefer the 
Table 3 Sorbitol (8-12% w/v), magnesium chloride (MgCl2: 5-12% w/v) and monosodium glutamate 
(MSG: 5-12% w/v) tested in a central composite circumscribed design. D-antigen recoveries were 







T1 T2 T3 T1 T2 T3
O1 8% 5% 5% 98.6 96.5 85.7 91.9 97.0 55.2
O2 12% 5% 5% 88.9 88.7 65.2 87.6 91.6 73.7
O3 8% 12% 5% 76.0 82.4 33.6 62.5 49.2 12.2
O4 12% 12% 5% 89.4 91.7 59.1 95.8 90.8 48.2
O5 8% 5% 12% 90.6 81.9 70.7 86.0 81.4 57.5
O6 12% 5% 12% 79.3 82.5 62.1 80.2 77.0 39.4
O7 8% 12% 12% 84.9 86.7 64.6 92.0 84.6 63.5
O8 12% 12% 12% 87.9 82.5 73.0 90.3 86.7 69.8
O9 6.6% 8.5% 8.5% 90.0 99.3 84.8 93.3 90.6 73.0
O10 13.4% 8.5% 8.5% 86.2 85.3 67.4 86.1 85.3 69.3
O11 10% 2.6% 8.5% 77.5 72.4 47.4 74.4 60.7 29.9
O12 10% 14.4% 8.5% 89.1 84.6 63.6 91.7 72.7 40.0
O13 10% 8.5% 2.6% 98.1 85.2 49.2 93.0 83.3 42.2
O14 10% 8.5% 14.4% 84.7 70.3 66.3 74.8 81.2 35.5
O15 10% 8.5% 8.5% 86.6 88.4 68.2 90.1 91.1 67.3
O16 10% 8.5% 8.5% 92.2 90.8 75.1 93.5 89.1 69.2
O17 10% 8.5% 8.5% 96.0 98.3 76.7 91.7 94.0 57.0
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presence of MSG and MgCl2 during stability testing. The surface response plots demonstrate 
that for type 1, the highest DU recoveries after lyophilization were found in a formulation 
containing 10% sorbitol in the presence of the highest amounts of MSG, regardless the 
MgCl2 concentration, whereas both additives have no significant effect on type 2 (Figure 5B). 
Though, type 3 showed to be most delicate for small differences in excipient concentrations 
with maximal D-antigen recoveries of more than 80% with a formulation containing 10% 
sorbitol, 5-10% MgCl2 and 4-8% MSG. 
Figure 6 Contour plots show the effect of MSG (5-12% w/v) and MgCl2 (5-12% w/v) in combination with 
8% (A), 10% (B) or 12% w/v sorbitol (C) on the D-antigen recovery after lyophilization and subsequent 
accelerated stability testing for serotype 3.
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Optimization
With the purpose to optimize the formulation, a response surface methodology design 
was implemented. Hence, a central composite circumscribed (CCC) [43] study set-up with 
the factors sorbitol (8-12% w/v), MSG (8-12% w/v) and MgCl2 (5-10% w/v) was designed 
(Table 3) and D-antigen recovery was determined directly after lyophilization. An extensive 
stability study was included here as well to test whether the dried IPV formulation has an 
improved stability when compared with the conventional liquid IPV. 
Within the design of the study, all formulations resulted in comparable recoveries after 
lyophilization and subsequent storage (Table 3). This indicates the formulation robustness 
of the formulation based on sorbitol (8-12% w/v), MSG (8-12% w/v) and MgCl2 (5-10% 
w/v). Due to these small differences in D-antigen recovery after lyophilization and stability 
assessment between the tested formulations, it was not possible to obtain a valid model to 
describe the data. With all formulations, satisfying stabilization was achieved for serotypes 
1 and 2, which showed recoveries of between 75% and 100% directly after lyophilization 
and only a small loss (0% to maximal 15%) during accelerated stability testing (Table 3). As 
mentioned above, type 3 showed to be the determining aspect in the decision for the final 
concentrations of the three excipients in our IPV formulation. Therefore, we decided to focus 
on the stability data of this serotype. PLS regression describes the accelerated stability data 
(one-week incubation at 45°C) well with high values for model validity and reproducibility 
(respectively 0.67 and 0.86). However, the predicting power of the model is limited (Q2 = 
0.43 instead of Q2 >0.5). Despite this limitation, we requested the contour plots (Figure 6) to 
get an indication of the important parameters to stabilize serotype 3. It seems that the best 
D-antigen recoveries (>70%) were obtained with the lowest sorbitol (8% w/v) concentration 
in combination with the highest concentrations of both MgCl2 and MSG (>10% w/v) or the 
highest sorbitol (12% w/v) content combined with relatively low amounts of MgCl2 and MSG 
(<8% w/v) (Figure 6).
This experiment showed the robustness of the formulation since many formulations 
containing sorbitol, MgCl2 and MSG in the tested concentrations showed high recoveries 
directly after lyophilization and preserved antigenicity during accelerated stability. Based on 
excellent D-antigen recoveries after lyophilization and subsequent stability testing (Table 3), 
the formulation containing 10% (w/v) sorbitol, 8.5% (w/v) MgCl2 and 8.5% (w/v) MSG was 
selected for additional extensive stability testing up to 24 weeks at 25°C and 37°C, and up to 
one month at 45°C. Both the conventional liquid IPV and lyophilized IPV formulation remain 
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stable during long-term incubation at ambient temperature (Figure 7A). However, at elevated 
temperatures, the lyophilized IPV formulation revealed its improved stability profile. Despite 
its relatively high residual moisture content, which was determined at 4.5 ± 0.9%, minimal 
loss was observed for the dried IPV after storage at temperatures above room temperature 
where the liquid IPV has lost its antigenicity completely (Figure 7B and 7C).
The current study shows the feasibility to convert IPV into the dry state using lyophilization. 
The focus here was on development and optimization of a dried IPV formulation. However, 
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Figure 7 Stability testing of a lyophilized trivalent IPV formulation containing 10% (w/v) sorbitol, 8.5% 
(w/v) MgCl2 and 8.5% (w/v) MSG at 25°C (A), 37°C (B) or up to 4 weeks at 45°C (C). The freezedried 
formulation (FD IPV, pink lines) was compared with the conventional liquid IPV (L IPV, blue lines) and 
a liquid IPV dialyzed against McIlvaine buffer (L dIPV, grey lines), which is the buffer of choice during 
lyophilization.
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the lyophilization process needs optimization as well, since the RMC of our lyophilized IPV 
formulation exceeds the limit of 3% water content from the European Pharmacopoeia. This 
high residual water content is probably due to the presence of MgCl2, a hexahydrate with 
strongly bound water, in the IPV formulation. The duration of the secondary drying step 
dictates the residual moisture level in a lyophilized product [20], so probably prolongation of 
this drying step and raising the end temperature of the lyophilization process could decrease 
the RMC and thus could possibly improve the final product.
 
CONCLUSION
The aim of the study was to develop a dried IPV formulation with minimal loss during the 
drying process and improved stability when compared with the conventional liquid IPV, which 
could allow distribution and storage under unrefrigerated conditions. Extensive screening 
of a large number of excipients combined with a DoE approach yielded a lyophilized IPV 
formulation with remaining antigenicity for all serotypes when kept at ambient or even higher 
temperatures. 
Although further improvement and research is still possible, this study showed the 
potential of a highly stable and safe lyophilized polio vaccine, which could be distributed in 
developing countries without the need of a cold-chain transport.
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Table S1   Commonly used excipients tested using a design of experiments approach. D-antigen 
recoveries were determined per serotype by ELISA directly after lyophilization. 
Sucrose Trehalose Mannitol Dextran NaCl (mM)
D-antigen recovery (%)
T1 T2 T3
P1 - - - - - 8.5 11.3 1.8
P2 20% 20% - - - 30.3 58.0 22.5
P3 20% - 10% - - 45.3 68.3 46.4
P4 - 20% 10% - - 44.4 68.5 40.5
P5 * 11.4% 11.4% 5.7% 5.7% - 30.5 51.1 29.9
P6 - - 6.7% 10% - 25.9 54.1 8.9
P7 - 6.7% 10% 10% - 31.6 62.2 16.3
P8 * 13.3% 13.3% 2.2% 6.7% - 33.9 57.8 25.9
P9 6.7% - 10% 10% - 34.9 58.1 27.5
P10 10% 10% - 5% - 22.2 45.0 8.2
P11 10% 10% 5% - - 35.5 62.7 34.9
P12 20% - - - 63 32.8 59.3 33.3
P13 - 20% - - 63 21.7 47.6 7.1
P14 - - 10% - 63 39.8 57.9 44.2
P15 - - - 10% 63 8.2 15.1 4.0
P16 10% - 5% 5% 31.5 31.9 56.7 31.5
P17 10% 10% 5% 5% 63 29.2 49.6 25.2
P18 16% 16% 8% - 50 42.3 64.6 42.0
P19 * 13.3% 13.3% - 6.7% 41.7 22.7 43.7 9.9
P20 * 11.4% - 5.7% 5.7% 35.7 33.1 56.3 32.9
P21 - 16% 8% 8% 50 25.9 49.1 16.2
P22 * 13.3% 6.7% 3.3% 3.3% 41.7 29.2 52.2 27.2
P23 10% 10% 5% 5% 31.5 29.2 49.6 25.2
P24 10% 10% 5% 5% 31.5 30.3 52.8 27.2
P25 10% 10% 5% 5% 31.5 34.0 58.1 28.1
 
* Concentrations differ from design due to maximal solubility of the formulation.
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CHAPTER 2
A hexavalent vaccine containing diphtheria toxoid, tetanus toxoid, whole cell 
pertussis, Haemophilius influenza type B, hepatitis B and inactivated polio 
vaccine (IPV) may: i) increase the efficiency of vaccination campaigns, ii) reduce 
the number of injections thereby reducing needle-stick injuries, and iii) ensure 
better protection against pertussis as compared to vaccines containing acellular 
pertussis antigens. An approach to obtain a hexavalent vaccine might be 
reconstituting lyophilized polio vaccine (IPV-LYO) with liquid pentavalent vaccine 
just before intramuscular delivery. The potential limitations of this approach were 
investigated including thermostability of IPV as measured by D-antigen ELISA 
and rat potency, the compatibility of fluid and lyophilized IPV in combination with 
thimerosal and thimerosal containing hexavalent vaccine.
The rat potency of polio type 3 in IPV-LYO was 2 to 3-fold lower than standardized 
on the D-antigen content, suggesting an alteration of the polio type 3 D-antigen 
particle by lyophilization. Type 1 and 2 had unaffected antigenicity/immunogenicity 
ratios. Alteration of type 3 D-antigen could be detected by showing reduced 
thermostability at 45°C compared to type 3 in non-lyophilized liquid controls. 
Reconstituting IPV-LYO in the presence of thimerosal (TM) resulted in a fast 
temperature dependent loss of polio type 1-3 D-antigen. The presence of 0.005% 
TM reduced the D-antigen content by ~20% (polio type 2/3) and ~60% (polio 
type 1) in 6 hours at 25°C, which are WHO open vial policy conditions. At 37°C, 
D-antigen was diminished even faster, suggesting that very fast, i.e., immediately 
after preparation, intramuscular delivery of the conceived hexavalent vaccine 
would not be a feasible option. Use of the TM-scavenger, L-cysteine, to bind 
TM (or mercury containing TM degradation products), resulted in a hexavalent 





LYOPHILIZED IPV COMBINED WITH PENTAVALENT VACCINE
73
INTRODUCTION
Combination vaccines are very successful, especially for delivery in children. The 
inclusion of multiple vaccine antigens in a single formulation reduces the number of 
injections, facilitates inclusion of new vaccines and increases coverage of routine pediatric 
immunization programs. For example, the use of pentavalent vaccine combining diphtheria-
tetanus-pertussis (DTP), Haemophilus influenzae type B (Hib) and hepatitis B (HBV) antigens 
has raised the coverage of Hib and hepatitis B in the poorest developing (Gavi-supported) 
countries [1].
One of the challenges for an IPV-containing hexavalent vaccine is the presence of the 
preservative thimerosal (TM). TM negatively affects the antigenicity and immunogenicity of 
IPV [2] and is used in the production process of whole cell pertussis (wP) vaccine as an 
inactivating agent as well as a preservative [3]. Hence, pentavalent vaccine contains trace 
amounts of TM (<0.01 % (w/v)).
Currently, the globally marketed IPV-containing hexavalent pediatric combination 
vaccines (Infanrix Hexa® (GSK) and Hexaxim® (Sanofi Pasteur)) contain an acellular pertussis 
(aP) component, which is devoid of TM. The use of wP in hexavalent vaccines intended for 
developing countries is important because of the lower costs and emerging doubts about the 
long-term effectiveness of aP vaccines. Unfortunately, no hexavalent combinations with wP 
(without TM) are licensed or in late-stage development [1]. 
The aim of this study is to investigate whether IPV-LYO, as previously developed [4], could 
be used in combination with a wP-containing pentavalent vaccine to generate a concept 
hexavalent vaccine, for example, for use in developing countries. By reconstituting IPV-LYO 
with pentavalent vaccine no substantial change in total volume is anticipated, likely the same 
injection volume for IM-injection may be used. This study addresses the (thermo)stability of 
IPV-LYO with respect to both D-antigenicity and immunogenicity (rat potency) and shows 





The IPV used in this study is a ten times concentrated trivalent bulk containing the 
inactivated Mahoney (type 1), MEF (type 2) and Saukett (type 3) strains at a nominal D-antigen 
content (expressed in D-units, DU) of 400-80-320 DU/mL (for types 1, 2 and 3, respectively) 
and produced under cGMP conditions according to a routine production process [5]. The 
pentavalent vaccine, Diphtheria, Tetanus, (whole cell) Pertussis, Hepatitis B and Heamophilus 
influenza type b Conjugate Vaccine Adsorbed, was a gift from Serum Institute of India (SII).  
D-Sorbitol, magnesium chloride hexahydrate (MgCl2.6H20) and monosodium glutamate 
monohydrate were from Sigma-Aldrich (St. Louis, MO). Citric acid (Sigma-Aldrich, St. Louis, 
MO) and disodium hydrogen phosphate (Fluka, Buchs, Switzerland) were used to prepare 
McIlvaine buffer. Thimerosal (TM) and L-cysteine were from Sigma-Aldrich (St. Louis, MO). 
All excipients used were of reagent quality or of a higher grade.
Methods
Formulating IPV
Unless indicated otherwise, the trivalent IPV bulk material was dialyzed against 10 mM 
McIlvaine buffer (pH 7.0) using a low-binding regenerated cellulose membrane dialysis 
cassette (Mw cut-off = 10 kDa). The dialyzed IPV was diluted 1:1 with formulation buffer 
containing: D-sorbitol (20% w/v), MgCl2.6H20 (17% w/v), and monosodium glutamate 
monohydrate (17% w/v) in McIlvaine buffer (10 mM, pH 7.0). This formulated IPV was used 
for the preparation of IPV-LYO. Liquid IPV was prepared by 1:1 dilution of (not dialyzed) 
trivalent IPV with ultrapure water. This material was used as a control in experiments.
Lyophilization 
Injection vials (3 mL, Aluglas BV, Uithoorn, The Netherlands) were filled with 0.2 mL of the 
formulated IPV and half-stoppered with pre-dried (overnight at 105°C) 13 mm lyophilization 
stoppers (PH21/50 from Aluglas BV, Uithoorn, The Netherlands). Vials were loaded on 
precooled shelves (-50°C) and the solidified material was subsequently lyophilized. Primary 
drying was done at 0.045 mbar and -45°C for 26 hours. Secondary drying was done at a 
pressure of 0.01 mbar and shelf temperature that increased from -45°C to 25°C in 13.3 hours. 
Thereafter, both shelf temperature (25°C) and pressure (0.01 mbar) were kept constant for 24 
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hours. After lyophilization, vials were closed under vacuum, sealed with alu-caps and stored 
for stability testing.
Stability testing
For stability studies, liquid IPV (0.2 mL in stoppered and capped 3 mL injection vials) and 
IPV-LYO (in stoppered and capped 3 mL vials) were incubated at 2-8, 25, 37, and 45 °C. After 
various periods of time, vials were taken for analysis. 
Effect of thimerosal
The effect of thimerosal (TM) on liquid IPV was studied by diluting trivalent IPV 10-fold 
with a solution of TM in ultrapure water. IPV-LYO was reconstituted either with ultrapure water 
(0.5 mL), 0.5 mL TM solution, or 0.5 mL pentavalent SII-vaccine containing 0.005% (w/v) TM. 
Final TM concentrations were 0.005 and 0.01% (w/v).
The possible neutralizing effect of L-cysteine on TM was investigated by pre-incubating 
pentavalent vaccine for one hour with 0.05% (w/v) L-cysteine or ultrapure water as negative 
control. Subsequently, IPV-LYO was reconstituted with the pre-incubated pentavalent 
vaccines or with ultrapure water as a control. D-antigen recoveries were determined directly 
after mixing or after subsequent storage at 37°C for 24h.
Analysis
D-antigen ELISA
The D-antigen ELISA was performed as described elsewhere [6]. Microtiter plates were 
coated with serotype-specific bovine anti-polio serum (Bilthoven Biologicals, Bilthoven, 
The Netherlands). After washing, dilutions of IPV (reconstituted IPV-LYO or liquid) were 
added. After an incubation period of 30 minutes at 37°C under gentle shaking, plates were 
washed. Subsequently, a mixture of serotype-specific anti-poliovirus monoclonal antibody 
(3-4E4, 3-14-4 and 1-12-9 for type 1, 2 and 3, respectively) and HRP-labeled anti-mouse 
IgG (GE Healthcare, Buckinghamshire, UK) was added and plates were incubated for 30 
min. at 37°C while shaking. Subsequently, plates were washed followed by addition of ELISA 
HighLight signal reagent (ZomerBloemen BV, Zeist, The Netherlands). Chemiluminescence 
was measured for 10-15 min by using a luminometer (Berthold Centro LB960). The signal 





Antigenicity was also measured using a Biacore T200 (GE Healthcare, Hoevelaken, The 
Netherlands), equipped with an anti-polio biosensor as described elsewhere [7]. Goat anti-
mouse IgG Fc-specific (Thermo Fisher Scientific Inc, Waltham, MA), antibodies were covalently 
immobilized on the dextran layer of a CM3 sensorchip (GE Healthcare, Hoevelaken, The 
Netherlands) by primary amine coupling, following the manufacturers recommendations (GE 
Healthcare, Hoevelaken, The Netherlands). Serotype-specific monoclonal antibodies (3-4E4 
(antigenic site 1, type 1), 3-14-4 (antigenic site 1, type 2), HYB300-06 (antigenic site 1, type 
3) and 1-12-9 (antigenic site 2/3/4, type 3) were bound to the sensor, followed by IPV. The 
sensor chip was regenerated with 10 mM glycine-HCl (pH 1.5). Assay data were analyzed 
by four-parameter curve fitting using the Biacore T200 evaluation software. Antigenicity was 
calculated relative to the international reference PU91-01.
Rat potency 
Immunogenicity of IPV-LYO was measured in the rat potency test performed as described 
earlier [7] with the exception that the highest dilution of the vaccine was not included. Animal 
experiments were conducted in accordance with the guidelines provided by the Dutch 
Animal Protection Act, and were approved by the Committee for Animal Experimentation 
of Intravacc. RIVM-TOX rats were immunized with four threefold dilutions of reconstituted 
IPV-LYO, the liquid IPV control, and the reference vaccine (PU91-01). After three weeks, sera 
were collected and neutralizing antibodies against all three poliovirus types were measured 
separately by inoculating Vero cells with 100 TCID50 of the wild-type strains (Mahoney, 
MEF-1 and Saukett) as described previously [8]. Two-fold serial serum dilutions were made 
and serum/virus mixtures were incubated for three hours at 36°C and 5% CO2 followed 
by overnight incubation at 5°C. Subsequently, Vero cells were added and after 7 days of 
incubation at 36°C and 5% CO2 the plates were stained and fixed with crystal violet and 
the results were read macroscopically. Virus-neutralizing (VN) titers were expressed as 
the last serum dilution that has an intact monolayer (no signs of cytopathogenic effect). 
Immunogenicity was expressed in two ways: A) as the relative potency to the reference 
vaccine using the parallel-line model, and B) as the average virus-neutralizing antibody 
endpoint titer at the second (1/15 dilution) or third (1/45 dilution) highest vaccine dose.
Moisture content analysis
Residual moisture content was determined using a Karl Fischer Coulometer C30 (Mettler-
Toledo, Tiel, The Netherlands) according to the literature [4]. Samples were weighed, 
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reconstituted in Hydranal Coulomat A (Fluka, Buchs, Switzerland), and injected into the 
titration vessel. The empty vials were weighed and water content was calculated based on the 
measured water content, the weight of the lyophilized product in the vial, the reconstitution 
volume of the reagent, the titration volume, and the water content of the blank titration. 
Statistical analysis
For comparative analysis of immunogenicity, data were tested by one-way analysis of 
variance (ANOVA) followed by a Bonferonni test for multiple comparisons. Probability (p) 
values <0.05 were considered significant. All statistical analyses were performed using 
GraphPad Prism version 6.0 (GraphPad Software Inc., La Jolla, CA).
RESULTS
Immunogenicity of IPV-LYO 
Two batches of IPV-LYO were prepared, characterized and used for further experiments. 
The D-antigen composition, D-antigen recovery, and RMC (Table 1), and thermostability 
(data not shown) of both batches were comparable. Immediately after lyophilization, the rat 
potency of IPV-LYO was 0.88, 1.17 and 0.39, respectively for polio type 1, 2 and 3. The rat 
potency of type 3 was lower than anticipated as based on: A) the D-antigen concentration, 
and B) historical data of polio containing vaccines (data not shown). Virus-neutralizing (VN) 
titers of polio type 3 were significantly lower in rats immunized with IPV-LYO if compared to 
liquid IPV (Figure 1A). This unanticipated result was confirmed with an independent IPV-LYO 
preparation and throughout subsequent experiments (see paragraph Stability of IPV-LYO).
Table 1 Characterization of two IPV-LYO batches that were used for further stability testing. D-antigen composition 
(DU/mL), D-antigen recovery and residual moisture content (RMC) of both batches were determined. Mean values and 
SD are shown (n=3). Rat potency of batch 2 was determined as well. Relative rat potency values and lower and upper 
limits (95% confidence intervals (CI)) are shown.
IPV-LYO RMC (%) Type 1 Type 2 Type 3
Batch 1 8.9 ± 0.4
Composition (DU/mL) - 180 ± 16 37 ± 5 138 ± 5
D-antigen recovery (%) - 83 ± 7  78 ± 10 75 ± 3
Batch 2 8.0 ± 0.3
Composition (DU/mL) - 155 ± 2 34 ± 2 126 ± 4











In an earlier study it was demonstrated that disruption of antigenic site 1 diminished the 
rat potency of polio type 3 [9]. However, Biosensor analysis showed that antigenic site 1 
remained intact after freeze-drying, as observed D-antigen concentrations were 130 ± 5 DU/
mL (IPV-LYO) and 137 ± 1 DU/mL (liquid IPV). 
Stability of IPV-LYO
Accelerated stability testing for two weeks at 45°C, showed significantly higher VN-titers 
for all three serotypes in IPV-LYO when compared to liquid IPV (Figure 1B), the low average 
VN-titer of type 3 in IPV-LYO was retained, whereas it was completely nullified in liquid IPV.
In general, at temperatures of 37°C and 45°C, the recovery of type 1-3 D-antigen was 
lower in liquid IPV than in IPV-LYO (Figure 2). After four weeks storage at 25°C, the rat 
potency of liquid IPV was approximately 1 for all serotypes, whereas significantly lower 
potency values were observed after short-term storage at 37°C or 45°C (Figure 2A). In 
contrast, IPV-LYO maintained its potency after short-term storage at 25-45°C. Even after 
storage for up to 6 months at 2-8°C or 25°C, no further decrease in potency was observed 
in case of IPV-LYO (Figure 2B). During 6 months of storage at 37°C, liquid IPV showed no 
measurable D-antigen recovery and the rat potency was almost completely lost, whereas 
IPV-LYO still showed D-antigen recoveries of 39±4%, 122±11% and 73±4%, respectively for 










































































Figure 1 Mean virus-neutralizing (VN) titers of serum from rats (n=10) immunized with 1/45 human dose 
(panel A) or 1/15 human dose (panel B) of liquid IPV (L IPV, in black) or IPV-LYO (in red) directly after 
preparation or after subsequent two weeks storage at 45°C. Individual VN titers specific for serotype 1 
(circles), 2 (triangles) and 3 (diamonds) were shown. Mean values were depicted as horizontal line and 
error bars showed 95% confidence interval (CI) values. Asterisks indicate significant differences between 
groups (*p<0.01, **p<0.001, ***p<0.0001).
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rat potency of polio type 3 in IPV-LYO was consistently 2 to 3-fold lower than anticipated as 
based on the recovered D-antigen percentage (Figure 2A and B).








































































































































































Figure 2 Rat potency of liquid IPV (L IPV) and IPV-LYO after incubation for a short period of time; 2 
weeks at 45°C or one month at 25°C or 37°C (panel A), or long period of time (6 months at 4°C, 25°C or 
37°C) (panel B). The rat potency is calculated based on a theoretical composition of 40, 8, 32 D-antigen 
for type 1, 2, and 3, respectively.  
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CHAPTER 4
Thermostability of polio type 3 in reconstituted IPV-LYO 
To examine whether IPV-LYO (type 3) after reconstitution was more vulnerable to higher 
temperatures than liquid IPV, a thermostability experiment was performed using reconstituted 



































































Figure 3 Stability of reconstituted IPV-LYO. Liquid IPV (L IPV, black bars), formulated (liquid) IPV prior 
to lyophilization (L IPV:form, striped bars), and reconstituted IPV-LYO (red bars) were incubated for 24 
hours at 4°C, 37°C or 45°C. Subsequently, D-antigen recoveries were determined by ELISA, specific for 
type 1 (panel A), type 2 (panel B) and type 3 (panel C), and normalized for D-antigen recoveries directly 
after lyophilization. Mean values (n=3) and SD are shown.
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An incubation period of 24 hours at either 4°C or 37°C did not result in a difference 
between the samples (Figure 3A-C). However, at 45°C the D-antigen recovery of liquid IPV 
was clearly lower than the formulated liquid IPV, and reconstituted IPV-LYO. From figure 3C it 
is clear that freeze-drying and resuspension rendered a type 3 particle characterized by less 
thermoresistance (recovery 33%) than its formulated counterpart (recovery 71%). Such a 
difference was not observed in case of polio serotype 1 and 2 (Figure 3A and B). From these 
findings it is hypothesized that the type 3 particle was altered by the lyophilization process 
rendering type 3 with a lower thermostability and a lower specific immunogenicity. 
Effect of thimerosal containing pentavalent vaccine on IPV-
LYO
Reconstitution of IPV-LYO with pentavalent vaccine (0.005% thimerosal, TM) resulted in 
an evident negative trend in D-antigen recovery (Figure 4). The control, IPV-LYO reconstituted 
with ultrapure water, showed either no (in case of type 1 and 2) or a minimal loss (in case of 
type 3) in D-antigen recovery during incubation for 24 hours at 37°C.
The negative effect of TM on polio D-antigen was increased at a higher temperature in the 
range from 2-8°C to 37°C. After 6 hours at 25°C (relevant conditions for the WHO open vial 
policy), there was already a marked (and unacceptable) loss of ~20% in case of type 2 and 
3 and ~60% in case of type 1.
A similar drop in D-antigenicity was observed when incubating IPV-LYO with 0.005% TM 
solution (data not shown) indicating that the negative effect on D-antigen recovery of IPV-
LYO was most likely caused by the presence of TM. 
Effect of pentavalent vaccine on IPV-LYO after pre-
incubation with L-cysteine 
Low molecular weight thiols are well known for the ability to scavenge mercury and/or 
mercury containing compounds such as TM [10, 11]. Therefore, pentavalent vaccine was 
pre-incubated with the TM-scavenger L-cysteine and was used thereafter to reconstitute 
IPV-LYO. Figure 5A shows a small initial loss of the D-antigen recovery upon reconstituting 
IPV-LYO with pentavalent vaccine. This initial loss is absent in samples that are reconstituted 
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Figure 4 Effect of pentavalent vaccine on IPV-LYO. IPV-LYO was reconstituted with pentavalent vaccine 
(penta) containing 0.005% of thimerosal at temperatures of 2-8°C (closed circles, grey), 25°C (closed 
squares, blue) or 37°C (closed triangles, red) for up to 24 hours. Subsequently, D-antigen recoveries were 
determined by ELISA, specific for type 1 (panel A), type 2 (panel B) and type 3 (panel C). Mean values 
(n=3) and SD are shown.
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After 24 hours at 37°C there is almost no recoverable D-antigen in case pentavalent 
vaccine was used to reconstitute IPV-LYO (Figure 5B). However, when IPV-LYO was 
reconstituted with L-cysteine containing pentavalent vaccine, D-antigen could be clearly be 
recovered, values were 61±7%, 107±2% and 96±4% for type 1, 2 and 3, respectively. 
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Figure 5 Effect of cysteine on the stability of IPV-LYO mixed with pentavalent vaccine. IPV-LYO 
was mixed with pentavalent vaccine (penta) pre-incubated for one hour in the absence or presence 
of L-cysteine (cys). Subsequently, D-antigen recoveries directly after mixing (panel A) and after 24h 
incubation at 37°C (panel B) were determined by ELISA, specific for type 1 (black bars), type 2 (striped 
bars) and type 3 (red bars), and normalized for D-antigen recoveries of IPV-LYO prior to mixing and 




Detrimental effect of lyophilization on the rat potency of 
polio type 3
For release of inactivated polio vaccines two assays are available: an ELISA for determining 
the D-antigen concentration (antigenicity) and the rat potency test for determining the relative 
rat potency (immunogenicity). The European Pharmacopoeia (EP) allows to omit the rat 
potency test and to rely exclusively on the more accurate D-antigen ELISA. Hence, there 
should be a relationship between the in vitro and in vivo test, despite the considerable test 
variation in the rat potency test. Remarkably, in our study the in vitro test content was not 
predictable for the immunogenicity of IPV-LYO type 3 (contrary to the normal in vitro – in 
vivo relationship observed with type 1 and 2). The type 3 rat potency in IPV-LYO was 2 to 
3-fold lower than anticipated as based on the measured D-antigen concentration. Earlier 
studies reported significant lower virus-neutralizing titers against type 3 in rats immunized 
with lyophilized IPV formulated in dissolvable mini-implants (Bioneedles) [12] or weaker 
serological responses to IPV type 3 after microneedle patch vaccination of rhesus macaques 
compared to intramuscular injection [13]. 
The use of certain site-specific monoclonal antibodies in the ELISA is critical for the 
antigenicity-immunogenicity relation [14]. In the case of detection of polio serotype 3, it has 
been recommended to include measurement of antigenic site 1, because disruption of this 
site strongly diminishes the rat potency [14]. No evidence for antigenic site 1 disruption was 
observed in this study. However, by performing accelerated stability testing it was revealed that 
freeze-drying and reconstitution reduced the thermostability of polio type 3 and did not affect 
the thermostability of type 1 and 2. This observation suggested the existence of an altered 
type 3 particle formed by freeze-drying, which compared to the formulated control could be 
characterized by a reduced thermostability and a lower immunogenicity in rats. This altered 
type 3 particle was not characterized further, but might be an intermediate in the transition 
from D-antigen to C-antigen stabilized by excipients. Future formulation development and 
antigen characterization is required to address this. For example, in the development of dried 
IPV formulations, a proper D-antigen characterization after reconstitution and subsequent 
stress treatment (e.g., thermal stressing) might give a more reliable prediction of the potency 
of the dried IPV.
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Interestingly, improved thermostability was observed in formulated liquid IPV compared 
to conventional liquid IPV without extra excipients. This indicates that it is possible to stabilize 
the polio antigen in the liquid state by the addition of excipients.
Use of IPV-LYO in a hexavalent vaccine: overcoming the 
detrimental effect of thimerosal
The current study investigated the possible use of lyophilized IPV as a component 
for mixing with a pentavalent vaccine (DTwP-Hib-HBV) thereby forming a hexavalent 
mixture. These licensed pentavalent vaccines all contain traces of thimerosal (TM), an 
organomercury compound known for its antiseptic and antifungal properties. Unfortunately 
TM may also negatively affect the antigenicity and immunogenicity of IPV [2]. Within hours 
after reconstitution of IPV-LYO with pentavalent vaccine (containing 0.005% TM), a strong 
reduction in D-antigenicity was observed. The antigenicity decrease  was even more evident 
when the vaccine was kept at 37 °C showing that also immediate IM-delivery, after mixing 
IPV-LYO and pentavalent vaccine, is probably not a feasible option to mitigate the negative 
impact of TM on polio D-antigen, which is consistent with reported findings [2]. 
Pre-incubation of the TM-containing pentavalent vaccine with L-cysteine reduced the 
negative effect of TM on D-antigenicity of IPV-LYO after reconstitution with the pentavalent 
vaccine. The use of L-cysteine for neutralization of TM in a pentavalent vaccine has not 
been published before. However, the use of L-cysteine as a TM-scavenger is well-known 
[10, 11, 15]. The use of compounds, which compete with polio D-antigen for binding to TM 
or stabilize IPV, might offer a potential step towards a TM-resistant IPV formulation, which 
can be used as a component in a hexavalent vaccine. On the other hand, removing TM 
completely from the vaccine may be considered as well by, for example, reformulating wP 




This research demonstrated a clear difference in rat potency between IPV-LYO and 
liquid IPV serotype 3. The reduced thermostability of type 3 in IPV-LYO after reconstitution 
suggested the formation of an altered particle, presumably an D-antigen-intermediate 
between D-antigen and C-antigen, during the lyophilization process. 
Use of IPV-LYO as a component in a hexavalent vaccine by mixing with licensed 
pentavalent vaccine (DTwP-Hib-HBV) requires neutralization of TM by for example L-cysteine. 
Improving the vaccine formulation by the inclusion of low molecular weight thiols, which have 
the ability to bind to TM, could offer a possible solution to neutralize the damaging effect of 
TM on the polio D-antigen. 
Further formulation development is needed, in which screening based on D-antigen 
thermostability is included, to improve the potency of IPV-LYO type 3.  
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CHAPTER 2
In the near future oral polio vaccine (OPV) will be replaced by inactivated polio 
vaccine (IPV) as part of the eradication program of polio. For that reason, there 
is a need for substantial amount of safe and more affordable IPV for low-income 
countries. Bioneedles, which are biodegradable mini-implants, have the potential 
to deliver vaccines outside the cold-chain and administer them without the 
use of needles and syringes. In the current study, Bioneedles were filled with 
IPV, subsequently lyophilized, and antigenic recoveries were determined both 
directly after IPV-Bioneedle preparation as well as after elevated stability testing. 
Further, we assessed the immunogenicity of IPV-filled Bioneedles in rats and the 
residence time at the site of administration.
Trivalent IPV was formulated in Bioneedles with recoveries of 101 ± 10%, 113 
± 18%, and 92 ± 15%, respectively for serotype 1, 2 and 3. IPV in Bioneedles 
is more resistant to elevated temperatures than liquid IPV: liquid IPV retained 
less than half of its antigenicity after one day at 45°C and IPV in Bioneedles 
showed remaining recoveries of 80 ± 10%, 85 ± 4% and 63 ± 4% for the three 
serotypes. In vivo imaging revealed that IPV administered via Bioneedles as well 
as subcutaneously injected liquid IPV showed a retention time of three days at 
the site of administration. Finally, an immunogenicity study showed that IPV-filled 
Bioneedles are able to induce virus neutralizing antibody titers similar to those 
obtained by liquid intramuscular injection when administered in a booster regime. 
The addition of LPS-derivate PagL in IPV-filled Bioneedles did not increase 
immunogenicity compared to IPV-Bioneedles without adjuvant. 
The current study demonstrates the preclinical proof of concept of IPV-filled 
Bioneedles as a syringe-free alternative delivery system. Further preclinical and 
clinical studies will be required to assess the feasibility whether IPV-Bioneedles 
show sufficient safety and efficacy, and may contribute to the efforts to eradicate 
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INTRODUCTION
Poliomyelitis is caused by any one of three serotypes of poliovirus (type 1, type 2 or 
type 3) that can be prevented through vaccination. Since the launch of the Global Polio 
Eradication Initiative (GPEI) in 1988, the global incidence of polio has reduced by more than 
99% and the number of countries with endemic polio has decreased from 125 to three. While 
the live attenuated oral polio vaccine (OPV) is currently the vaccine of choice in developing 
countries, it is associated with safety concerns, i.e., reversion of the vaccine virus to a form 
that causes paralysis and the risk of circulating vaccine-derived polioviruses (cVDPVs) [1]. 
Therefore, replacement of OPV by inactivated polio vaccine (IPV) is the new strategy striving 
towards global polio eradication. The cost increase is a main issue in replacing OPV with 
the more expensive IPV. In this context, adjuvants, like the lipopolysaccharide (LPS) derivate 
PagL, were shown to have dose-sparing capacity for IPV prepared from attenuated Sabin 
strains [2].
Alternative delivery technologies, via the skin [3, 4] or mucosal sites [5, 6] might further 
benefit the administration of IPV in the field if they are at least non-inferior in human. These 
delivery technologies can have advantages, such as easy and fast administration, minimizing/
eliminating the risk on needle-stick injuries or reuse of needles and/or minimal generation 
of waste [7, 8]. Among the alternative delivery technologies that might be used for IPV is 
the Bioneedle technology, which allows parenteral vaccine administration without the use of 
needle and syringe. Bioneedles are small hollow mini-implants from biodegradable polymers 
that can be filled with antigen followed by a lyophilization process. After subcutaneous 
delivery, the implant dissolves and thereby releases the antigen. Preclinical data with different 
antigens showed the feasibility of Bioneedles as vaccine delivery system [9-12]. A first 
phase 1 clinical study with solid Bioneedles (without antigen) revealed good tolerability [13]. 
Besides, if formulated properly, vaccines in Bioneedles are thermostable, which can diminish 
the dependence on the cold-chain [10-12]. 
Recently, we have developed a formulation that stabilizes IPV during lyophilization and 
subsequent storage at higher temperatures [14]. The aim of current study is to develop a 
syringe-free administered polio vaccine by using the Bioneedle technology. Therefore, 
Bioneedles containing lyophilized IPV were developed, thermostability was assessed 
by D-antigen ELISA, and the immunogenicity in rats was evaluated by determining virus 
neutralizing (VN) antibody titers. To investigate whether the immune response elicited by 
IPV-filled Bioneedles could be increased by using an adjuvant, a formulation containing the 
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LPS-derivate PagL was included in this study. As the kinetics at the site of administration 
of a dry, encapsulated vaccine may be different compared to fluid injection, we performed a 
real-time in vivo imaging study.
MATERIALS AND METHODS
Materials
The IPV used in this study is a ten times concentrated trivalent bulk at a nominal D-antigen 
content (expressed in D units, DU) of 400-80-320 DU/mL (for type 1, 2 and 3 respectively, 
Salk strains) and routinely produced by the Netherlands Vaccine Institute as described 
previously [15].
D-sorbitol, monosodium glutamate and magnesium chloride hexahydrate were from 
Sigma (St. Louis, MO). Citric acid (Sigma-Aldrich, St. Louis, MO) and Na2HPO4 (Fluka, Buchs, 
Switzerland) were used to prepare McIlvaine buffer. All excipients used were of reagent 
quality or higher grade. IRDye800CW® protein labeling kit used for the in vivo imaging study 
was obtained from LI-COR Biosciences (Lincoln, NE). The adjuvant PagL LPS is obtained 
through expression of the Bordetella bronchiseptica PagL gene in Neisseria meningitides 
LPS as described by Arenas et al. [16].
Methods
IPV Bioneedle production 
Trivalent IPV bulk was concentrated using 10 kDa Amicon Ultra centrifugal filters (Merck 
Millipore, Billerica, MA) and formulated with 8% (w/v) sorbitol, 5% (w/v) monosodium 
glutamate and 5% (w/v) magnesium chloride in McIlvaine buffer (10 mM, pH 7.0).  For the 
imaging experiment, IPV was labeled with fluorescent probe IRDye800 CW® according to 
the accompanying instructions. 
Empty Bioneedles (0.9 x 12 mm, made of extruded starch) were obtained from the 
Bioneedle Technologies Group and filled with 5 µL of the liquid IPV formulation (with or 
without adjuvant) using a specially designed filling apparatus and immediately frozen on 
a plate at -50°C. Subsequently, Bioneedles were loaded on a Zirbus freeze-drying unit 
sublimator 2-3-3 with pre-cooled shelves at -50°C. The lyophilization process was based on 
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a process used for IPV in vials [14]. In brief, primary drying was performed at -45°C (0.045 
mbar) and secondary drying by further increasing the shelf temperature to 25°C followed by 
a 24 h drying step at 25°C (0.01 mbar). The lyophilized Bioneedles were individually stored in 
vials, closed under vacuum and sealed with alu-caps.
D-antigen content of the Bioneedles directly after lyophilization and during stability testing 
at 45°C for four weeks and at 60°C for one week, was determined by a sandwich ELISA as 
described previously [17]. DU recovery was expressed relative to the liquid formulation prior 
to lyophilization.
In vivo fluorescence imaging
Animal experiments were conducted in accordance with the guidelines provided by the 
Dutch Animal Protection Act, and were approved by the Committee for Animal Experimentation 
of Intravacc. Female CD Hairless rats (Crl:CD-Prsshr8, Charles River, Sulzfeld, Germany) 
received IRDye800CW®-labeled trivalent IPV (40-8-32 DU per dose) via subcutaneous liquid 
injection (0.1 mL per dose) or Bioneedle administration using a sterilized trocar with mandrin as 
described previously (5 animals/group, unless other stated) [11]. Scans of animals, positioned 
in dorsal recumbence, were performed eight times during 72 h after immunization under 2% 
isofluran/O2 anesthesia using an IVIS Spectrum imaging system (PerkinElmer, Waltham, MA). 
The threshold was set using a background scan made prior to immunization. The imaging 
sequences were 760, 780, 800, 820 and 840 nm for emission and 710 nm as excitation. 
Spectral unmixing was performed to decompose the emitted light into autofluorescence and 
label-specific fluorescence. The data represent the quantity of the fluorophore at each pixel. 
Data was analyzed using the Living Imaging software 4.1 from PerkinElmer and GraphPad 
Prism 6.4 software. The relative fluorescence intensity (percentage of initial fluorescence) at 
the site of administration was calculated for each animal.
Immunization study
Outbred Wistar rats (HsdCpb:WU, Harlan Laboratories, The Netherlands) received 
trivalent IPV (2.7-0.6-2.1 DU/dose, 10 animals/group) with or without PagL LPS (1 µg/
dose). Liquid formulations were administered intramuscularly (i.m.) or subcutaneously 
(s.c.) by injection in the hind limb or neck between the ears, respectively, and Bioneedles 
were implanted as described above. All immunizations were performed under isofluran/O2 
anesthesia. Vaccinations were given on days 0 (prime) and 28 (boost), and sera collected 
prior to immunization on day 0, on day 21 and on day 35. On day 49, animals were sacrificed 
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under anesthesia by bleeding (heart puncture).
Serum polio-specific IgG and virus neutralizing (VN) antibodies against all three poliovirus 
serotypes were determined as described earlier [2]. Baseline VN titers reported are based on 
four animals receiving mock vaccine as negative control.
Statistical analysis
For comparative analysis of immunogenicity, data were tested by one-way analysis of 
variance (ANOVA) followed by a Tukey-Kramer test for multiple comparisons. Probability 
(p) values <0.05 were considered significant. All statistical analyses were performed using 
GraphPad Prism version 6.0 (GraphPad Software Inc., La Jolla, CA).
RESULTS
IPV-Bioneedle: process and product stability 
Bioneedles were filled with a trivalent IPV formulation containing excipients that are 
known to stabilize the antigen during lyophilization and subsequent storage. Directly after 
lyophilization, the D-antigen content was determined by dissolving Bioneedles, followed by 
a D-antigen ELISA. DU recoveries were 101 ± 10%, 113 ± 18% and 92 ± 15%, respectively 
for type 1, 2 and 3 (n=3).
Product stability was evaluated by incubating Bioneedles for up to one month at 45°C or 
one week at 60°C. Subsequently, DU recovery was determined and compared to the liquid 
IPV stored at the same conditions (Figure 1). Liquid IPV stored for 24h at 45°C showed 
recoveries of 10 ± 2%, 47 ± 0% and 18 ± 5% for type 1, 2 and 3, respectively, whereas the 
IPV Bioneedle maintained its D-antigen content at respectively 80 ± 10%, 85 ± 4% and 63 ± 
4% (Figure 1A). One-week storage of the liquid IPV formulation at 45°C resulted in complete 
loss of type 1 D-antigenicity and 80% loss of type 2 and 3. After four weeks also type 2 and 
3 were not detectable anymore. In contrast, Bioneedles showed about 60% type 1 recovery 
and complete type 2 recovery and about 50% type 3 recovery after one week 45°C.  After 
four weeks at 45°C DU recoveries were 27±10% for type 1, 64 ± 15% for type 2, and 18 ± 
13% for type 3. IPV Bioneedles containing the PagL adjuvant were also subjected to stability 
studies and showed DU recoveries that were comparable to those of IPV Bioneedles without 
PagL (data not shown). 
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At 60°C, the liquid formulation showed complete loss of D-antigenicity after 15 minutes, 
whereas no loss in DU recovery for type 1 was observed in IPV-filled Bioneedles and remaining 
recoveries of 73±6% for type 2 and 81 ± 5% for 3 were found (Figure 1B). Upon storage for 





























































































































































A BStability at 45°C Stability at 60°C
Figure 1 Thermostability of IPV Bioneedles. Liquid IPV formulations and IPV-filled Bioneedles were 
incubated at 45°C (A) and 60°C (B). Subsequently, for each serotype D-antigen content (D-antigen 
recovery) was determined by ELISA. Bars represent mean D-antigen recoveries ± SD (n=3) normalized 
for the D-antigen recovery directly after lyophilization.
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serotypes 1 and 3. After one week at 60°C, the Bioneedles did not contain any D-antigen 
anymore.
In order to test whether the formulations used in this study were able to resist real-life, 
unrefrigerated and thus varying conditions, liquid IPV and IPV-Bioneedles were taken on a 
three-week trip through Middle Eastern countries. Temperature was tracked during those 
weeks and DU content was determined afterwards (Figure 2B). The average temperature 
was determined at 26.0°C with a minimum of 17.0°C and a maximum of 46.5°C. During the 
trip, the IPV Bioneedles and liquid IPV were four times exposed to a temperature above 40°C 
(Figure 2A). For type 2 and 3, DU recoveries of 70-80% were found for both the liquid and 
Bioneedle formulations. However, whereas liquid IPV did not contain type 1 D-antigen, 100% 
DU recovery was observed in the IPV Bioneedle (Figure 2B).
Biodistribution study
To determine the kinetics of the antigen release from the Bioneedle and removal from the 
injection site, a real-time in vivo imaging study was performed over the course of time post 
inoculation. Within five hours after administration, the fluorescent signal from a Bioneedle 
filled with free IR-dye (not linked to IPV) decreased to background level (Figure 3B). Labeled 
IPV was removed from the injection site considerably slower than free dye irrespective of the 
administration method (injection or Bioneedle). Surprisingly, IPV in Bioneedles disappeared 
with the same kinetics as fluid injection. At 72 h post immunization, labeled IPV was not 
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Figure 2 Stability of IPV-Bioneedles outside the cold-chain. Liquid IPV formulations and IPV-filled 
Bioneedles were taken on a travel through Mideast Asia countries. Temperature was logged for three 
weeks (A) and, subsequently, D-antigen content (D-antigen recovery) was determined by ELISA (B). Bars 
represent mean D-antigen recoveries ± SD (n=3) normalized for the D-antigen recovery directly after 
lyophilization.
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Figure 3 Kinetics of the antigen at the site of administration following IPV immunization either via liquid 
injection or Bioneedle insertion. Whole-body fluorescence images of nude rats in dorsal recumbence 
at different time points post immunization by s.c. liquid injection with labeled IPV or Bioneedle (BN) 
insertion with either labeled IPV or free IR dye. Depicted animals were representative for the whole group 
(A). The relative fluorescence intensity at the site of administration was quantified (B). Data represent 
means ± SD from five animals (except for BN free dye group where only two animals were used).
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Figure 4 Mean virus neutralizing (VN) antibody titers in serum. Rats (n=10) received IPV in the absence 
(closed symbols) or presence of PagL LPS (open symbols) as adjuvant. Four animals received mock 
vaccine as negative control and are the source of the baseline VN titers. Immunizations were given via 
intramuscular (i.m.) or subcutaneous (s.c.) liquid injection or via subcutaneous Bioneedle insertion and 
the neutralizing capacity of serum antibodies was determined three weeks after prime (day 21, A-C) or 
three weeks after booster immunization (day 49, D-F). Asterisks indicate significant differences between 
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Immunization study
Wistar rats were immunized with IPV, delivered via either Bioneedles or liquid injection, in 
a prime-booster regime. Subsequently, immune responses elicited by IPV-filled Bioneedles 
were compared with those obtained via liquid injection. 
After prime immunization, rats that received i.m. liquid injection showed low VN titers 
and only two of them elicited a detectable response against type 1 (Figure 4A), whereas 
all animals showed a VN titer against type 2 following i.m. immunization with IPV (Figure 
4B). Rats receiving a prime immunization with an IPV-Bioneedle showed VN titers for type 1 
and 2 that were similar to those obtained with i.m. liquid injection using syringe and needle. 
Although prime immunization with an IPV-containing Bioneedle induced significant lower VN 
titers for type 3 compared to i.m. liquid injection (p<0.01), it induced similar VN type 3 titers 
compared to s.c. liquid injection (Figure 4C). In general, higher numbers of responders were 
observed in the groups immunized with IPV in the presence of PagL LPS (Figure 4A-C). 
These responses were only significantly higher after the boost immunization for type 1 and 2. 
VN titers in rats were comparable for all serotypes after booster immunization via either 
IPV-filled Bioneedles or i.m. IPV injection (Figure 4D-F). The route of administration had no 
effect on the induction of VN antibodies after booster immunization. The addition of PagL LPS 
showed significant improved VN titers for type 1 and 2 when administered via i.m. injection 
(Figure 4D-E). Serum IgG titers, which were determined by ELISA, showed similar results for 
all serotypes compared with the VN titers (data not shown). 
DISCUSSION AND CONCLUSIONS
The current proof of concept study demonstrated the potential of an alternative delivered 
IPV using the Bioneedle technology. Compared with liquid IPV, IPV formulated in Bioneedles 
showed improved thermostability and similar kinetics at the site of injection as well as 
comparable immunogenicity when administered in a booster regime. Whereas improved 
immunogenicity was generated by addition of PagL to liquid IPV, immune responses elicited 
by IPV-Bioneedles were not potentiated by PagL.
The lyophilization step needed during the production of vaccine-filled Bioneedles is 
an important characteristic of the Bioneedle technology that might make it an interesting 
vaccine delivery approach without dependence on the cold-chain [10-12]. However, 
lyophilization of polio vaccines while maintaining their functionality showed to be challenging 
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[18]. Excipients are required to protect the antigen against freezing and drying stresses that 
occur during the lyophilization process. For production of Bioneedles containing vaccine 
formulations in general, the disaccharide trehalose (5% w/v) was able to fully protect tetanus 
toxoid [10], hepatitis B surface antigen [11] and the influenza hemagglutinin antigen (HA) 
during lyophilization [12]. Nevertheless, even 10% (w/v) trehalose or sucrose was not enough 
to maintain the D-antigen content of IPV during the freezing and subsequent drying steps 
[14]. The formulation used in IPV-Bioneedles was inferred from an earlier study where a 
combination of sorbitol, monosodium glutamate (MSG) and magnesium chloride (MgCl2) was 
able to protect IPV during lyophilization and storage [14]. In order to obtain an appropriate 
viscosity for the use in Bioneedles, it was required to use the reported optimized formulation 
at lower amounts of the same excipients (8-5-5% instead of 10-8.5-8.5% sorbitol, MSG and 
MgCl2, respectively) [14]. This formulation yielded similar D-antigen recoveries as compared 
with the optimal formulation in vials as described in the lyophilization study [14]. 
At temperatures above 56°C, within minutes poliovirus and vaccine are converted to 
C-antigen [19], which are not able to induce VN antibodies [20]. Therefore, accelerated stability 
was determined above and below this threshold: 45°C and 60°C. The lyophilized formulation 
used in this study was slightly less stable when compared to the optimal formulation in vials, 
both in Bioneedles and vials [14]. In contrast, whereas the lyophilized IPV formulation in vials 
maintained type 1 antigenicity after a one-week incubation at 45°C [14], a significant loss 
in type 1 D-antigen was observed for the same formulation in Bioneedles. The optimized 
formulation in vials had a residual moisture content above 3%, the European Pharmacopoeia 
limit [14]. Unfortunately, we were not able to measure the water content in Bioneedles due 
to interference of the Bioneedle-material with the assay. Since this formulation was less 
stable than the optimized lyophilized IPV formulation (in vials), we expect a higher residual 
moisture content for lyophilized IPV in Bioneedles, potentially resulting in the observed 
decrease in thermostability when compared to lyophilized IPV in vials. Nevertheless, the 
lyophilized IPV formulated in Bioneedles was more thermostable than the liquid IPV for all 
serotypes. Optimization of the IPV-Bioneedle formulation and lyophilization process, e.g., 
by prolongation of the secondary drying step and thereby reducing the residual moisture 
content, could probably further increase the stability of IPV-filled Bioneedles.
Earlier, it was suggested that Bioneedles might induce a short-term ‘depot effect’ or 
alter the kinetics of antigen recognition and processing, which could explain the enhanced 
immunogenicity of Bioneedles for some antigens [10, 12]. Some vaccine delivery systems 
are able to prolong the localization period of the antigen at the site of injection, thereby 
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slowly releasing the antigens at the injection site for a period of up to more than one week 
[21]. An in vivo imaging study was performed using infrared-dye labeled IPV to investigate 
whether the residence time at and release from the administration site was different between 
IPV formulated in Bioneedles and subcutaneously injected liquid IPV. Both administration 
methods (Bioneedle and liquid injection) showed a comparable release from the injection site 
and a similar distribution pattern over time. Within a few days, the labeled IPV in Bioneedles 
completely disappeared from the site of administration showing comparable clearance as 
subcutaneously injected ovalbumin alone in mice [22]. This demonstrated that Bioneedles 
did not form a depot (at least for IPV and the formulation used) at the site of injection and 
supports the fact that in general the immunogenicity of Bioneedle formulated antigens 
seemed to be comparable to injected fluid vaccine, which is an advantage in the licensing 
process.
Immunogenicity of IPV Bioneedles was evaluated in rats measuring VN capacity of 
serum, which is a surrogate marker for protection [23]. A booster regime seemed to be 
essential for a proper immune response similar to that induced by IPV injection in the rat 
model. The observed low VN titers after prime immunization were not surprising, since other 
IPV formulations showed also moderate immunogenicity, as indicated by low VN titers and 
low numbers of responders following a single vaccination (i.m.) [2, 24]. 
In order to increase the immunogenicity of IPV, PagL was included as adjuvant. Several 
studies have shown the potential of dose sparing by using adjuvants for IPV based on Salk 
[24-27] and Sabin strains [2, 28]. PagL LPS is able to enhance the potency of Sabin IPV after 
both prime and booster immunization (via the i.m. route), serotype 3 being most immunogenic 
[2]. Since type 3 is the most vulnerable serotype during lyophilization and subsequent storage 
of dried IPV [14], it was decided to include PagL in Bioneedles to compensate for possible 
loss of immunogenicity. The addition of PagL in the lyophilized IPV-Bioneedles did not result 
in improved VN titers at the dose evaluated. However, PagL was able to enhance the immune 
response against the poliovirus serotypes when administered via liquid injection (36-, 10-, 
8-fold VN titer-increase for type 1, 2 and 3, respectively), albeit to a lesser extent as observed 
for Sabin IPV in a booster-regime (294-, 578- and 2352-fold for type 1, 2 and 3, respectively) 
[2]. The lack of comparability between wild type (Salk) IPV and Sabin IPV, which is due to their 
different antigenic and immunogenic properties, has been reported extensively [29-31]. The 
lack of adjuvant activity in the Bioneedle material may be the result of interaction between 
adjuvant and Bioneedle. However, another LPS-derivate, LpxL1, was able to enhance the 
immunogenicity of Bioneedles in combination with hepatitis B vaccine in mice [11]. Further 
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investigation on the PagL dose, kinetics and routing upon delivery is needed (e.g., by in 
vivo imaging). In the study reported here significant adjuvant effects of PagL included in IPV 
Bioneedles, at least for the evaluated dose, were not seen. 
This study demonstrated the preclinical proof of concept of Bioneedles for IPV. When 
formulated in Bioneedles, IPV was more thermostable as compared with the liquid IPV. A 
clinical study in healthy volunteers showed already that solid Bioneedles without antigen were 
well tolerated [13]. However, several steps should be taken in the further development of this 
alternative delivery system for polio vaccination, including toxicity and dose finding studies. 
Those (pre-) clinical studies, using an approved applicator for Bioneedle administration, 
should prove the practical use, safety, and efficacy of Bioneedles for human vaccination, and 
their usefulness to strive for polio eradication and in the period thereafter.
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CHAPTER 2
Because of their large surface area and immunological competence, mucosal 
tissues are attractive administration and target sites for vaccination. An important 
characteristic of mucosal vaccination is its ability to elicit local immune responses, 
which act against infection at the site of pathogen entry. However, mucosal 
surfaces are endowed with potent and sophisticated tolerance mechanisms 
to prevent the immune system from overreacting to the many environmental 
antigens. Hence, mucosal vaccination may suppress the immune system instead 
of induce a protective immune response. Therefore, mucosal adjuvants and/
or special antigen delivery systems as well as appropriate dosage forms are 
required in order to develop potent mucosal vaccines.
Whereas oral, nasal and pulmonary vaccine delivery strategies have been described 
extensively, the sublingual and buccal routes have received considerably less 
attention. In this review, the characteristics of and approaches for sublingual and 
buccal vaccine delivery are described and compared with other mucosal vaccine 
delivery sites. We discuss recent progress and highlight promising developments 
in the search for vaccine formulations, including adjuvants and suitable dosage 
forms, which are likely critical for designing a successful sublingual or buccal 
vaccine. Finally, we outline the challenges, hurdles to overcome and formulation 
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INTRODUCTION
Among public health interventions, vaccination is by far the most effective strategy in 
maintaining population health and combating infectious diseases, especially in developing 
countries and disaster areas. Vaccination saves millions of lives every year, while bringing 
numerous social and economic benefits [1]. Since the vast majority of pathogens infect their 
host through the mucosa, an ideal vaccine should induce protective immunity at mucosal 
sites in order to act as a first line of defense against infections. However, most of the vaccines 
currently in use are administered via injection, e.g., via the subcutaneous or intramuscular 
route. This generally induces poor mucosal immunity, whereas vaccines administered via 
mucosal routes have proven to be effective for the induction of both systemic and local 
immunity [2]. Additionally, mucosal immunization makes vaccine delivery easier and safer 
than parenteral administration routes, is very suitable for mass immunization during pandemic 
situations, and improves acceptability especially among children [3, 4].
Despite the advantages mentioned above, there are currently only few mucosal vaccines 
for human use on the market [5]. The reason for this is that mucosal vaccination poses 
several challenges, such as immune regulation and tolerance, as well as overcoming fast 
removal of the vaccine by body fluids and enzymes, as has been reviewed for the oral [3, 
6], the nasal [7] and the pulmonary route [8]. Compared to the above-mentioned traditional 
mucosal routes, sublingual and buccal vaccine administration has received less attention. 
For many years, these routes have been used for the delivery of low-molecular-weight drugs 
to the bloodstream. Currently, the only vaccines that are widely being used for delivery via 
the oral mucosae are therapeutic sublingual allergy vaccines. These vaccines are used for 
sublingual immunotherapy (SLIT) to treat allergic hypersensitivity. Sublingual delivery of 
allergens can activate regulatory T cells that can suppress undesired immune reactions [9]. 
This has resulted in several approved sublingual products for allergy immunotherapy, such 
as SLITone®, Sublivac®, Grazax®, Oralair®, AllerSlit®forte. Allergy vaccines are reviewed by 
Valenta et al. [10] and are beyond the scope of this review since they are aimed at immune 
regulation (tolerance) instead of activation of the adaptive immune system.
 In this review, we will describe the potential and limitations of the sublingual and 
buccal mucosae as vaccine delivery sites and the mucosal immune responses that are 
induced upon sublingual or buccal vaccination. Further, the current status of sublingual and 
buccal vaccine delivery will be discussed and suitable vaccine antigens and potent adjuvants 
(immune potentiators and/ or delivery systems) will be highlighted. Appropriate dosage forms 
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that are required for a successful sublingual or buccal vaccine will also be outlined. Finally, 
the forthcoming perspectives are given, including the existing research and development 
gaps in this field and the potential of improved or controlled release vaccine formulations for 
sublingual and buccal vaccine delivery.
SUBLINGUAL AND BUCCAL MUCOSAL SITES 
FOR VACCINE DELIVERY
Mucosal vaccine delivery in the mouth can be subdivided into sublingual and buccal 
delivery. Sublingual delivery occurs via the mucosa of the ventral surface of the tongue and 
the floor of the mouth under the tongue, whereas buccal delivery occurs via the buccal 
mucosa, which is located in the cheeks, the gums and the upper and lower inner lips (Figure 
1). The specific structure and cell composition of the sublingual and buccal regions in the 
mouth define whether they are more or less suitable for vaccine delivery (as described further).
Within the oral cavity, some mucosal regions are lined by a keratinized stratified 
epithelium (gingival, hard palate, outer lips), whereas other regions are lined by a non-
keratinized stratified epithelium (Figure 1). The epithelium is supported by a basement 
Floor of the mouth
[SUBLINGUAL REGION]











Inner lip [BUCCAL REGION]
Figure 1 The anatomy of the oral cavity. The sublingual and buccal regions for vaccine delivery are 
indicated.
6
BUCCAL AND SUBLINGUAL VACCINE DELIVERY
109
membrane, which separates the two major layers of the oral mucosa: the epithelium and 
the underlying connective tissue or lamina propria. The arrangement of the hard palate and 
gingival, including the pluristratified keratinized mucosal epithelium and the lamina propria 
that is anchored onto the periostium of the underlying bone, makes these regions chemically 
and mechanically resistant to withstand the shearing forces associated with chewing food. 
The floor of the mouth, the inner surface of the lips and cheeks, and the ventral side of the 
tongue are covered by a non-keratinized epithelium, rendering these relatively more elastic 
and pervious than keratinized mucosae, and thus potentially more suitable for drug or antigen 
delivery. 
The epithelium serves as a mechanical barrier protecting underlying tissues and consists 
of a basal layer, an intermediate layer, and a superficial layer. From the basal to superficial 
layer the cells become larger, more flattened, more proteinaceous in the form of protein 
monofilaments, and less viable due to the absence of organelles (Figure 2). The compacted, 
flattened cells of the lower superficial and intermediate layers form the major physical barrier 
to transport, whereas the intercellular lipids play an important role in the permeability of 
the mucosa. Besides epithelial cells, the oral mucosal epithelium also contains three other 
cell types. The basal layer includes Merkel cells, which are endocrine cells associated with 
nerve fibers that contribute to the overall barrier function of the epithelium. They have also 
been suggested to play a role in the regenerative processes of oral mucosa [11]. Further, 
the suprabasal layer contains two types of cells: melanocytes, which produce the pigment 
melanin and are thus responsible for the color of the mucosa; and Langerhans cells (LCs), 
which are the most superficial antigen-presenting cells and an important target for the 
induction of an immune response. Other antigen-presenting cells below the mucosa are the 
myeloid dendritic cells (mDCs) located along the lamina propria and the plasmacytoid DCs 
(pDCs) found in the submucosal tissue (Figure 2).
Salivary glands, which are located just below the mucosa in the mouth, produce mucin, 
a major component of the mucus layer on the mucosal surface, and help to promote the 
production and secretion of saliva. Saliva is needed to moisten and lubricate the mucosae 
and assists the masticatory process by binding the food bolus prior to and during swallowing. 
Additionally, salivary secretions protect the oral epithelium from potential harmful substances 
and regulate the composition of the oral microbial flora by its enzyme activity and by 
maintaining the oral pH between 5.5 and 7.0 [12].
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Implications for mucosal vaccine delivery and comparison 
with other mucosal sites  
Sublingual and buccal mucosae are attractive vaccine delivery sites that may have 
advantages over other routes, because of their anatomy and physiology. Table 1 shows 
an overview of characteristics of different sites that have been investigated for vaccine 
delivery. The dermal delivery site has been included because it contains comparable features 
with the buccal and sublingual sites, such as the presence of LCs as a main target for the 
vaccine antigen. However, dermal vaccination has the disadvantage that the impermeable 
thick keratinized stratum corneum acts as a physiological barrier for the diffusion of antigens 
to reach LCs after topical administration. As a result, dermal vaccination in general needs 



















antigen uptake by DCs
(30-60 min)
migration to draining
lymph nodes (12-24 h)
induction of adaptive
immune response (24 h)
migration to distant sites
basal layer
Figure 2 Antigen delivery and antigen presentation following sublingual or buccal vaccination. Upon 
vaccine delivery, the antigen is likely to be captured by Langerhans cells (LC) within the mucosa itself and 
myeloid dendritic cells (mDCs) along the lamina propria. Antigen-bearing DCs will migrate to draining 
lymph nodes where they interact with naïve CD4 and CD8 T cells to support the differentiation into 
effector T cells (i.e., helper (Th) and cytotoxic T cells (CTL)) and thereby induction of the adaptive immune 
response.
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the LCs to induce an immune response [13]. In contrast, sublingual and buccal mucosae 
suitable for vaccine delivery lack keratinized epithelium.
Compared to gastro-intestinal mucosal routes, degradation by gastric fluids and 
gastrointestinal enzymes is avoided during sublingual or buccal delivery, although some 
enzymatic activity is present in the mouth.
Most of the mucosal routes have special ‘gateways’, the so-called microfold (M) cells 
that are present in the epithelium covering the follicles of mucosal tissues. These M cells take 
care of the transport of antigens to mucosa-associated lymphoid tissues (MALT). The Peyer’s 
patches (PP), nasopharynx-associated lymphoid tissue (NALT) and bronchus-associated 
lymphoid tissue (BALT) are important inductive tissues that generate mucosal immunity 
upon vaccination via the gastro-intestinal (oral), nasal and pulmonary routes, respectively. In 
addition, the buccal and sublingual mucosal epithelia are covered with squamous stratified 
epithelium, whereas the epithelial cells of the small intestine, nasal cavity, trachea and bronchi 
are covered with columnar epithelium.
Compared to other routes, the sublingual and buccal routes have the potential to induce 
mucosal immune responses in a broad range of tissues (Table 1) as described in more detail 
in section 2.2 (‘Mucosal immune responses’).
Nagai et al. (2014) recently reported the transport of sublingual antigens across sublingual 
ductal epithelial cells to ductal APCs in mice [14]. Since different studies failed to detect 
specific sampling cells (or M-like structures) in the sublingual or buccal mucosa[14, 15], it 
seems most likely that antigens cross the ductal epithelium via paracellular and transcellular 
pathways [14]. So, probably the efficiency of vaccine delivery via these routes is directly 
related to the permeability of the mucosal membrane. This permeability is influenced by the 
thickness and the degree of keratinization of these membranes. The thickness of the human 
buccal mucosa has been estimated to be in the range of 500-800 µm, whereas the mucosal 
thickness of the sublingual region is about 100-200 µm [16]. In terms of permeability, the 
sublingual region is more permeable than the buccal region, which in turn is more permeable 
than the palatal region (Figure 1). Sublingual administration can provide a rapid uptake of 
macromolecules and thus appears to be an attractive route for dosage forms with a short 
delivery period. 
In the development of sublingual or buccal vaccines, the presence of saliva should 
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certain dosage forms, it can be disadvantageous since the salivary composition, pH, and 
flow rate are variable. Excessive secretion and salivary flow may dilute the antigen or lead 
to swallowing of the dosage form before the antigen is absorbed through the mucosa, the 
so-called ‘saliva washout’ [12]. Moreover, the presence of digestive enzymes could lead to 
degradation of the antigen.
Since pH is a critical parameter for antigen absorption, the pH values at the different oral 
mucosal sites should be kept in mind for successful vaccine delivery. For example in adults, 
the pH of the floor of the mouth is about 6.5, whereas that of the buccal region is about 6.3 
[17]. However, factors, such as diet and saliva flow rate, may affect the pH of the oral mucosa. 
In section 4 (‘Dosage forms’), we describe different ways to circumvent the challenging 
characteristics of sublingual or buccal vaccine delivery.
Mucosal immune responses
Unlike small synthetic drugs, vaccine antigens do not reach the bloodstream after 
entering the sublingual or buccal mucosa, but are rather captured by antigen-presenting 
DCs, mainly LCs, in the mucosa. The antigen uptake, process and the presentation of their 
epitopes to T cells by antigen-presenting cells are required to induce effective adaptive 
immunity. For example, the ovalbumin antigen crosses the epithelial barrier within 15 to 30 
minutes and the uptake by sublingual DCs occurs within 30 to 60 minutes after sublingual 
administration in mice [18]. Rare pro-inflammatory cells, i.e., histamine-containing mast cells 
(MC) or eosinophils (Eos) (Figure 2), are found in oral tissues, and these cells are mainly 
spread in the muscular layer beneath the mucosa [18, 19]. Therefore, it is likely that most of 
the antigen is mainly captured by LCs and other oral DCs in the upper layers prior to reaching 
pro-inflammatory cells. The relatively high frequency of LCs and low numbers of mast cells in 
the buccal region [19] make the buccal mucosa an attractive site for vaccine delivery despite 
its thicker epithelium and lower permeability as compared to the sublingual mucosa.
Antigen-bearing DCs migrate to the lymph nodes draining the sublingual and buccal 
area where they are able to prime both naïve CD4 and CD8 T cells (Figure 2, T0 cells). For 
example, Eriksson et al. reported that a substantial number of DCs leave the buccal epithelium 
after topical buccal immunization and migrate to draining lymph nodes where they present 
processed antigen to CD4 T lymphocytes [20]. Another study revealed the buccal epithelium 
as inductive site of efficient priming of CD8 T lymphocytes [21]. Upon activation, T and B cells 
leave the site of the initial antigen presentation, enter the circulation and then disperse to 
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selected mucosal sites, where they differentiate into memory or effector cells. The activation 
of CD4 T lymphocytes leads to the induction of antigen-specific helper T (Th cells) and/or 
regulatory T cell (Treg) mediated immune responses (Figure 2), whereas CD8 T cells facilitate 
the induction of cytotoxic T lymphocyte (CTL) responses (Figure 2). The tissue destination 
of these cells appears to be largely determined by site-specific integrins, supposed ‘homing 
receptors’, on their surface that will bind to mucosal tissue-specific receptors (addressins) 
on vascular endothelial cells [22]. Recent work of Hervouet et al. demonstrates that antigen-
bearing DCs that have captured the antigen in the sublingual mucosa are encountered 
in distant lymph nodes and spleen following sublingual immunization of mice [23], which 
suggests that sublingual DCs are capable to enter the blood circulation to seed distant 
lymphoid organs.
The migration of immune cells from the inductive MALT to distant effector tissues is 
the cellular basis for the so-called ‘common mucosal immune system’. The MALT contains 
T-cell zones, B-cell enriched areas containing a high frequency of sIgA-positive B cells and 
a subepithelial area with antigen-presenting cells to induce specific immune responses. As 
mentioned earlier, the oral mucosa lacks a certain immunological structure as observed in 
Peyer’s patches of the intestine where the antigen is sampled by specialized M cells. However, 
different studies describe the concept of oral lymphoid foci, the equivalent of the germinal 
centers observed in other MALT, suggesting that the oral mucosa serves as a site for immune 
induction. The role of oral DCs in deciding whether to induce adaptive immunity or tolerance, 
and whether there exist germinal centers in oral lymphoid foci are discussed extensively 
by others [24, 25]. The distribution of immune cells, particularly the abundant presence of 
oral LCs, makes the oral mucosa an attractive site for vaccine delivery. Both sublingual and 
buccal immunization are able to promote mucosal immunity, as well as systemic immunity, 
against pathogens entering the human body at more distant sites than the mouth (mucosa), 
such as the respiratory tract or reproductive tract (Table 1).
6
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CURRENT STATUS OF SUBLINGUAL AND 
BUCCAL VACCINE DELIVERY
In the section below, we will describe the use of live (attenuated) pathogens, recombinant 
(heterologous expression) and inactivated vaccines. Furthermore, we will outline adjuvants, 
i.e., immune potentiators and/or delivery systems, that have been evaluated for vaccination 
via the sublingual or buccal route. A summary of the published studies on sublingual and 
buccal vaccination is given in Table 2.
Live attenuated vaccines
Live attenuated viral vaccines
Sublingual immunization of mice with live attenuated influenza virus (A/PR/8 strain, 
H1N1) has been found to be safe and effective for inducing protective immune responses in 
mucosal and systemic compartments. Song et al. concluded that the observed protection 
was mediated by the induction of influenza virus-specific IgG in the serum and secretory 
IgA (sIgA) in the respiratory mucosa, which limit virus entry and replication in the respiratory 
tract. A single sublingual dose of A/PR/8 virus prevented lung pathology induced by 
influenza virus challenge and provided a broad-range cross-protection against different 
influenza virus subtypes. Thereby, the risk of potential passage of vaccine virus to the 
olfactory bulb was avoided using the sublingual route since no viral RNA was detected in 
brains of sublingually vaccinated mice, in contrast to mice that received the same vaccine 
intranasally [26]. Similarly, sublingual administration of live-attenuated virus lacking the non-
structural protein 1 (DeltaNS1) was as protective against influenza virus challenges in mice as 
intranasal immunization. Sublingual immunization with these DeltaNS1 viruses induced high 
levels of virus-specific antibodies and stimulated immune cells in mucosa-associated and 
systemic lymphoid organs [27]. Moreover, the vaccine was well tolerated and did not induce 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































   






























































































Recombinant virus based (RNA-) vaccines
Replication-defective adenovirus vectors (rAdV) have been widely explored for the delivery 
of antigens. Infection by adenoviruses occurs through the airway epithelium and replication 
takes place in mucosal tissues of the respiratory tract. These characteristics make these 
vectors suitable for mucosal vaccine delivery. Sublingual immunization with rAdV encoding the 
conserved influenza nucleoprotein antigen [28] or the soluble globular head of hemagglutinin 
[29] protected mice against influenza virus infection. Furthermore, sublingual administration 
of rAd5 vectors encoding HIV proteins induced both significant antigen-specific humoral 
(serum and mucosal IgG and IgA) [30] and cellular (systemic and mucosal CTL responses) [31] 
immune responses. Moreover, sublingual vaccination with rAdV encoding a truncated S protein 
(rAdV-S), which is a major antigenic protein present on severe acute respiratory syndrome-
associated coronavirus (SARS-CoV), induced systemic neutralizing antibodies and airway 
IgA antibody responses in mice. These immune responses were similar to those induced by 
intranasal administration. It is worth noting that intranasal delivery of rAdV redirected the virus 
vector to the olfactory bulb, whereas no adenoviral DNA was detected after sublingual delivery 
[32]. Choi et al. reported that both mice and guinea pigs were protected against a lethal Ebola 
challenge after a single sublingual immunization with an AdV-based vaccine expressing the 
Zaire glycoprotein in a manner similar to that of traditional intramuscular vaccination [33].
Recombinant bacterial vaccines
With the availability of genetic tools for heterologous gene expression, the concept of 
live vaccine vehicles has sparked renewed interest, especially for the mucosal routes [34]. 
Several studies have shown that engineered Bacillus (B) subtilis is able to generate systemic 
and mucosal antibodies against heterologous antigens. B. subtilis delivered sublingually and 
expressing tetanus toxin C-fragment, evoked protective immunity in both mice [35] and piglets 
[36]. Batista et al. reported the use of ‘gut-colonizing’ B. subtilis spores as a new mucosal 
vaccine delivery platform consisting of two antigen expression strategies. One is active during 
spore formation, which leads to the display of recombinant adhesins at the spore surface 
that facilitates adhesion to mucosal surfaces. In addition, the recombinant spores have been 
shown to germinate after oral delivery resulting in intracellular expression of the antigen. 
Mice immunized with three doses of B. subtilis spores via the sublingual route, developed 
higher specific serum IgG titers when compared with the mice orally immunized with a nine-
fold higher dose of spores of the same strains. Although not proven in this study, the authors 
speculated that sublingual delivery of these spores will also result in intracellular antigen 
6
BUCCAL AND SUBLINGUAL VACCINE DELIVERY
125
expression once they are captured by intraepithelial antigen-presenting cells and germinate 
[37]. The better immune response to sublingual vaccination might be ascribed to the fact that 
sublingual delivery has a smaller distribution volume and a less aggressive environment than 
gastro-intestinal delivery.
Inactivated vaccines
In a study by Cho et al., different routes, i.e., intranasal, intravaginal, transdermal, sublingual 
and intramuscular, were compared in a mouse study using human papillomavirus 16 L1 
(HPV16L1) protein vaccine. Among these routes, the intranasal and sublingual routes provided 
the highest HPV16L1-specific levels of vaginal sIgA and systemic IgG responses that were 
comparable to those elicited via the intramuscular route [45]. Sublingual vaccination against 
respiratory syncytial virus (RSV) with a purified G protein fragment (Gcf) without the addition 
of adjuvants induced strong serum IgG and mucosal IgA responses (similar to intranasal 
vaccination) in mice. Interestingly, these antibody responses could be elicited by Gcf without 
the need for an adjuvant. The study demonstrated that the chemotactic activity exhibited by 
Gcf was necessary to induce protective immunity. Therefore, the authors proposed that Gcf 
has a self-adjuvanting property [46].
Murugappan et al. investigated whether sublingual administration of whole β-propiolactone 
(BPL)-inactivated influenza virus can prime the immune system for a later intramuscular boost 
with a heterologous vaccine. Although sublingual priming did not induce any detectable 
immune responses, it strongly enhanced hemagglutination inhibition (HI) titers against both the 
homologous as well as the heterologous vaccine after the intramuscular booster. In addition, 
sublingual priming induced IgA responses in the lung and nose, while intramuscular priming 
showed higher IgA responses in the lung, but not in the nose [40]. In a study by Song et al., 
a sublingual booster was given, instead of an intramuscular booster, and immune responses 
were analyzed more extensively. Immunization with formalin-inactivated influenza virus via the 
sublingual mucosa induced protective immune responses, elevated mucosal sIgA antibody 
levels, and enhanced virus-specific CTL responses [26]. The different procedures used for virus 
inactivation affect the membrane fusion properties of the virus to a certain extent, resulting in a 
less optimal activation of CTLs. Inactivation with formalin severely compromises fusion activity 
of the virus, while BPL-inactivation reveals preservation of the fusion activity [60]. However, a 
sublingual booster vaccination with formalin-inactivated influenza induced significant elevated 
virus-specific CTL responses in mice. Unfortunately, the analysis of CTL activation is lacking in 
the study using BPL-inactivated influenza.
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As with mucosal immunization in general, sublingual (and buccal) vaccination with non-
replicative antigens does not induce sIgA and serum IgG responses without the addition of 
adjuvants. Strong immune potentiators or delivery systems are needed to break mucosal 
tolerance and facilitate uptake through the oral mucosae. For example, a mucosal adjuvant 
(cholera toxin, CT) was needed to induce immune responses upon sublingual immunization 
with a human immunodeficiency virus (HIV) subunit vaccine [48]. Çuburu et al. evaluated 
the sublingual route for vaccine delivery using ovalbumin (OVA) as a model antigen. Mice 
received three doses of 200 μg OVA and although systemic IgG responses were measurable, 
mucosal OVA-specific antibody responses were absent after sublingual immunization of 
OVA alone. Co-administration of a mucosal adjuvant (CT) generated high OVA-specific IgA 
responses in saliva and nasal wash. These responses were of the same magnitude as those 
induced by intranasal administration [58]. 
Recently, sublingual administration of a subunit influenza vaccine was evaluated in mice. 
After three doses, detectable, but rather low, antigen-specific systemic IgG and HI titers 
were found after sublingual immunization, whereas mucosal IgA antibodies were below the 
detection limit. The addition of the mucosal adjuvant LTK63 was needed to those obtained 
after conventional intramuscular immunization [41]. A Salmonella vaccine consisting of 
sonicated Salmonella proteins induced protection only after sublingual immunization in the 
presence of adjuvants (CpG DNA or CT). This was observed in both adult [51] and neonatal 
mice [50]. 
Although mucosal adjuvants improve immune responses upon sublingual immunization 
using non-replicating/inactivated antigens, in some studies systemic and/or mucosal 
immunity was obtained with sublingual delivery of non-adjuvanted inactivated (subunit) 
vaccines [45, 46, 58]. In general, high doses were used and even the size of the antigen 
seemed to be an issue for successful immunization since small proteins/antigens showed the 
induction of both systemic and mucosal immune responses upon sublingual administration.
Adjuvants used in buccal and sublingual vaccines
Immune potentiators
Bacterial enterotoxins - The most powerful and hence the best-studied mucosal 
adjuvants are the bacterial enterotoxins cholera toxin (CT) and the Escherichia coli heat-labile 
toxin (LT), which have structural and biological similarities.
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The adjuvant effect of sublingually administered CT has been documented with a number 
of antigens, including influenza [43] and HIV [48] subunit vaccines, Salmonella proteins [50, 
51] and Helicobacter pylori lysates [54, 55] with the latter two as undefined vaccines. LT, 
when co-administered sublingually with tetanus toxoid (TT) induced higher specific IgG and 
mucosal IgA antibody titers when compared to TT alone [57]. However, CT and LT cause 
severe diarrhea in humans and are involved in the clinical occurrences of cholera and 
enterotoxigenic E. coli enteritis, and therefore not suitable as an oral or sublingual adjuvant 
for human use [61-63]. Since enterotoxicity is mainly caused by the enzymatically active 
A-subunit, mutated enterotoxins with reduced toxicity but retained adjuvant properties, 
have been developed. LT(R192G), also named mLT, showed reduced toxicity in mice, but 
maintained its adjuvanticity to a level nearly equivalent to that of LT [64, 65]. Building on 
this mutant, a double mutant of LT, R192G/L211A or dmLT, showed adjuvanticity for a co-
administered antigen equivalent to mLT upon oral administration (gastro-intestinal delivery) 
[66]. Recently, dmLT has been evaluated as an adjuvant for sublingual and buccal vaccination 
with a whole-cell pneumococcal vaccine that induces protection in mice [52]. In the search 
for an alternative adjuvant for a Helicobacter pylori lysate vaccine, dmLT was compared to 
CT. Earlier studies have shown that a strong mucosal adjuvant like CT was needed to induce 
protective immune responses against Helicobacter pylori infection. Sublingual immunization 
with Helicobacter pylori lysate and dmLT significantly decreased the bacterial burden after 
Helicobacter pylori infection compared to unimmunized mice and to the same extent as 
when using CT as adjuvant [55]. Moreover, cellular immune responses that are known to 
correlate with protection were also fully comparable when using dmLT and CT as adjuvants. 
In a study by Cho et al., HPV16L1 protein provided both vaginal and salivary sIgA, and 
serum IgG responses after sublingual administration in mice (150 μg) [45]. Several adjuvants 
were tested, including the B subunit of cholera toxin (CTB), three toll-like receptor agonists 
(i.e., Poly(I:C), MPL, imiquimod), three nucleotide-binding oligomerization-domain agonists 
(L18-MDP, murabutide, PGN), vitamin D3 and poly-gamma-glutamic acid. Among the 
adjuvants tested, only CTB provided improved mucosal sIgA and systemic IgG induction. 
Sublingually applied CTB also enhanced the production of IL-4 and IFN-y by stimulated 
CD4+ T cells from the spleen, as well as the number of IFN-y producing CD8+ T cells that 
were isolated from the spleen or submandibular lymph node (SMLN). The other adjuvants 
had no effect on the immune response when compared to the unadjuvanted control [45]. 
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Toll-like receptor (TLR) ligands – Despite the negative results mentioned above, TLR 
agonists can significantly improve immune responses after sublingual vaccination. A mouse 
study evaluating TLR agonists (i.e., FSL-1, Poly(I:C), monophosphoryl lipid A (MPLA), 
Pam3CSK4, R848, cytosine-phosphate-guanosine (CpG))  in different mucosal routes using 
HIV gp140 and a tetanus toxoid revealed clear differences in immunogenicity [49]. MPLA, a 
TLR-4 agonist, suppressed systemic responses when administered sublingually, while the 
responses were enhanced after intranasal or subcutaneous immunisation. CpG, a TLR-9 
ligand, evoked enhanced immune responses upon sublingual and intranasal immunization 
whereas it did not affect the responses after subcutaneous immunization [49]. Another study 
revealed that sublingual immunization with an Ad5 vector expressing a TLR agonist derived 
from Eimeriatenella significantly activated NK cells, natural killer T (NKT) cells, B cells, and 
CD4+ T cells in the spleen. In addition, the number of cells expressing MHC-II increased [30]. 
Bacterial DNA or synthetic oligodeoxynucleotides (ODNs) containing CpG motifs act 
as mucosal adjuvants. These TLR 9 ligands induced strong Th1 responses in mice after 
sublingual delivery of a Salmonella vaccine [67].
Delivery systems
Virus-like particles (VLPs) and virosomes have been evaluated for sublingual delivery. 
Cho et al. showed that sublingual delivery of HPV16L1 VLPs in mice induced systemic IgG 
and mucosal sIgA responses that were similar to the intranasal route, but significantly higher 
compared to other delivery (intravaginal, transdermal, intramuscular) routes [45]. In contrast to 
this study in mice, a clinical trial by Huo et al. with Gardasil® (Sanofi Pasteur), which contains 
the same L1-based VLPs from HPV but is co-administered with aluminumhydroxyphosphate 
as an adjuvant, showed that sublingual immunization is much less effective than intramuscular 
immunization [68]. However, this alum adjuvanted VLP formulation is not suitable for 
sublingual HPV vaccination, which is likely due to the fact that alum adjuvants consist of 
relatively large (micrometer range) particles that are probably poorly taken up by mucosal 
epithelial cells. Other adjuvants as well as improved dosage forms (see section 4) may help 
to increase the immune response to the VLPs. 
A sublingual vaccine containing influenza H5N1 virosomes (2 µg HA) in combination with 
the mucosal adjuvant (3’,5’)-cyclic diguanylic acid (c-di-GMP) effectively induced local and 
systemic H5N1-specific humoral and cellular immune responses in mice. The systemic IgG 
and nasal sIgA antibody levels were lower than those induced by intranasal administration, 
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but the IgG levels were comparable to those obtained after intramuscular administration, 
whereas nasal sIgA levels were higher than the levels upon intramuscular administration [42]. 
DOSAGE FORMS
Optimized dosage forms may improve the performance of sublingual and buccal vaccines 
substantially. Several dosage forms exist for sublingual and buccal delivery of marketed drugs. 
These range from droplets, sprays, and orally disintegrating tablets to oral films. However, 
only a few dosage forms have been used to explore sublingual or buccal delivery of vaccines. 
Almost all sublingual vaccination studies reported here have been performed by the simple 
application of droplets of a vaccine under the tongue. There are no studies on the role of 
potentially crucial variables, like contact time, vaccine viscosity and antigen release kinetics on 
immunogenicity. 
In preclinical studies, vaccine droplets are applied under the tongue on the floor of the 
mouth and the animal is kept under sedation for less than one hour to allow the vaccine to be 
taken up (Table 2). For sublingual vaccination of mice 5 µL can be applied sublingually without 
transfer of the vaccine to the stomach (including a sedation time of 30 minutes) [48, 57]. 
Sublingual administration of allergens to humans by droplets has been used for years in 
Europe in sublingual immune therapy (SLIT) against allergies. Typically, in SLIT, droplets of a 
highly viscous glycerol formulation containing the allergen extract are applied under the tongue. 
The high viscosity contributes to antigen retention under the tongue and as such facilitates the 
efficacy of the immune therapy. 
In a recent clinical trial, HPV vaccine was applied sublingually to humans. Compared to SLIT 
with glycerol droplets, a relatively complicated administration protocol was used in this study. 
In brief, subjects rinsed their mouths with water, the sublingual area was dried and then 0.5 mL 
of vaccine was applied on the floor of the mouth. Adsorbent pads were applied in the mouth to 
absorb the saliva during and after the vaccine application. Despite the elaborate administration 
protocol, in only three of the twelve subjects were virus-neutralizing antibodies induced in serum 
after three standard doses of HPV vaccine via the sublingual route. These neutralizing antibody 
titers were still 1000-fold lower than in the intramuscular group. Researchers concluded that 
alternative delivery systems and adjuvants would be required to enhance and evaluate immune 
responses following sublingual immunization in humans [68]. 
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The disappointing results of this clinical trial may be related to several factors. First, a 
significant amount of solution (0.5 mL versus ‘a couple of droplets’ in SLIT therapy) was 
applied. Despite the extensive administration protocol, a certain high volume will easily be 
digested and will follow the gastro-intestinal route. Secondly, the vaccine used in the study 
(Gardasil®) is a VLP based vaccine containing aluminium hydroxyphosphate sulphate as 
adjuvant. An alum-adsorbed vaccine has a large particle size (in the range of 1 µm) and thus 
is not ideal for transfer over membranes. Finally, alum is not known to be a good adjuvant for 
mucosal vaccination. 
Droplets for improved (extended) mucosal retention are currently under development by 
PATH [69]. Their technology is based on a thermoresponsive gel of undisclosed composition. 
The vaccine is presented as a liquid solution at room temperature, which enables sublingual 
delivery with an oral dropper, and transforms into a gel upon contact with the oral mucosa. 
Typical thermo-responsive gel formulations that gelate at a temperature above 30°C are 
based on polymers, such as poloxamer and mucoadhesive polysaccharides. The gel matrix 
enables adherence (retention > 20 min.) to the sublingual mucosa thereby preventing rapid 
clearance caused by salivation or swallowing and protecting the vaccine antigen from 
degradation caused by salivary enzymes. Vaccinating mice with a gel formulation containing 
tetanus toxoid elicits high levels of IgG and IgA in serum as well as in secretions of the 
mouth, gastrointestinal and reproductive tract. Currently, PATH is evaluating (preclinically) 
whether the addition of a mucosal adjuvant, dmLT, can contribute to the efficacy of sublingual 
vaccination using thermo-responsive gel formulations [69].
Thermoresponsive gels - Formulations that are liquid at room temperature (left vial) and turn into a 
solid gel at body temperature (right vial).
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Sprays
Sublingual sprays have been used for years for the sublingual administration of 
nitroglycerine to patients in order to counter an acute angina pectoris. The most used 
nitroglycerine sprays are based on a formulation containing the drug substance, ethanol, 
a small amount of mint oil and a propellant, like tetrafluoroethane, to aerosolize of the 
formulation. We are not aware of any investigations into direct spraying of the vaccine onto 
the sublingual or buccal mucosa. 
A few studies, however, have applied vaccine sprays into the whole mouth. Immunization 
of humans with influenza whole inactivated virus (H1N1) without additives, such as an oral 
spray using a simple nasal spraying device (no use of propellant), did not result in IgA antibody 
responses in nasal secretions and only resulted in marginally increased IgA antibodies in 
saliva. Although no stimulation of cytotoxic T cells was shown, an increase in systemic 
influenza-specific antibodies was found [70]. 
To what extent the immune response elicited by sublingual vaccination is the result of 
direct immune activation of the tonsils remains a matter of debate. For example, it has been 
shown that direct immunization via the tonsils can give rise to adequate immune responses. 
Oral spray immunization with replication-deficient viral vector vaccines encoding simian 
immunodeficiency virus (SIV) sprayed directly on the tonsils of rhesus macaques induced 
cellular and humoral immune responses. Additionally, after SIV challenge viral RNA levels 
were equally reduced after systemic vaccination and vaccination through the use of the oral 
mucosal spray [139].
Controlled release formulations
Several oral formulations are already licensed or are in development for drug delivery 
in the mouth. Based on their drug release kinetics and manufacturing method they can be 
categorized as: (i) orally disintegrating preparations (tablets and fast-dissolving films) and 
(ii) extended (slow) release tablets and films. Although their value for sublingual and buccal 
delivery of antigens has not yet been extensively evaluated, they will be described briefly 
in the next section since they may play an important role in the development of potent and 
thermostable sublingual vaccines.
Orally disintegrating preparations
Orally disintegrating tablets for sublingual or buccal delivery are in general relatively small 
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and porous. Tablets for buccal delivery facilitate fast disintegration and drug or vaccine release 
without inclusion of a disintegrant. In general, these tablets dissolve within a few seconds 
after being placed in the mouth without water, making them dried (stable) alternatives for 
droplets. 
Recently, several excipients were studied for their wafer formation abilities (highly porous 
tablets made by direct compression) with the intention to formulate wafers containing HPV 
vaccine for sublingual vaccination [71]. A typical fast-disintegrating formulation for the 
generation of wafers with a diameter of 4 mm that showed a dissolution time of less than 25 
seconds (in 3 ml at 37°C) consisted of approximately 65% (w/w) myo-inositol (the placebo 
HPV powder) and 35% microcrystalline cellulose (MCC) [71].
Extended release films and tablets
To effectively vaccinate via the sublingual and buccal mucosae, the contact time of the 
antigen with the mucosa is expected to be critical, although this remains to be demonstrated. 
Sustained release dosage forms adhere to the mucosa and direct transport of the antigen to 
the mucosa may improve the efficacy of sublingual and buccal vaccination. In this regard, 
extended release films or tablets that consist of multiple layers with different functions (Figure 
3) may be applied. The sublingual mucosa is exposed to a high saliva flow, which might be 





- permanent:  shielding antigen from enzymatic 
  degradation
- dissolvable:  delayed / extended release
- different antigen dissolution
 OR
- shielding between layers
- contains vaccine antigen
 OR
- adhesion purposes only
contains vaccine antigen
Figure 3 Multi-layered films or tablets. The layers of multi-layered dosage forms have different functions. 
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also cause loss of the antigen and adjuvant due to salivary washout. Therefore, the much 
lower saliva flow of buccal mucosa makes this route probably a better target for a sustained 
release system.
Extended release tablets are typically based on gelling hydrophilic polymers, so-called 
hydrophilic matrix tablets. The polymers form a gel layer around the tablet when they make 
contact with water. The release profile is controlled by the overall swelling and erosion [72]
[72]. Most polymers that are used as mucoadhesives are hydrophilic polymers that gelate 
upon contact with saliva, allowing adherence to the buccal mucosa by interfacial forces, 
such as hydrogen bonding, electrostatic interaction as well as van der Waal’s bonds. 
Borde et al. [73] prepared extended release tablets for the model antigen ovalbumin, 
based on two-layer tablets consisting of a mucoadhesive layer, which is composed of 
carbopol, and a controlled release layer. Since the tablets were not able to adhere to the floor 
of the mouth in mice, the tablets were applied upside down to the ventral side of the tongue, 
resulting in the release of the antigen towards the sublingual region. Immunization studies 
were performed with tablets containing 250 μg ovalbumin directly followed by sublingual 
administration of a 1 μg/mL CT solution (7.5 μL) as adjuvant. Immunization with a fast-
releasing tablet was favorable over extended release formulations and comparable to the 
liquid reference (ovalbumin with CT) for the immune response. However, the production of 
saliva was induced by administering pilocarpine subcutaneously before administering the 
tablet to provide better swelling and adhesion of the tablets [73]. The authors concluded 
Oral mucosal films - Polymer-based oral dissolving films for buccal or sublingual vaccine delivery. The 
size of the film depicted here is suitable for in vivo testing in small animals. 
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that extended release formulations for sublingual vaccination have to be investigated more 
in detail. Extended release formulations for mice have to be optimized to direct the antigen 
toward the ventral sublingual mucosa. This will improve the antigen diffusion and prevent the 
salivary washout and the impact of enzymes by shielding.
Extended release films based on multiple layers are generally made by the solvent 
casting method [74] for which the antigen is added to a coating mass (e.g., cellulose, 
polysaccharides) and subsequently cast onto a film application apparatus. After drying and 
solvent evaporation, the films can be cut into single doses. 
The viscosity and density of the coating mass are critical for successful film casting 
(layer-by-layer coating). Moreover, the vaccine antigen needs to be formulated in the coating 
mass with proper excipients to guarantee resistance to the applied drying stresses [75]. 
Formulations that have been proven to protect vaccines during the fabrication of coated 
solid dosage forms have been described in literature but are not yet used to produce 
vaccine-containing films. For example, the group of Prausnitz applied formulations based on 
trehalose, surfactant (poloxamer) and a polymer (PVP) to coat microneedles with vaccines 
such as the whole inactivated influenza virus [76] and measles [77] for dermal vaccination. An 
additional advantage of dried formulations is the improved thermal stability during storage.
PERSPECTIVES
The oral mucosa, in particular the sublingual and buccal regions are attractive sites for the 
delivery of antigens, since their accessibility, non-invasive and (immunological) advantages 
over other (mucosal) routes (section 2.1). Therefore, sublingual vaccine delivery has gained 
significant attention during the past few years, as shown by the numerous preclinical studies 
published in the last decade (Table 2). 
The preclinical proof of concept of the sublingual route for vaccine delivery has been 
proven for several antigens. In general, high doses of antigen (10-500 µg) are administered 
in mice using a multiple dosing regimen (Table 2). However, well-designed studies including 
proper dose response and tracking (PK/PD) studies are still lacking. Nevertheless, the use 
of strong mucosal adjuvants seems to be necessary to induce protective immune responses 
upon sublingual vaccination using inactivated vaccines. Reported studies on screening and 
comparison of adjuvants for sublingual vaccination, unfortunately, are still limited. Of the 
adjuvants investigated thus far (CT, CTB, LT, LTB, mLT, dmLT, CpG, c-di-GMP, L18-MDP, FSL-
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1, Poly(I:C), MPLA, Pam3CSK4, R848, murabutide, peptidoglycans, vitamin D3, chitosan and 
poly-gamma-glutamic acid), enterotoxins (and their mutants) and TLR-9 agonists resulted 
in the highest antibody responses whereas the other adjuvants did not improve immune 
responses upon sublingual delivery. The most used adjuvants for sublingual vaccine delivery 
are the enterotoxins CT and LT, which are considered too toxic for human use. However, 
genetically defined mutants of these toxins, which have reduced or minimal toxicity, seemed 
to be promising adjuvants to augment both systemic and mucosal immunity in response to 
sublingual administration.  
Recombinant live carriers expressing the vaccine antigen seemed to elicit protective 
immunity by inducing both antigen-specific systemic as well as mucosal antibodies at 
distinct mucosal sites [28, 32]. The exact advantage of such live vaccines over inactivated 
vaccines is still not clear, but it could be related to factors such as receptor-mediated uptake, 
intracellular replication of antigens and co-delivery of immune potentiators and antigens to 
APCs. 
An approach that resembles the characteristics of the live pathogens, e.g., by co-delivery 
of immune potentiator and antigen, is needed to develop an effective inactivated (subunit) 
vaccine for the sublingual route. Unfortunately, to date, limited studies have focused on such 
approaches that use tailored formulations, such as nanoparticles or conjugated antigen-
adjuvant formulations. In the design of these formulations, mucoadhesive or receptor-binding 
properties may be built in to increase interaction with the oral mucosa and thereby facilitate 
antigen uptake. 
In addition to delivery systems, dosage forms may improve the efficacy of sublingual 
and buccal vaccines. Today, research on dosage form optimization for sublingual or buccal 
vaccination appears marginal. The few reported studies use mouse models to evaluate 
sublingual vaccination in vivo. Nevertheless, the small space under the tongue of animals 
used for preclinical studies makes testing of sublingual solid dosage forms challenging. 
For example, Muragappan et al. faced the problem that sublingual tablets were not able to 
dissolve under the tongue of mice [40]. Moreover, two-layered extended release tablets failed 
to adhere to the floor of the mouth in mice, resulting in a suboptimal administration that applied 
the tablet upside down on the ventral side of the tongue [73]. Potential problems related to 
the sublingual application of slow release formulations are due to the lack of an expanse of 
smooth or (relatively) immobile mucosa, which make it difficult to keep the dosage form in 
contact with the sublingual mucosa. Other dosage forms, such as wafers, films and thermo-
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responsive gels, should be explored as these may likely increase the potential of sublingual 
vaccine delivery. Sustained dosage forms (e.g., multi-layered oral films or tablets) are probably 
better suited for application on the buccal mucosa, which is considerably less permeable 
than the sublingual mucosa. The few current studies on buccal vaccine delivery use buccal 
injections instead of a topical application. However, the development of the extended release 
formulations would make topical buccal cheek vaccination easier. Compared to the sublingual 
route, buccal administration in small animals, such as mice, is more complicated since the 
buccal compartment has a minimal anatomical barrier with the sublingual compartment. 
Besides the animal size, the anatomical features of the oral cavity should be taken into account, 
because of the specialized histological characteristics and immunological competences 
of the oral mucosae in humans. However, most rodents, such as mice, rats and hamsters, 
have buccal mucosa that contains keratinized epithelium, in contrast to non-keratinized 
epithelium of sublingual and cheek mucosae in human. For buccal cheek administration, other 
animal models such as rabbits, dogs and pigs are more appropriate since they contain non-
keratinized buccal mucosae. Moreover, the thickness of the buccal mucosa in these animal 
models (rabbit, 600 µm; dog and pig, 770 µm) is comparable to that of humans (500-800 µm) 
[78]. Current literature does not address to which extent mucoadhesive formulations increase 
the delivery of the antigen to oral mucosal APCs after sublingual or buccal administration, 
requiring proper tracking (pharmacokinetics, PK) studies in relation with immunological 
outcome (pharmacodynamics, PD) in adequate animal models (Table 3).
To select suitable formulations and dosage forms, an in vitro model for the mucosa that can 
predict the transport of an antigen might be useful. Porcine buccal mucosa is often chosen for 
in vitro studies on buccal delivery of medicines because of its close resemblance to human 
buccal mucosa with respect to structure, enzyme activity as well as permeability characteristics 
[79]. However, mechanistic studies evaluating the conditions for sublingual or buccal antigen 
delivery, such as optimal contact time of the dosage form and the differences between the 
oral mucosal routes, are lacking in literature. Moreover, the importance of specific molecular 
features of the antigen and/or antigen formulation, such as size (e.g., 1-10 nm proteins versus 
10-250 nm viruses versus 250 nm-2 µm bacteria), surface charge or specific receptor ligands, 
is still not investigated systematically.
Most preclinical studies (in vivo animal models) are used to evaluate the vaccine candidate’s 
efficiency to induce protective mucosal (and systemic) immunity. Secretory IgA (sIgA) provides 
antigen-specific immune protection in mucosal tissues. As a result, most preclinical studies 
on sublingual vaccination include the detection of sIgA in mucosal secretions. Unfortunately, 
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most studies are designed for an optimal readout of systemic immune responses, making 
assumptions on mucosal immunity not fully conclusive. Moreover, in general, the presence of 
sIgA is determined in saliva, which is not the best readout for mucosal immunity, especially 
for rodents [80]. A more predictive method to measure mucosal immunity in mucosal tissues 
of rodents is the ‘Perfext method’, which is a direct method for quantitative assessment of in 
vivo antibody or cytokine production at the local level [81]. The method uses the collection of 
heparinized mucosal tissue of the animal followed by detergent treatment and the detection of 
antigen-specific antibodies by ELISA [53, 55].
Based on several preclinical studies, it would be highly interesting to follow the expected 
upcoming clinical studies on sublingual vaccine delivery (using live attenuated vaccines). These 
studies should build on the experience of previous preclinical studies that were designed to 
evaluate mucosal immunity as a correlate of protection, which would require standardized 
and validated assays predictive of mucosal immune protection [82]. For example, a method 
described by Saletti et al. allows measurements of both systemic and mucosal antibody 
responses to vaccines by detecting antigen-specific plasmablasts with a specific mucosal 
pedigree (e.g., α4β7, CCR10) on small amounts of whole blood [83]. Although it was developed 
for clinical samples, a certain type of mucosal readout would also be useful for preclinical 
studies, amid limited blood volumes that can be sequentially withdrawn from small animals. 
The full benefits of sublingual vaccination can only be revealed by the determination both local 
and systemic responses.
Table 3 Current challenges in the development of sublingual and buccal vaccines.
Challenges Research should focus on:
Get more insight into pharmacokinetics and 
pharmacodynamics (PK/PD) 
- Dose response studies
     Dose-sparing possibilities
     Multiple dose regime needed?
     Potent and safe adjuvants
- In vivo imaging (tracking) studies
Get more insight into immunological 
mechanisms
- Role of oral DCs upon buccal/sublingual immunization
- Antigen uptake and transport
- Use of proper animal models
- Readout for mucosal immunity
Development optimized vaccine formulations 
and proper dosage forms
- Tailored vaccine delivery: oral DCs as vaccine target
- Stable vaccine formulations
- Optimal contact time (mucoadhesive)
- Optimal antigen release time
- Use of proper animal models
Development of predictive assays for mucosal 
immunity
- Optimal sampling for mucosal readout
- Validated assays for (pre-)clinical studies
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Current literature on sublingual and buccal vaccination with a broad range of antigens 
provides a strong base for further testing of these non-invasive vaccine delivery routes. This 
testing should include mechanistic studies on the superiority of live vaccines over inactivated 
antigens, including dose-response studies (Table 3). Based on the findings, tailored vaccine 
formulations for inactivated antigens may be designed in the near future. Development of 
these sophisticated formulations and optimized dosage forms that facilitate antigen uptake 
by the oral mucosa will be an important step forward towards successful sublingual and/or 
buccal vaccination. Finally, upcoming clinical studies that confirm the suggested safety and 
efficiency (by proper readout of both mucosal and systemic immunity) may result in the first 
approved sublingual vaccination strategy.
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Polio is on the brink of eradication. Improved inactivated polio vaccines (IPV) are 
needed towards complete eradication and for the use in the period thereafter. 
Vaccination via mucosal surfaces has important potential advantages over 
intramuscular injection using conventional needle and syringe, the currently used 
delivery method for IPV. One of them is the ability to induce both serum and 
mucosal immune responses: the latter may  provide protection at the port of virus 
entry. 
The current study evaluated the possibilities of polio vaccination via mucosal 
surfaces using IPV based on attenuated Sabin strains (sIPV). Mice received three 
immunizations with trivalent sIPV via intramuscular injection, or via the intranasal 
or sublingual route. The need of an adjuvant for the mucosal routes was 
investigated as well, by testing sIPV in combination with the mucosal adjuvant 
cholera toxin. 
Both intranasal and sublingual sIPV immunization induced systemic polio-specific 
serum IgG in mice that were functional as measured by poliovirus neutralization. 
Intranasal administration of sIPV plus adjuvant induced significant higher 
systemic poliovirus type 3 neutralizing antibody titers than sIPV delivered via the 
intramuscular route. Moreover, mucosal sIPV delivery elicited polio-specific IgA 
titers at different mucosal sites (IgA in saliva, fecal extracts and intestinal tissue) 
and IgA-producing B-cells in the spleen, where conventional intramuscular 
vaccination was unable to do so. However, it is likely that a mucosal adjuvant 
is required for sublingual vaccination. Further research on polio vaccination 
via sublingual mucosal route should include the search for safe and effective 
adjuvants, and the development of novel oral dosage forms that improve antigen 
uptake by oral mucosa, thereby increasing vaccine immunogenicity. This study 
indicates that both the intranasal and sublingual routes might be valuable 
approaches for use in routine vaccination or outbreak control in the period after 
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INTRODUCTION
During the past decades, the global incidence of paralytic poliomyelitis has decreased 
by more than 99% since 1988. Type 2 wild poliovirus was eradicated in 1999 and the last 
reported case of type 3 wild poliovirus was from 2012. Since 2015, cases of type 1 wild 
poliovirus were only detected in the remaining endemic countries (i.e., Pakistan, Afghanistan 
and Nigeria) [1]. It is expected that wild poliovirus will be eradicated within a few years. 
However, to accomplish a polio-free world, eradication efforts should focus on both wild 
polioviruses as well as vaccine-derived viruses. Therefore, the endgame strategy of the 
Global Polio Eradication Initiative (GPEI) includes a phased withdrawal of the live-attenuated 
oral polio vaccine (OPV), the source of vaccine-derived viruses, and the worldwide inclusion 
of the inactivated polio vaccine (IPV) into all routine immunization programs [2]. The GPEI 
is pursuing several priority approaches for the development of a new generation of IPV [3]. 
To this extent, Intravacc has developed a new polio vaccine based on Sabin polio viruses, 
Sabin IPV (sIPV),  that is being transferred to local vaccine manufacturers to support post-
eradication goals in terms of biosafety and IPV availability [4-7].
A new generation of sIPV should not only be affordable and safe to produce, but preferably 
should also induce mucosal immunity, remain stable, and be easy to administer. This is 
important with regard to stockpiling and outbreak management in the period after cessation 
of OPV and after eradication. Several alternative polio vaccine delivery strategies are in 
development, with a focus on dermal delivery of polio vaccines [8]. Vaccination via mucosal 
sites has the benefits of needle free vaccine delivery . Moreover, mucosal immunization 
is able to elicit strong mucosal immunity, even at distant effector sites. As we know from 
OPV, polio-specific mucosal immunity in the gut is a powerful mechanism for protection and 
interruption of polio transmission [9].
The current study evaluated the potential of different mucosal routes, i.e., intranasal and 
sublingual, in mice. It was investigated whether intranasal or sublingual vaccination with sIPV 






Monovalent Sabin IPV bulk material used in this study was produced as described 
previously [10]. For the preparation of trivalent sIPV, monovalent type 1, type 2 and type 
3 were mixed and diluted in M199 medium (Bilthoven Biologicals, The Netherlands) to a 
nominal concentration of 1000-1600-3200 D-antigen units (DU) per mL for type 1, type 2 and 
type 3, respectively. Cholera toxin from Vibrio Cholerae was purchased from Sigma-Aldrich 
(St. Louis, MO).
Immunization study
The animal experiment was performed according to the guidelines provided by the Dutch 
Animal Protection Act, and was approved by the Committee of Animal Experimentation 
(DEC) of the National Institute of Public Health and Environment (RIVM). Balb/cOlaHsd mice 
(8-10 weeks old from Envigo, The Netherlands) were anesthetized with ketamine-xylazine, 
and received a single human dose (based on previous clinical studies [6, 11]) trivalent sIPV 
(10-16-32 DU/dose) via the intramuscular (IM, injection of 50 µL in hind limb), intranasal (IN, 
pipetting 10 µL in the nose) or sublingual (SL, pipetting 10 µL under the tongue) route at day 
0, 7 and 28. Adjuvanted groups received 5 µg/dose cholera toxin. Upon SL immunization, 
mice were maintained in upright position to minimize the risk of swallowing. Blood samples 
were taken at day 0 (prior to immunization) and day 14 (after second immunization). At day 
35, anesthetized animals received an intraperitoneal injection of 0.1 mL of 0.05 M pilocarpine 
(Sigma-Aldrich, St. Louis, MO) in PBS to induce saliva production. Saliva was collected 
and, subsequently, animals were sacrificed by bleeding. Post-mortem, fecal samples were 
isolated from the large intestine, weighted and stored at -80ºC until analysis. Spleens were 
placed in RPMI-1640 medium (Gibco, Invitrogen) supplemented with 5% fetal bovine serum 
and placed on ice for the B-cell ELISPOT. Small intestines were harvested and placed in 
3 mL PBS containing 50 mM EDTA (Gibco, Invitrogen) and protease inhibitors (Complete, 
Mini, EDTA free, Roche Applied Sciences). Small intestines were extensively vortexed and 
centrifuged for 15 min at 300 g (4ºC). Supernatants, mentioned further as intestinal wash, 
were collected and stored at -80ºC until analysis (IgA ELISA). Subsequently, small intestines 
were cut into small pieces, transferred to cryotubes, and 2 µL PBS containing 2% saponin 
(Sigma Aldrich, St. Louis, MO) and protease inhibitors was added per mg intestinal sample. 
After a fast freezing step, samples were centrifuged for 20 min at 4600 rpm and supernatants 
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were filtered through 0.22 µm filters (Merck Millipore, Darmstadt, Germany). Intestinal tissue 
samples were stored at -80ºC until further analysis. The presence of both excreted (intestinal 
washes) and intracellular (intestinal tissue samples) polio-specific IgA in small intestine was 
assessed by ELISA.
IgG and IgA ELISA 
Enzyme linked immunosorbent assays (ELISA) were performed to determine polio-
specific antibody titers in sera, saliva, feces, intestinal washes and intestinal tissue samples. 
Fecal extracts were prepared by adding fecal extract buffer, PBS containing 10% normal 
goat serum (Sigma Aldrich, St. Louis, MO) and protease inhibitors, to the fecal pellets (0.2 
g/mL). Fecal extracts were extensively vortexed and, subsequently, centrifuged for 15 min 
at 13000 g. Supernatants were filtered through 0.22 µm filters and immediately tested. For 
the ELISA, polystyrene 96 wells microtiter plates (Greiner Bio-One, Alphen a/d Rijn, The 
Netherlands) were coated overnight at 4°C with bovine anti-poliovirus serum (Bilthoven 
Biologicals, Bilthoven, The Netherlands) in PBS (Gibco from Invitrogen, Paisley, UK). After 
washing coated plates with 0.05% (v/v) Tween 80 (Merck, Darmstadt, Germany) in tap water, 
trivalent inactivated polio vaccine diluted in assay buffer, PBS containing 0.5% (w/v) Protifar 
(Nutricia, Zoetermeer, The Netherlands) and 0.05% (v/v) Tween 80 (Merck, Darmstadt, 
Germany), was added and incubated for 2h at 37°C. Subsequently, plates were washed and 
threefold sample dilutions in assay buffer were added and incubated for another 2h at 37°C. 
After washing, plates were incubated with horse-radish peroxidase (HRP)-conjugated goat-
anti-mouse IgG or HRP-conjugated goat-anti-mouse IgA (Southern Biotech, Birmingham, 
AL). After 1h incubation at 37°C, plates were washed and TMB substrate solution, 
containing 1.1 M sodium acetate (Bilthoven Biologicals, Bilthoven, The Netherlands), 100 
mg/mL 3,3’,5,5’-tetramethylbenzidine (Sigma-Aldrich, St. Louis, MO), and 0.006% (v/v) 
hydrogen peroxide (Merck, Darmstadt, Germany), was added to each well. After 10-15 
minutes, the reaction was stopped with 2 M sulfuric acid (Bilthoven Biologicals, Bilthoven, 
The Netherlands) and absorbance was measured at 450 nm by using a Biotek L808 plate 
reader. For the CT-specific ELISA, plates were coated with 1 µg/mL CT and blocked with 
1% Protifar in PBS. ELISA was further performed as described above. Endpoint titers were 
determined by 4-parameter analysis using the Gen5™ 2.0 Data Analysis software (BioTek 
Instruments, Inc., Winooski, VT) and defined as the reciprocal of the serum dilution producing 




Virus neutralization (VN) assay
Neutralizing antibodies against all three poliovirus types were measured separately by 
inoculating Vero cells with 100 TCID50 of the wild-type strains (Mahoney, MEF-1 and Saukett) 
as described previously [12, 13]. Twofold serial serum dilutions were made and serum/
virus mixtures were incubated for three hours at 36°C and 5% CO2 followed by overnight 
incubation at 5°C. Subsequently, Vero cells were added and after 7 days of incubation at 
36°C and 5% CO2, the plates were stained and fixed with crystal violet and results were read 
macroscopically. Virus neutralizing (VN) titers were expressed as the last serum dilution that 
has an intact monolayer (no signs of cytopathogenic effect). 
B-cell ELISPOT
MultiScreen-HTS IP 96 wells filter plates (Merck Millipore, Darmstadt, Germany) were 
wet by adding 35% ethanol, immediately washed twice with PBS and, subsequently, coated 
overnight with 5 µg/mL monovalent IPV type 1, 2 or 3. As a positive control, wells were 
coated with a mixture of 7 µg/mL purified goat-anti-mouse kappa and 7 µg/mL purified goat-
anti-mouse lambda (Southern Biotech). As a negative control, wells were left uncoated (PBS). 
After washing with PBS, plates were blocked with RPMI-1640 medium (Gibco, Invitrogen) 
with 2% Protifar (Nutricia, Zoetermeer, The Netherlands) for 1 hour at room temperature. 
Spleens were homogenized using a 70-µm cell strainer (BD Falcon, BD Biosciences) and 
cells were collected in RPMI-1640 supplemented with 10% fetal bovine serum and antibiotics 
(Penicillin-Streptomycin-L-Glutamine, 100x (Gibco, Invitrogen)). Erythrocytes were removed 
by ACK lysis buffer (Gibco, Invitrogen). After washing, cells were counted and 5x105 cells/
well were added to coated plates. After overnight incubation at 37°C and 5% CO2 plates were 
washed extensively and wells were developed by stepwise incubations with AP-conjugated 
goat-anti-mouse IgA (Southern Biotech) and washing with PBS followed by the addition of 
BCIP-NBT liquid substrate (Sigma Aldrich, St. Louis, MO). Plates were kept in dark during 
spot development and thereafter, the reaction was stopped by discarding the substrate and 
extensively washing of both sides of the filter with tap water. Plates were dried overnight at 
37°C and spots were counted using EliSpot reader (AID iSpot FluoroSpot Reader System, 
Autoimmun Diagnostika GmbH, Strassberg, Germany) and AID EliSpot software.
Statistical analysis
Data was statistically analyzed by comparing all groups by a Kruskal-Wallis test followed 
by a Dunn’s multiple comparisons test. Probability (p) values of p < 0.05 were considered 
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statistically significant. Statistics were performed using GraphPad Prism version 6.07 
(GraphPad Software Inc., La Jolla, CA).
RESULTS
Systemic immunity elicited after mucosal sIPV 
administration
To assess whether systemic immunity was induced after vaccination of mice with sIPV 
via conventional intramuscular (IM) injection, via the nose (intranasal, IN), or under the tongue 
(sublingual, SL), polio-specific IgG antibodies were measured in serum. For both mucosal 
routes (SL and IN), the vaccine was also given in the presence of cholera toxin (CT), which is 
known as a strong mucosal adjuvant [14-16]. Prior to immunization, no polio-specific immune 
responses were detected (data not shown). After two immunizations (day 14), evident polio-
specific IgG antibody titers were already induced in the group of mice vaccinated with sIPV 
via the conventional intramuscular route using needle and syringe (Figure 1A). Intranasal 
and sublingual administered sIPV without adjuvant induced significantly lower anti-polio 
type 1 IgG titers than the intramuscular control group (respectively, p<0.05 and p<0.001) 
(Figure 1A and 1B). However, the inclusion of CT as adjuvant significantly improved systemic 
IgG responses after intranasal sIPV vaccination. Animals that received sIPV plus CT via the 
intranasal route induced polio-specific IgG antibody titers similar to those obtained after 
intramuscular vaccination, both at day 14 (2 immunizations) (Figure 1A) and day 35 (3 
immunizations) (Figure 1B). For the sublingual route, higher numbers of responders were 
observed after immunization with sIPV plus CT with a significant enhanced IgG antibody titers 
against polio type 3 induced after 2 immunizations (day 14) (Figure 1A). For the induction of 
detectable systemic IgG after sublingual sIPV delivery, an adjuvant (Figure 1A) and/or at least 
3 vaccinations were needed (Figure 1B). 
To investigate the functionality, the virus-neutralizing capacity of the sera was determined 
after three immunizations. All mice from the intramuscular control group showed distinct 
neutralizing antibody titers against all three poliovirus types (Figure 2). The presence of CT 
adjuvant was beneficial for the induction of virus-neutralizing antibodies after sIPV vaccination 
via the sublingual or intranasal route. For all serotypes higher numbers of animals responded 
after mucosal sIPV immunization plus CT (Figure 2). Besides, significantly higher virus-
neutralizing (VN) titers were induced after intranasal vaccination of sIPV plus CT compared 





















































































































































































































Figure 1 Systemic immunity induced after vaccination with sIPV via parenteral or mucosal routes. 
Polio-specific IgG antibody endpoint titers in serum from mice (n = 8) immunized with sIPV via conventional 
intramuscular (IM, circles) injection or via sublingual (SL, squares) or intranasal (IN, triangles) route. For 
both mucosal routes, vaccinations were given in the absence (black symbols) or presence (pink symbols) 
of the mucosal adjuvant cholera toxin (CT). Sera were collected one week after the second (day 14, 
panel A) and third immunization (day 35, panel B). Bars represent mean values and error bars depict 
95% confidence interval values. Asterisks indicate significant differences between groups (* p<0.05, ** 





























































































Figure 2 Virus-neutralizing capacity of serum from mice immunized with sIPV via parenteral 
or mucosal routes. Virus-neutralizing (VN) serum antibody titers were measured from mice (n = 8) 
immunized three times with sIPV via conventional intramuscular (IM) injection or via sublingual (SL) or 
intranasal (IN) route. For both mucosal routes, vaccinations were given in the absence (black symbols) or 
presence (pink symbols) of the mucosal adjuvant cholera toxin (CT). Sera were collected one week after 
the third immunization (day 35). Bars represent mean VN titers and error bars depict 95% confidence 
interval values. Asterisks indicate significant differences between groups (* p<0.05, ** p<0.01). Hashtags 
indicate a significant difference with the conventional IM group (# p<0.05).
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(p<0.05). Similar VN titers were obtained after sublingual vaccination in the presence of an 
adjuvant compared to conventional intramuscular immunization (without adjuvant), although 
some non-responders were observed after sublingual vaccination (Figure 2). Interestingly, 
superior type 3-specific VN titers were observed after sIPV (plus adjuvant) delivery via the 
nose, even when compared to intramuscular injected sIPV (p<0.05) (Figure 2).
To evaluate whether differences in systemic immune responses could be assigned to a 
difference in antigen penetration through and uptake by mucosae, antibody titers against the 
adjuvant, the highly immunogenic cholera toxin (CT), were measured in sera from mice that 
received sIPV plus CT. After three immunizations, all animals induced evident CT-specific IgG 
antibody titers (Figure 3). Even after vaccination via the sublingual route, no non-responders 
were observed, whereas in some animals no detectable polio-specific IgG titers were found 
(Figure 1). Significantly improved IgG antibody titers against CT were observed after intranasal 
vaccination compared with those obtained after sublingual immunization (p<0.01) (Figure 3).
Mucosal immune responses induced after SL and IN 
immunization with sIPV
Polio-specific IgA antibody endpoint titers were determined in different mucosal 
samples to evaluate mucosal immunity after sIPV immunization of previously mentioned 
administration routes. Both sublingual and intranasal administration of sIPV induced polio-
specific IgA antibody responses in saliva (Figure 4A) and feces (Figure 4B), whereas the 


















Figure 3  Systemic antibody titers induced against cholera toxin (CT) delivered via sublingual or 
intranasal routes. CT-specific IgG antibody titers were measured in serum from mice (n = 8) immunized 
with sIPV plus CT as adjuvant via sublingual or intranasal route. Sera were collected one week after the 
third immunization (day 35). Individual (pink symbols) and mean (bars) are depicted. Error bars represent 




route induced no detectable salivary IgA against polio type 1 and 2, and no polio-specific 
fecal IgA (Figure 4A and 4B). Sublingual vaccination of sIPV in combination with CT resulted 
in higher numbers of mice having detectable IgA titers in mucosal samples. For type 3, 
significant salivary IgA titers were elicited after sublingual administration of sIPV plus CT 
(Figure 4A). Also significantly enhanced polio-specific IgA titers (all serotypes) were observed 
in mice immunized intranasally with sIPV plus CT, both in saliva (p<0.001) and feces (p<0.001) 
(Figure 4A and 4B). 
To evaluate the intestinal immune responses further, local IgA antibody production was 
determined by ELISA on detergent extractions of small intestinal samples. No intestinal 
immunity was induced after intramuscular vaccination with sIPV. Only for type 3, 25% of 
the animals induced polio-specific IgA in the intestine after sublingual delivery of sIPV, with 
or without adjuvant (Figure 4C). Again, animals immunized via the intranasal route with sIPV 
plus CT showed significantly improved IgA antibodies against polio type 1 (p<0.001), type 2 
(p<0.05) and type 3 (p<0.001) (Figure 4C). 
Polio-specific B cell responses elicited after SL and IN 
immunization with sIPV
The effect of the different immunization routes on the numbers of polio-specific plasma 
cells was evaluated in single cell suspensions from spleens. Whereas no IgA-secreting 
plasma cell responses were found in splenocytes from mice immunized via intramuscular 
injection, significantly enhanced numbers of IgA-producing B-cells were found in spleens 
of mice immunized via the intranasal route with either unadjuvanted sIPV (type 2 (p<0.05); 
type 3 (p<0.01)) or CT-adjuvanted sIPV (type 1 (p<0.001); type 2 (p<0.001); type 3 (p<0.05)) 
(Figure 5). The presence of CT enhanced the B cell responses after sublingual delivery of 
sIPV, since a higher number of animals showed IgA-producing B cell responses compared 
to the unadjuvanted sublingual group. Moreover, mice vaccinated sublingually with sIPV plus 
CT showed significantly enhanced numbers of polio type 2-specific IgA-secreting B cells 
(p<0.01) (Figure 5). 
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Figure 4  Mucosal immunity induced after sIPV delivery via mucosal routes. Polio-specific IgA 
endpoint titers in saliva, fecal extracts and intestinal tissue samples from mice (n = 8) immunized with sIPV 
in the absence (black symbols) or presence (pink symbols) of the mucosal adjuvant cholera toxin (CT) 
were measured. Immunizations were given via conventional intramuscular (IM) injection or via sublingual 
(SL) or intranasal (IN) routes. One week after the third immunization polio-specific IgA antibody titers 
were measured in saliva (panel A), fecal extracts (panel B) and intestinal tissue samples (panel C) were 
measured. Bars represent mean values and error bars depict 95% confidence interval values. Asterisks 
indicate significant differences between groups (* p<0.05, ** p<0.01, *** p<0.001) and hashtags indicate 




The goal of the current study was to evaluate whether mucosal administration of sIPV 
could elicit both systemic immunity and polio-specific mucosal IgA at distinct mucosal 
sites. sIPV delivered via the sublingual or intranasal route was able to induce systemic polio-
specific IgG responses with poliovirus-neutralizing capacity. Besides, mucosal vaccination 
of sIPV elicited polio-specific IgA antibody titers at distinct mucosal sites including strong 
intestinal responses after IN immunization and IgA-producing B cell responses in the spleen 
both after IN and SL immunization. 
Mucosal compartmentalization restricts the induction of intestinal immunity upon 
intranasal immunization [17, 18]. The existing paradigm that only gut-resident dendritic 
cells (DCs) can recruit T cells to the gastrointestinal tract is difficult to reconcile with our 
findings and other reports of gastrointestinal T cell responses and protective gut immunity 
after intranasal immunization of influenza [19, 20] or Salmonella antigen [21]. Ruane et al. 
showed that lung DCs, which were targeted by intranasal immunization, stimulated gut-
homing integrin α4β7 expression on CD4+ T cells in the lungs, and induced cell migration to 




























































































Figure 5  IgA-secreting B cell responses elicited after mucosal sIPV immunization. An ELISpot assay 
was performed to detect polio-specific IgA-secreting B cells from spleens from mice (n = 8) immunized 
with sIPV in the absence (black symbols) or presence (pink symbols) of the mucosal adjuvant cholera 
toxin (CT). Immunizations were given via conventional intramuscular (IM) injection or via sublingual (SL) 
or intranasal (IN) route. Bars represent mean antibody-secreting cell (ASC) numbers and error bars 
depict 95% confidence interval values. Asterisks indicate significant differences with the conventional 
IM control group (* p<0.05, ** p<0.01, *** p<0.001). 
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able to recruit antigen-specific immune cells to the gut and thereby inducing local intestinal 
immunity, which is in agreement with our findings.
Mucosal vaccine delivery has several practical advantages over vaccination via parenteral 
routes using needle and syringes, as previously mentioned. However, only relatively few 
mucosal vaccines for human use are licensed [23]. With the exception of some cholera 
vaccines, which have a very strong intrinsic immune potentiating capacity [24], all these 
mucosal vaccines are live attenuated vaccines, like OPV or intranasal influenza vaccines 
(Flumist/Fluenz) [8, 25]. In contrast to OPV, mucosal polio vaccination based on IPV is 
expected to require the inclusion of an adjuvant to evoke appropriate immunity against polio 
[13], which was confirmed in the current preclinical study. Both intranasal and sublingual 
vaccination of sIPV plus cholera toxin (CT) as adjuvant were able to significantly enhance 
functional systemic immunity and polio-specific IgA titers in mucosal samples compared 
to immune responses obtained after mucosal sIPV vaccination without adjuvant. However, 
CT and the Escherichia coli-derived heat-labile toxin (LT) are well known as potent mucosal 
adjuvants, but are also associated with adverse effects in humans. Concerns has been raised 
after an undesired association between facial nerve paralysis (Bell’s palsy) and the intranasally 
delivered inactivated influenza vaccine (Nasalflu) containing an enzymatically active LT 
adjuvant [26]. Probably the neuronal-binding capacity of the LT-derived adjuvant was the 
cause of this adverse effect suggesting that nasal administration of LT or CT molecules is 
inadvisable [27]. Migration to or accumulation in the central nerve system might be avoided 
by vaccine administration under the tongue [28-30]. Moreover, in a recent Phase 1 study 
(NCT00820144) conducted in France, the sublingual administration of recombinant CT B 
subunit in healthy subjects was found to be safe. Therefore, a new safe mucosal adjuvant 
with strong immune potentiating capacity should be included in the further development 
of a mucosal (Sabin) IPV although adverse effects after sublingual immunization are not 
documented as far as we know. Since the mucosal route is minimally addressed for IPV yet, 
current experience is limited to the use of a double mutant of LT (dmLT) in combination with 
the sublingual route as described by White et al. [31]. Adjuvants (e.g., LPS derivative PagL, 
oil-in-water emulsions, CpG ODN) that have shown their potential for (Sabin) IPV via the 
parenteral route could also be evaluated for mucosal vaccination [12, 32]. 
In the last decade, sublingual vaccine delivery has gained significant attention as shown 
by the numerous published preclinical studies that provide a strong base for further testing of 
this non-invasive route [33]. Our findings and earlier research indicates that the inclusion of an 
adjuvant might be needed to avoid tolerance or low-to-undetectable immune responses after 
156
CHAPTER 7
sublingual delivery of IPV [31]. Besides the inclusion of an adjuvant as immune potentiator, 
novel oral dosage forms to improve contact time or to facilitate transport through the mucosal 
barrier, may be required to achieve successful vaccination. White et al. studied the sublingual 
route for IPV (based on Salk strains) using a thermoresponsive gel (TRG) delivery system [31]. 
Whereas sublingual administration of IPV as a liquid or as TRG in the absence of an adjuvant 
was not able to induce any immune response in mice, sublingual administered IPV as TRG in 
combination with the mucosal adjuvant dmLT led to systemic poliovirus-neutralizing antibody 
titers, and salivary and fecal IgA production [31]. A comparison between the liquid and TRG 
formulation (both with or without adjuvant) is missing, but it is expected that mucoadhesive 
dosage forms that prolong the residence time of the vaccine at the oral mucosa and thereby 
facilitate antigen uptake by local antigen-presenting cells, are needed [13, 33]. Research on 
sublingual polio vaccination may, besides the use of novel adjuvants, comprise development 
of extended release formulations, including solid dosage forms that at the same time improve 
the thermostability of the vaccine as well. Earlier studies revealed that dried IPV can be more 
resistant to higher temperatures compared to liquid IPV [34-36]. 
The phased withdrawal of OPV and inclusion of IPV into all global routine immunization 
programs will create a market for non-invasive delivery of polio vaccines, even a considerable 
time after eradication either for routine immunization or stock piling. Improved polio vaccine 
delivery strategies should be suitable for the final target population: infants. The current study 
demonstrated the potential of both the intranasal and sublingual routes for polio vaccination 
with IPV based on Sabin strains. Intranasal vaccination showed to be more efficient in 
eliciting both systemic and mucosal immune responses compared with the sublingual route. 
However, besides possible redirection to olfactory bulbs (Bell’s palsy), the risk of wheezing in 
young children exists [8]. The sublingual route could be an easy and safe polio immunization 
approach. Nevertheless, for the induction of evident immunity upon sIPV vaccination under 
the tongue, strong mucosal adjuvants might be required. Therefore, further research on 
polio vaccination via the sublingual route should include the search for a safe and effective 
adjuvant and the development of novel oral dosage forms that improve antigen uptake by 
the oral mucosa.
7
INTRANASAL AND SUBLINGUAL DELIVERY OF IPV 
157
ACKNOWLEDGMENTS
The authors would like to thank the colleagues from the animal research center of 
Intravacc for their assistance with the animal studies, and Geert-Jan Willems for performing 




1. Global Polio Eradication Initiative.  History of 
Polio. Available from: http://polioeradication.org/; 
[accessed on 3 January 2017].
2. Global Polio Eradication Initiative. Polio Eradication 
& Endgame Strategic Plan 2013-2018. Available 
from: http://polioeradication.org/wp-content/
uploads/2016/07/PEESP_EN_A4.pdf; 2013; 
[accessed on 3 January 2017].
3. Okayasu H, Sutter RW, Jafari HS, Takane M, Aylward 
RB. Affordable inactivated poliovirus vaccine: 
strategies and progress. J Infect Dis. 2014;210 
Suppl 1:S459-64.
4. Thomassen YE, van ‘t Oever AG, van Oijen MG, 
Wijffels RH, van der Pol LA, Bakker WA. Next 
generation inactivated polio vaccine manufacturing 
to support post polio-eradication biosafety goals. 
PLoS One. 2013;8:e83374.
5. Verdijk P, Rots NY, van Oijen MG, Oberste MS, Boog 
CJ, Okayasu H, et al. Safety and immunogenicity of 
inactivated poliovirus vaccine based on Sabin strains 
with and without aluminum hydroxide: a phase I trial 
in healthy adults. Vaccine. 2013;31:5531-6.
6. Verdijk P, Rots NY, van Oijen MG, Weldon WC, 
Oberste MS, Okayasu H, et al. Safety and 
immunogenicity of a primary series of Sabin-IPV with 
and without aluminum hydroxide in infants. Vaccine. 
2014;32:4938-44.
7. Resik S, Tejeda A, Fonseca M, Alemani N, Diaz M, 
Martinez Y, et al. Reactogenicity and immunogenicity 
of inactivated poliovirus vaccine produced from 
Sabin strains: a phase I Trial in healthy adults in 
Cuba. Vaccine. 2014;32:5399-404.
8. Kraan H, van der Stel W, Kersten G, Amorij JP. 
Alternative administration routes and delivery 
technologies for polio vaccines. Expert Rev 
Vaccines. 2016;15:1029-40.
9. Hird TR, Grassly NC. Systematic review of 
mucosal immunity induced by oral and inactivated 
poliovirus vaccines against virus shedding 
following oral poliovirus challenge. PLoS Pathog. 
2012;8:e1002599.
10. Thomassen YE, Rubingh O, Wijffels RH, van der 
Pol LA, Bakker WA. Improved poliovirus D-antigen 
yields by application of different Vero cell cultivation 
methods. Vaccine. 2014;32:2782-8.
11. Soonawala D, Verdijk P, Wijmenga-Monsuur AJ, 
Boog CJ, Koedam P, Visser LG, et al. Intradermal 
fractional booster dose of inactivated poliomyelitis 
vaccine with a jet injector in healthy adults. Vaccine. 
2013;31:3688-94.
12. Westdijk J, Koedam P, Barro M, Steil BP, Collin N, 
Vedvick TS, et al. Antigen sparing with adjuvanted 
inactivated polio vaccine based on Sabin strains. 
Vaccine. 2013;31:1298-304.
13. Kraan H, van der Stel W, Kersten G, Amorij JP. 
Alternative administration routes and delivery 
technologies for polio vaccines. Expert Rev 
Vaccines. 2016:1-12.
14. Amorij JP, Westra TA, Hinrichs WL, Huckriede A, 
Frijlink HW. Towards an oral influenza vaccine: 
comparison between intragastric and intracolonic 
delivery of influenza subunit vaccine in a murine 
model. Vaccine. 2007;26:67-76.
15. Cuburu N, Kweon MN, Hervouet C, Cha HR, Pang 
YY, Holmgren J, et al. Sublingual immunization with 
nonreplicating antigens induces antibody-forming 
cells and cytotoxic T cells in the female genital tract 
mucosa and protects against genital papillomavirus 
infection. J Immunol. 2009;183:7851-9.
16. Sjokvist Ottsjo L, Jeverstam F, Yrlid L, Wenzel AU, 
Walduck AK, Raghavan S. Induction of mucosal 
immune responses against Helicobacter pylori 
infection after sublingual and intragastric route of 
immunization. Immunology. 2017;150:172-83.
17. Quiding-Jarbrink M, Granstrom G, Nordstrom 
I, Holmgren J, Czerkinsky C. Induction of 
compartmentalized B-cell responses in human 
tonsils. Infect Immun. 1995;63:853-7.
18. Quiding-Jarbrink M, Nordstrom I, Granstrom G, 
Kilander A, Jertborn M, Butcher EC, et al. Differential 
expression of tissue-specific adhesion molecules 
on human circulating antibody-forming cells after 
systemic, enteric, and nasal immunizations. A 
molecular basis for the compartmentalization 
of effector B cell responses. J Clin Invest. 
1997;99:1281-6.
19. Masopust D, Choo D, Vezys V, Wherry EJ, 
Duraiswamy J, Akondy R, et al. Dynamic T cell 
migration program provides resident memory within 
intestinal epithelium. J Exp Med. 2010;207:553-64.
20. Esplugues E, Huber S, Gagliani N, Hauser AE, Town 
T, Wan YY, et al. Control of TH17 cells occurs in the 
small intestine. Nature. 2011;475:514-8.
21. Pigny F, Lassus A, Terrettaz J, Tranquart F, Corthesy 
B, Bioley G. Intranasal Vaccination With Salmonella-
Derived Serodominant Secreted Effector Protein B 
Associated With Gas-Filled Microbubbles Partially 
Protects Against Gut Infection in Mice. J Infect Dis. 
2016;214:438-46.
22. Ruane D, Brane L, Reis BS, Cheong C, Poles J, 
Do Y, et al. Lung dendritic cells induce migration of 
protective T cells to the gastrointestinal tract. J Exp 
Med. 2013;210:1871-88.
23. Holmgren J, Svennerholm AM. Vaccines 
against mucosal infections. Curr Opin Immunol. 
2012;24:343-53.
24. Cong Y, Bowdon HR, Elson CO. Identification of an 
immunodominant T cell epitope on cholera toxin. Eur 
J Immunol. 1996;26:2587-94.
25. Amorij JP, Hinrichs W, Frijlink HW, Wilschut JC, 
Huckriede A. Needle-free influenza vaccination. The 
Lancet Infectious diseases. 2010;10:699-711.
26. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, 
Linder T, et al. Use of the inactivated intranasal 
influenza vaccine and the risk of Bell’s palsy in 
Switzerland. The New England journal of medicine. 
2004;350:896-903.
27. Lewis DJ, Huo Z, Barnett S, Kromann I, Giemza R, 
Galiza E, et al. Transient facial nerve paralysis (Bell’s 
palsy) following intranasal delivery of a genetically 
detoxified mutant of Escherichia coli heat labile 
toxin. PloS one. 2009;4:e6999.
28. Cuburu N, Kweon MN, Song JH, Hervouet C, Luci 
C, Sun JB, et al. Sublingual immunization induces 
broad-based systemic and mucosal immune 
responses in mice. Vaccine. 2007;25:8598-610.
7
INTRANASAL AND SUBLINGUAL DELIVERY OF IPV 
159
29. Song JH, Nguyen HH, Cuburu N, Horimoto T, Ko SY, 
Park SH, et al. Sublingual vaccination with influenza 
virus protects mice against lethal viral infection. Proc 
Natl Acad Sci U S A. 2008;105:1644-9.
30. Shim BS, Stadler K, Nguyen HH, Yun CH, Kim 
DW, Chang J, et al. Sublingual immunization with 
recombinant adenovirus encoding SARS-CoV spike 
protein induces systemic and mucosal immunity 
without redirection of the virus to the brain. Virol J. 
2012;9:215.
31. White JA, Blum JS, Hosken NA, Marshak JO, 
Duncan L, Zhu C, et al. Serum and mucosal antibody 
responses to inactivated polio vaccine after 
sublingual immunization using a thermoresponsive 
gel delivery system. Human vaccines & 
immunotherapeutics. 2014;10:3611-21.
32. Yang C, Shi H, Zhou J, Liang Y, Xu H. CpG 
oligodeoxynucleotides are a potent adjuvant for 
an inactivated polio vaccine produced from Sabin 
strains of poliovirus. Vaccine. 2009;27:6558-63.
33. van der Maaden K, Trietsch SJ, Kraan H, Varypataki 
EM, Romeijn S, Zwier R, et al. Novel hollow 
microneedle technology for depth-controlled 
microinjection-mediated dermal vaccination: a study 
with polio vaccine in rats. Pharmaceutical research. 
2014;31:1846-54.
34. Kraan H, van Herpen P, Kersten G, Amorij 
JP. Development of thermostable lyophilized 
inactivated polio vaccine. Pharmaceutical research. 
2014;31:2618-29.
35. Kraan H, Ploemen I, van de Wijdeven G, Que I, 
Lowik C, Kersten G, et al. Alternative delivery of a 
thermostable inactivated polio vaccine. Vaccine. 
2015;33:2030-7.
36. Kraan H, Ten Have R, van der Maas L, Kersten 
G, Amorij JP. Incompatibility of lyophilized 
inactivated polio vaccine with liquid pentavalent 









dissolving films for 
polio vaccination
Heleen Kraan 1, J. Carolina Visser 2, Peter Soema 1, 
Geert-Jan Willems 1, Gideon Kersten 1,3, Henderik W. Frijlink 2, 
Jean-Pierre Amorij 1
1 Intravacc (Institute for Translational Vaccinology), Bilthoven, The Netherlands
2 Department of Pharmaceutical Technology and Biopharmacy, University of
 Groningen, Groningen, The Netherlands 
3 Division of Drug Delivery Technology, Leiden Academic Center for Drug 




Alternative delivery technologies for polio vaccination might be of importance in 
the development of improved polio vaccines that are needed towards complete 
polio eradication and their use in the period thereafter. Vaccination via oral 
mucosa, like the sublingual or buccal route, could be an easy applicable and safe 
polio immunization approach for routine immunization or as a tool for outbreak 
intervention after cessation of the live oral polio vaccine. 
Aim of the current study was to evaluate the possibility to make polymer-
based films containing trivalent sIPV and suitable for oromucosal vaccination. 
A combination of a Design of Experiments approach and the evaluation of 
excipients with already proven stabilizing capacity of polio antigens was used to 
develop sIPV-containing oral film formulations while preserving its D-antigenicity 
for 85-100% for type 1, 60-85% for type 2, and 50-75% for type 3. This study 
revealed that a combination of excipients based on sorbitol, magnesium chloride 
and monosodium glutamate, has strong stabilizing potential for sIPV-films, even 
when combined with different film formers, i.e., hydroxypropyl cellulose, sodium 
glutamate or sodium carboxymethyl cellulose. This pivotal study showed the 
promise of dried polymer-based sIPV-films that might be suitable for sublingual 
or buccal polio vaccination. Further optimization is required during future product 
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INTRODUCTION
Since eradication of polio is one of the top global health priorities, the need for inactivated 
polio vaccines (IPV) that are more affordable, more effective, and safer than existing polio 
vaccines is higher than ever. This new generation of IPV, for instance based on attenuated 
Sabin strains, should preferably also induce mucosal immunity, remain stable outside the 
cold-chain, and be easy to administer. Such a vaccine is valuable with regard to stockpiling 
and outbreak control in the period after complete cessation of the oral polio vaccine (OPV) 
and after polio eradication [1]. Vaccination via mucosal sites has the benefits of needle free 
vaccine delivery and may induce strong mucosal immunity, even at distant effector sites. 
The induction of polio-specific immunity in the gut protects against polio infection and may 
interrupt the person-to-person transmission of poliovirus [2]. 
A previous study in mice revealed that sublingual immunization with fluid Sabin IPV (sIPV) 
induced systemic poliovirus-neutralizing immune responses as well as polio-specific IgA-
producing B cells in the spleen. Moreover, sublingual sIPV delivery elicited polio-specific 
IgA antibodies at different mucosal sites, where conventional intramuscular vaccination 
was unable to do so [3]. In the same study, intranasal sIPV vaccination showed to be more 
efficient in eliciting polio-specific immune responses as compared with the sublingual route 
[3]. However, besides the concern of uptake by nervous tissue via the olfactory bulbs, which 
may cause adverse effects (like Bell’s palsy), the risk of wheezing in young children exists, 
making the intranasal route potentially less suitable for infants [1]. Sublingual vaccine delivery 
has gained significant attention as shown by the numerous studies on this innovative and 
non-invasive route [4]. For sublingual IPV delivery, the inclusion of an adjuvant may be 
required to circumvent tolerance or low-to-undetectable immune responses [3, 5]. Besides, 
novel oral dosage forms that facilitate transport through the oral mucosa, for example by 
extending the contact time of the antigen, might be desirable for successful vaccination. 
Several dosage forms exist for sublingual and buccal delivery of marketed drugs. 
However, not all of them will be suitable for oral mucosal vaccine delivery and only few have 
been used to explore sublingual delivery of vaccines. Novel dosage forms that might have 
the ability to retain the antigen at the sublingual or buccal delivery site are (mucoadhesive) 
oromucosal films or -tablets, and thermoresponsive gels. Currently, only thermoresponsive 
gels, which are aqueous solutions at room temperature but transform into gels when at body 
temperature (e.g., upon contact with the mucosa), have been non- and preclinical evaluated 
as new dosage form for sublingual delivery of IPV. Sublingual administration of these gels, 
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containing Salk IPV plus a double mutant heat-labile toxin (dmLT) as adjuvant, induced polio-
specific functional antibodies in serum as well as polio-specific IgA antibodies in mucosal 
samples [5]. Among the solid oral dosage forms are the (mucoadhesive) extended release 
films and tablets. Converting the vaccine into the dry state might improve the thermostability 
and could therefore reduce vaccine system costs tremendously. When vaccines no longer 
require cold storage, or could be kept out of the cold-chain long enough for their transport 
to remote areas in developing countries, logistic costs will decrease and vaccine availability 
will be improved [6, 7].
Aim of the current study was to evaluate the possibility to make polymer-based oromucosal 
films containing trivalent sIPV. First, a target product profile (TPP) describing the desired 
properties and characteristics of a final product was defined. Among those characteristics 
are the critical quality attributes (CQAs), which should be within an appropriate limit, range 
or distribution to ensure the desired product quality, efficacy and safety of the product when 
used [8, 9]. Further on, different film forming polymers (i.e., hydroxypropyl cellulose (HPC), 
sodium alginate and sodium carboxymethyl cellulose (CMC)) were selected from literature 
and tested in combination with excipients that were able to stabilize the antigen during the 
drying process. D-antigenicity of prepared oral films was assessed in an ELISA directly upon 
drying. To gain insight into the effects of the main components, i.e. film forming polymer 
and plasticizers, on both D-antigen recovery and physical/mechanical film characteristics, a 
Design of Experiments (DoE) approach was used. Subsequently, oral film formulations were 
further optimized based on D-antigen recovery of each serotype. It was investigated whether 
the addition of sugars or the combination sorbitol, magnesium chloride and monosodium 
glutamate could further improve the D-antigen recovery of each serotype in order to yield an 
oral film formulation with minimal loss of antigenicity during the drying process.
MATERIALS AND METHODS
Materials
Monovalent Sabin IPV bulk material used in this study was produced as described 
previously [10]. For the preparation of trivalent sIPV, monovalent type 1, type 2 and type 3 
were mixed and, subsequently, concentrated using 10 kDa Amicon® Ultra Centrifugal Filters 
(Merck Millipore, Billerica, MA). 
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The excipients hydroxypropyl cellulose (HPC), glycerol, D-sorbitol, D-trehalose 
dehydrate, sucrose, maltodextrin, L-glutamic acid monosodium salt monohydrate (MSG), 
magnesiumchloride hexahydrate and TRIS (Trizma Base) were purchased from Sigma Aldrich 
(St. Louis, MO). To prepare 10 mM phosphate buffer, 10 mM disodium hydrogen phosphate 
heptahydrate (Na2HPO4 * 7H20 from Merck, Darmstadt Germany) was added to 10 mM 
potassium dihydrogen phosphate (Na2HPO4 from Merck, Darmstadt, Germany) until pH 7.0 
was reached. All excipients used were of reagent quality or higher grade.
Methods
Preparation of casting solutions
For the preparation of stock solutions, excipients were dissolved in 10 mM TRIS (for 
HPC-containing films) or phosphate buffer (SA- or CMC-containing films) (under constant 
stirring). After complete dissolution, the pH was adjusted to 7.0 ± 0.1 and, subsequently, 
formulations were mixed with concentrated sIPV bulk using an Intelli-Mixer. Air bubbles were 
removed by a short spin in an Eppendorf centrifuge. Placebo film formulations were prepared 
for viscosity measurements and determination of film characteristics as described previously 
[11]. The viscosity of the casting solutions was measured directly after preparation at ambient 
temperature using a viscometer (Brookfield, Middleboro, USA). Depending on the viscosity of 
the casting solution spindle T-B or S04 was used.
Standard film casting method
The solutions were cast onto a release liner (Primeliner® 410/36, Loparex, Apeldoorn, The 
Netherlands) with a quadruple film applicator using a casting height of 1000 µm. The release 
liner was fixed to a COATMASTER film casting apparatus (Erichsen, Hemer, Germany) by 
vacuum suction. The casting speed was 10 mm/s and, subsequently, the film layer was 
dried at 30°C and at ambient relative humidity. Placebo films were punched using an Artemio 
perforator (Artemio, Wavre, Belgium) in squares of 1.8 x 1.8 cm, yielding stamp-shaped oral 




Ring-based film casting method
Formulations containing sIPV were cast into metal rings (Ø 1.6 cm) in a volume of 201 
µL/ring (corresponding with casting height of 1000 µm) onto polyethylene terephthalate 
foil (Silphan S75 M371, Siliconature, Treviso, Italy) as release liner (see Figure 1B). CMC-
containing films were cast in a volume of 301 µL/ring (casting height 1500 µm)), since films 
with holes were obtained when casting at 1000 µm casting height. Subsequently, the film 
layer was dried at 30°C and ambient relative humidity for up to 20h. This novel ring-based 
method was developed to avoid spreading or shrinkage of the liquid formulations with low 




Figure 1 Preparation of films was performed using different film production methods. Since standard 
film casting method using a film casting apparatus (A) resulted sometimes in spreading (A: upper right 
formulation) or shrinkage (A: lower formulations) of the liquid formulations with low viscosity, a ring-
based film casting method (B) was developed. sIPV-containing oral film formulations consisting of 
sodium carboxymethyl cellulose, sorbitol, magnesium chloride and monosodium glutamate resulted in 
transparent films that were easily removable from the release liner, either when cast with the standard 
(C) or ring-based film casting method (D). Due to shrinkage of the casting solution on the release liner 
directly upon standard casting, an irregular shaped film is formed (C), whereas the ring-based method 
yield a more uniform film surface.
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Physical and mechanical characterization of oral films
Placebo film formulations were prepared to evaluate physical and mechanical properties 
of oral films. The thickness was measured using a microscrew meter (Mitutoyo, Neuss, 
Germany) at five different points of the prepared film. Uniformity of mass was determined 
according to the Ph. Eur. 9th edition: uniformity of mass for single-dose preparations. Twenty 
randomly chosen oral films were weighed individually on an analytical balance and average 
mass was calculated. Residual water content of placebo film formulations was measured 
using an infrared moisture analyzer (Sartorius MA40, Sartorius Göttingen, Germany). 
Approximately 1.5 gram of oral films were weighed and heated at 105°C for at least 1.5h until 
equilibrium in weight was reached. Loss on drying was calculated as the difference (in %) in 
mass between the initial weight and the final weight at equilibrium:
The mechanical properties of oral films were analyzed as described previously [11]. A 
minimum of six punched films were tested using an Instron series 5500 load frame with 
a load cell of 100N (Instron, Norwood, USA). Films were fixed between two clamps that 
moved away from each other with a crosshead speed of 50 mm/min until film tearing or 
breakage. Tensile strength (N/mm2), Young’s modulus (N/mm2) and elongation at break (%) 
were calculated using the following equations:
D-antigen ELISA
Immediately after drying, sIPV-containing films were dissolved and analyzed for 
antigenically active D-antigen by ELISA as described earlier with some small adaptations 
[12]. Microtiter plates were coated overnight with serotype-specific bovine anti-polio serum 
Loss on drying = Initial film weight (t=0) - Film weight (t=1.5h)
Initial film weight (t=0)
x 100
Tensile strength = load at auto break
cross-sectional area of film
x 100
Young’s modulus = slope of stress-strain curve
lm thickness x cross-head speed









and, subsequently, blocked with 1% bovine serum albumin (Sigma Aldrich, St. Louis, MO) in 
PBS for 30 min at 37°C. After washing with 0.05% Tween 80 (Merck, Darmstadt, Germany) 
in PBS, serial dilutions of sIPV samples (reconstituted films or liquid controls) were added 
and incubated for 2h at 37°C. Subsequently, plates were washed and serotype-specific 
monoclonal antibodies (HYB295-17-02 (type 1), HYB294-06-02 (type 2), HYB300-06 (type 
3) from Thermo Fisher Scientific, or 4-8-7 (Bilthoven Biologicals, Bilthoven, The Netherlands) 
were added and incubated for 2h at 37°C. After another washing step, HRP-labeled anti-
mouse IgG (GE Healthcare, Buckinghamshire, UK) was added, plates were incubated for 1h 
at 37°C, washed, and SureBlue tetramethylbenzidine (TMB) Microwell Peroxidase Substrate 
(Kirkegaard & Perry Laboratories, Gaithersburg, MD) was added. After 10 min, the reaction 
was stopped with 0.2 M sulfuric acid and absorbance at 450 nm was measured. Assay data 
were analyzed by four-parameter logistic curve fitting and D-antigen content was calculated 
relative to the reference standard.
Design of Experiments (DoE)
A Design of Experiments (DoE) approach was used to evaluate the effects of HPC 
(10-15% w/v), glycerol (0-2.5% w/v) and sorbitol (0-5% w/v) on both D-antigen recovery 
upon drying and mechanical film properties. A full factorial screening design (Table 1) was 
performed and analyzed using Modde software (version 12, Umetrics AB, Umea, Sweden). 
Table 1 Design of Experiments worksheet. Composition of all formulations tested in a full factorial 
design were displayed in the design matrix.






N1 10 0 0
N2 15 0 0
N3 10 2.5 0
N4 15 2.5 0
N5 10 0 5
N6 15 0 5
N7 10 2.5 5
N8 15 2.5 5
N9 12.5 1.25 2.5
N10 12.5 1.25 2.5
N11 12.5 1.25 2.5
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Models were fitted using multilinear regression (MLR) and subsequent optimized by deleting 
non-significant terms leading to a model with the best model performance parameters, i.e., 
goodness of fit (R2), goodness of prediction (Q2), model validity and reproducibility.
RESULTS AND DISCUSSION
Target product profile
The establishment of a target product profile (TPP) is a helpful tool to focus research on a 
certain technology and product development efforts in order to support efficient and directed 
product development [9]. A TPP describes the desired properties and characteristics of 
a final product. The current study was started with the establishment of a TPP for sIPV-
containing orally dissolving film formulations appearing as (semi)-transparent films (Table 
2). Moreover, some of the characteristics were defined as critical quality attribute (CQA), 
because these properties should be within an appropriate limit to ensure the desired product 
quality and thereby adequate performance and safety of the product when used [8]. The TPP 
is a dynamic summary that changes as knowledge during product development increases. 
Therefore, the anticipated quality target product profile (QTPP) might also be subjected to 
changes (Table 2). 
Since the proposed administration route differs from the conventional route for sIPV 
(intramuscular or subcutaneous injection), dose-finding studies should define the single 
human dose for oral dosage forms, like oromucosal films. Moreover, the size of the film 
depends on what is acceptable for the intended target population and should thus be defined 
later in development (Table 2). Variability will affect efficacy, so content uniformity should 
be within certain limits, which will be defined upon selection of validated assays for the 
assessment of content and conform relevant guidelines. Moreover, a high or low pH will 
disrupt the polio particle thereby affecting the vaccine’s efficacy. The pH limits were set on 
pH 6.5 - 7.0.
Unfortunately, mechanistic studies designed to evaluate and define the optimal conditions 
for sublingual (or buccal) vaccine delivery are lacking in literature. It remains speculative what, 
for example, the optimal release profile of an oral dosage form for sublingual vaccination is. 
Moreover, to what extend residual water content of oral films might affect product performance 
or stability is still unknown. Hence, CQA targets, but also critical process parameters having 
an impact on CQAs, should be determined during future product development and based 
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on risk assessments. Although they are relevant for the final product, it was decided not to 
focus extensively on all critical quality characteristics, like water content, dissolution and 
disintegration time, during the current (preliminary) study on sIPV-oral films.
Table 2 Target product profile of an IPV-containing oromucosal film. The current table summarizes the 
desired target product profile of an orally dissolvable film containing Sabin IPV.
Attributes Target product profile (TPP)
Anticipated 
QTPP1 -  
CQA2
Justification





Target set to ensure recipient acceptability
Target population Infants No
Administration 
route
Buccal or sublingual No
Dose t.b.d. Yes Dose finding studies should define dose needed for 
buccal or sublingual route.








Antigen release within 
24h
Yes Release profile is important for bioavailability and 
antigen uptake. Also recipient acceptability plays 
a role.
Storage 2-8°C No Defined based on stability results.
Stability At least 36 months 
shelf-life at 2-8°C
Yes Ideally, oral sIPV films should be at least as 
stable as the liquid sIPV vaccine. Depending on 
acceptable dose range (efficacy and safety).
Container closure 
system
t.b.d. Yes Needed to achieve target shelf-life and ensure the 
product integrity during storage.
NB: If defined properly without having impact on 
product quality and integrity, this attribute is not 
critical.




t.b.d. Yes Depending on design space, acceptable RMC 
range and subsequent stability and D-antigen 
recovery as result of formulation and drying 
process.
NB: Limited amounts of water in oral dosage forms 
will not impact patient safety or efficacy.
Disintegration t.b.d. Yes Film strength will affect release profile and may 
impact efficacy.
1 Quality target product profile (QTPP) – prospective summary of the quality characteristics; critical quality attributes.
2 Critical Quality Attribute (CQA) - should be within defined targets to ensure the desired product quality.
Abbreviations used: n.a. - not applicable; t.b.d. - to be determined
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Table 3 Oral film formulations tested in full factorial screening experiment using a Design of Experiments 
(DoE) approach including hydroxypropyl cellulose (HPC), glycerol and sorbitol as excipients. Viscosity of 









































































































N1 296 + 25.2 ± 2.3 61.9 ± 5.1 2.93 20.2 ± 7.9 315.5 ± 49.3 2.8 ± 0.6 16.2 ± 2.1
N2 1490 + 35.9 ± 2.0 86.4 ± 5.1 3.14 28.1 ± 6.9 319.4 ± 22.9 3.2 ± 0.3 29.0 ± 3.2
N3 270 - n.d. n.d. n.d. n.d. n.d. n.d. n.d.
N4 1700 +/- 39.9 ± 3.4 91.4 ± 10.1 7.69 93.1 ± 35.6 71.2 ± 11.2 0.5 ± 0.2 19.7 ± 3.0
N5 458 - n.d. n.d. n.d. n.d. n.d. n.d. n.d.
N6 2900 - n.d. n.d. n.d. n.d. n.d. n.d. n.d.
N7 634 - n.d. n.d. n.d. n.d. n.d. n.d. n.d.
N8 3170 +/- 48.7 ± 2.9 137.1 ± 27.4 8.73 17.1 ± 6.0 61.3 ± 25.4 0.6 ± 0.2 14.8 ± 2.7
N9 890 +/- 38.5 ± 5.1 101.5 ± 12.1 6.39 14.6 ± 3.7 93.9 ± 30.8 0.8 ± 0.3 14.4 ± 4.7
n.d. – not detectable
Table 4 Oral film formulations tested in full factorial screening design including hydroxypropyl cellulose 









(% w/v) D-antigen recovery (%)
Type 1 Type 2 Type 3
N1 10 0 0 9.1 n.d 10.8
N2 15 0 0 13.6 n.d 20.0
N3 10 2.5 0 n.d. n.d 6.0
N4 15 2.5 0 n.d. n.d 5.5
N5 10 0 5 48.2 32.8 34.7
N6 15 0 5 40.8 19.7 34.6
N7 10 2.5 5 30.3 42.9 36.8
N8 15 2.5 5 27.0 39.5 39.0
N9 12.5 1.25 2.5 7.8 22.2 27.0
N10 12.5 1.25 2.5 7.1 17.8 24.4
N11 12.5 1.25 2.5 7.5 16.2 24.5




Full factorial screening design 
To gain insight into the effects of the main components of oral film formulations, i.e. film 
forming polymer hydroxypropyl cellulose (HPC), and plasticizers glycerol and sorbitol, on both 
physical/mechanical film characteristics and D-antigen recovery, a full factorial screening 
design was performed. Viscosity of the (placebo) casting solutions was measured and ranged 
from 270 to 634 mPa.s and from 1490 to 3170 mPa.s for formulations containing respectively 
10% (w/v) (N1, N3, N5 and N7) and 15% (w/v) HPC (N2, N4, N6 and N8) (Table 3). All solutions 
were homogenous and no air bubbles occurred during the casting procedure, so all were 
suitable for casting. Formulation N1, consisting of 10% (w/v) HPC only, spreads too much 
directly after casting due to the relatively low viscosity, whereas appropriate spreading occurred 
upon casting of formulation N2. Formulations containing the lowest concentration HPC (10% 
(w/v)) displayed holes and were defined as unsuitable for further testing due to their handling 
difficulty, since these formulations yielded very thin and fragile films that, in the presence of 
sorbitol and/or glycerol, cannot be removed from the release liner (Table 3). The inclusion of 
sorbitol resulted in sticky films that were at least difficult or unable to subtract from the release 
liner, so these formulations (N5, N6 and N7 of table 3) were not further analyzed for mechanical 
film properties. The sorbitol-containing formulations that could be taken from the release liner 
upon drying consisting of 15% w/v HPC, 2.5% w/v glycerol and 5% w/v sorbitol (N8) or 12.5% 
HPC, 1.25% glycerol and 2.5% w/v/ sorbitol (N9).
Upon removal from the release liner, oral film formulations were further characterized 
for their physical (i.e., mass, thickness, residual water content) and mechanical properties 
(elongation at break, Young’s Modulus, tensile strength and disintegration time). Increasing the 
concentration of excipients resulted in oral films with increased mass and thickness (Table 3). 
Moreover, addition of excipients resulted in higher percentages of residual water (defined as 
weight loss on drying) and negatively influenced the tensile strength (Table 3). 
The oral films disintegrated all within 30 seconds (Table 3). This is compliant with 
guidelines for orally disintegrating tablets in European Pharmacopoeia (EP) and United States 
Pharmacopoeia (USP) (disintegration within 180 s) [11, 13, 14]. However, these recommendations 
might be less useful for our vaccine-containing films as antigen-transport through oral mucosa 
and subsequent uptake by immune cells might be time-consuming steps, which might need a 
prolonged residence time of the vaccine-formulation into the mouth. As described in section 
3.1, it remains speculative what the optimal release profile of vaccine-containing oral films will 
be. As such, clearly defined requirements for disintegration time of oromucosal (fast or slow 
release) films have to be defined, subsequently by pharmaceutical guidelines.  
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Figure 2 Regression models for the D-antigen recoveries type 1 (A), type 2 (B) and type 3 (C) of oral 
film formulations directly after drying. On the left, summaries of fit for all models are depicted: goodness 
of fit (R2, values >0.5 indicate a good model), goodness of prediction (Q2, values >0.5 indicate a good 
prediction power), model validity (values >0.25 indicate that the model is smaller than the experimental 
error) and reproducibility (values >0.5 indicates a small experimental error). On the right, main and 
interaction effects of the components (i.e., hydroxypropyl cellulose (HPC), sorbitol (Sor) and glycerol 
(Gly)) that contribute (per serotype) to the best fitted model, according to their model performance 
parameters are shown in model coefficient plots. Note: The negative model validity value for type 1 (A) 
here is a direct result of the extremely good replicates and a reproducibility value close to 1. 
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To evaluate the effect of the excipients on D-antigen recovery upon drying, all formulations 
from the screening design were prepared freshly wherein sIPV was mixed (Table 1). To avoid 
spreading of the liquid formulations with low viscosity and allow film casting using small 
volumes to minimize the amount of antigen needed, vaccine-containing casting solutions 
were converted in films using the ring-based casting method. Directly after drying, films 
were dissolved and D-antigenicity was determined by ELISA (Table 4). Multilinear regression 
(MLR) models were fitted using the ELISA results and optimized per serotype, which resulted 
in valid models for the prediction of D-antigen recoveries of dried sIPV-films according to 
the model performance parameters for type 1 (Figure 2A), type 2 (Figure 2B) and type 3 
(Figure 2C). Model validity for the type 1 D-antigenicity was negative, which is likely a model 
artifact and a direct result of the very low variation in the replicates (N9-N11) resulting in 
a reproducibility value close to 1 [15]. In general, most of the D-antigen content was lost 
during the drying process as indicated by D-antigen recoveries of <50% for all serotypes 
with the highest D-antigen recoveries obtained in the presence of sorbitol in the formulation 
(N5-N9) (Table 4). The stabilizing effect of sorbitol was also confirmed by the significant 
positive regression coefficients of the prediction models for D-antigen recovery type 1, 2 and 
3 directly after drying (Figure 2). The film forming polymer HPC did not influence D-antigen 
recovery, whereas the addition of glycerol seemed to affect type 1 D-antigenicity negatively 
(Figure 2A), but have a slight stabilizing effect on type 2 D-antigenicity during the drying 
process (Figure 2B). Both for type 2 and 3, a significant interaction effect was observed when 
glycerol and sorbitol were combined in the formulation (Figure 1B-C). Response contour 
Figure 3 Response contour plots showed predicted D-antigen recoveries type 1 (A), type 2 (B) and type 
3 (C) of formulations containing HPC (10-15% w/v, on x-axis) and glycerol (0-2.5% w/v, on y-axis) in 
combination with 5% (w/v) sorbitol. 
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plots showed the challenge of developing a trivalent dried Sabin IPV since each serotype 
showed a different optimal combination of excipients (Figure 3). Earlier studies revealed the 
difficulty of drying IPV, which was based on Salk strains instead of the Sabin strains based 
IPV formulated here, using different drying methods [16-18]. Therefore, it was decided to 
focus on D-antigenicity, instead of film characteristics, in the upcoming experiments in order 
to improve vaccine’s stability during the drying process.
Sugar screening
To increase the D-antigen recovery of the film formulations after drying, additional 
excipients may be included. Sugars have the ability to protect biologicals, like proteins or 
vaccines, against dehydration stresses [19]. The carbohydrates sucrose, maltodextrin and 
trehalose were screened in combination with 10% (w/v) or 15% (w/v) HPC. Since sorbitol 
already showed to confer protection during drying, sorbitol was also included. Glycerol was 
excluded from this experiment, since no clear positive effect on the D-antigen recovery 
of HPC-containing film formulations directly upon drying was found (data not shown). For 
formulations containing 10% HPC (w/v), both sorbitol, sucrose and maltodextrin conferred 
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Figure 4 D-antigenicity of oral film formulations containing 10% (w/v) or 15% (w/v) hydroxypropyl 
cellulose (HPC) as film former and 5% (w/v) of sorbitol (SOR), sucrose (SUC), maltodextrin (MALTO) 
or trehalose (TREH). Directly upon drying, oral films were dissolved and D-antigen recoveries were 
determined for type 1 (black bars), type 2 (pink bars) and type 3 (striped bars) by ELISA. Mean values 
(n=3) and standard deviations are depicted. Asterisks indicate significant differences of formulations 
when compared with control formulation without additional sugars (-) marked with the same letter above 
bars (* p < 0.05, ** p < 0.01, *** p < 0.001).
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significantly improved D-antigen recoveries of sIPV type 2, whereas only adding maltodextrin 
resulted in higher sIPV type 3 recoveries (Figure 4). Oral films consisting of 15% (w/v) HPC 
profited only from the inclusion of sorbitol as revealed by significant improved D-antigen 
recoveries for type 1 and 2 (Figure 4). These results indicated that a more complex formulation 
is needed to obtain an oral dissolvable film formulation while maintaining D-antigenicity. This 
is in contrast with literature showing D-antigen recoveries of more than 50% for all serotypes 
with vacuum-dried Salk IPV in combination with only one of the carbohydrates, which were 
also tested in the current study [16, 18]. However, the combination of sorbitol, magnesium 
chloride (MgCl2) and monosodium glutamate (MSG) stabilized Salk IPV both during freeze-
drying and vacuum-drying to a higher extent than a formulation with sorbitol only [16, 18]. 
Effect of MgCl2 and MSG during drying
Certain excipients or combinations of excipients, like MgCl2 and MSG, have the ability 
to drastically improve IPV stability during drying [16, 18]. In order to evaluate the effect of 
MgCl2 and MSG in an oral film formulation, these excipients were tested in combination 
with sorbitol in HPC-films. Until now, highest type 3 D-antigen recoveries were obtained for 
the oral film consisting of 10% (w/v) HPC and 5% (w/v) maltodextrin, so this formulation 
was also tested in combination with MgCl2 and MSG. Unfortunately, formulations consisting 
of 15% (w/v) HPC and 5% (w/v) of a sugar/polyol in combination with MSG did not result 
in homogeneous casting solutions, so only 10% (w/v) HPC-films were evaluated in this 
experiment. In agreement with previous work, the combination of sorbitol, MgCl2 and MSG 
was able to protect the polio vaccine during drying as revealed by significant higher type 
2 and type 3 D-antigen recoveries directly upon drying when compared with the control 
formulation consisting of only 10% (w/v) HPC and 5% (w/v) sorbitol (Figure 5). D-antigen 
recoveries of type 1 were significantly higher than those obtained with only MgCl2 or MSG 
added to the control formulation. For type 3, the most vulnerable serotype, the combination 
of sorbitol, MgCl2 and MSG resulted in a substantial increase in recovery after drying. 
Using the carbohydrate maltodextrin, as a substitute for sorbitol, did not result in improved 
stabilization, but showed instead a significant drop in the D-antigen recovery of type 3. This 
experiment showed the potential of a sIPV-containing oral film formulation with less than 
25% loss in D-antigen content during drying. The formulation consisting of 10% (w/v) HPC, 
5% (w/v) sorbitol, 3% (w/v) MgCl2 and 3% (w/v) MSG resulted in an oral film with D-antigen 
recoveries of 110 ± 10% for type 1, 83 ± 7% for type 2, and 76 ± 3% for type 3. 
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However, although D-antigen recoveries were ideal or at least high, all sorbitol-containing 
formulations resulted in sticky films that were difficult to remove from the release liner and felt 
very fragile. It would be hard to apply such a formulation into the oral cavity. This may be solved 
by further matrix optimization with focus on better physical properties with remaining high 
antigen recovery. Alternatively, preparation of bilayered oral films might result in formulations 
with suitable film mechanical properties allowing easy handling and application [20, 21]. 
Sodium alginate and sodium carboxymethyl cellulose as 
film formers
Two polymers, i.e., sodium alginate (SA) and sodium carboxymethyl cellulose (CMC), 
were selected from literature and evaluated as film forming component in sIPV-containing oral 
films in order to try to improve film characteristics and maintaining high D-antigen recoveries. 
Preliminary experiments revealed that the addition of glycerol to SA-containing films resulted 
in more flexible films that can be easily removed from the release liner (data not shown). 
Therefore, oral film formulations comprising of 5% (w/v) SA, 5% (w/v) sorbitol and 1.25% 
glycerol were prepared and it was investigated whether the addition of both MgCl2 and MSG 
was able to further improved D-antigen recoveries directly upon drying. In agreement with 


























































Figure 5 D-antigenicity of oral film formulations containing 10% (w/v) hydroxypropyl cellulose (HPC) as 
filmformer and 5% (w/v) of sorbitol (SOR) or maltodextrin (MALTO). The stabilizing effect of magnesium 
chloride (MgCl2) and monosodium glutamate (MSG) was investigated. Directly upon drying, oral films 
were dissolved and D-antigen recoveries were determined for type 1 (black bars), type 2 (pink bars) 
and type 3 (striped bars) by ELISA. Mean values (n=3) and standard deviations are depicted. Asterisks 
indicate significant differences of formulation when compared with the formulation marked with the 
same letter above bars (* p < 0.05, ** p < 0.01, *** p < 0.001).
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was able to protect the polio antigen during drying in an oral film formulation using SA as 
film former as exposed by significant higher D-antigen recoveries for all serotypes when 
compared to those obtained after drying the same formulation in the absence of MgCl2 and 
MSG (Figure 6A). Using a lower concentration of film former, 2% (w/v) instead of 5% (w/v) 
SA, resulted in comparable D-antigen recoveries of 85-90% for type 1, 55-65% for type 2, 






































































































































Figure 6 D-antigenicity of oral film formulations comprising of film formers sodium alginate (SA) (A) or 
sodium carboxymethyl cellulose (CMC) (B) as film former combined with a basic combination of sorbitol, 
magnesium chloride (MgCl2) and monosodium glutamate (MSG). Directly upon drying, oral films were 
dissolved and D-antigen recoveries were determined for type 1 (black bars), type 2 (pink bars) and type 
3 (striped bars) by ELISA. All SA-containing films containing also 1.25% (v/v) glycerol (A). Mean values 
(n=3) and standard deviations are depicted. Asterisks indicate significant differences of formulation when 
compared with the formulation marked with the same letter above bars (* p < 0.05, ** p < 0.01, *** p < 
0.001).
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Subsequently, the combination of sorbitol, MgCl2 and MSG was evaluated in a formulation 
consisting 4% (w/v) CMC as film former. Besides, it was examined what the stabilizing effect 
was of each of these excipients was on the polio particle during drying. Directly upon drying, 
D-antigenicity of oral film formulations were assessed. Addition of each of the excipients 
(i.e., sorbitol, MgCl2 and MSG) resulted in significant higher type 1 D-antigen recoveries, 
whereas the combination thereof resulted in significantly improved antigenicity of sIPV for all 
serotypes (Figure 6B). Type 3 showed again to be the most vulnerable serotype to stabilize 
during drying with detectable, but low recoveries (25 ± 1%) when using 5-3-3% (w/v) of 
respectively sorbitol, MgCl2 and MSG. Addition of increasing amounts of the stabilizing 
components resulted in enhanced type 2 and type 3 D-antigen recoveries. The higher 
excipient concentrations (i.e., 10-8.5-8.5% (w/v) of respectively sorbitol, MgCl2 and MSG) 
were based on the optimal formulation in our previous study on lyophilized IPV [16].
CONCLUDING REMARKS
The oral mucosa, especially the sublingual region, might be an attractive vaccine 
delivery site since it is densely populated with specialized dendritic cells while the adjacent 
submucosal tissue is drained by lymphatic vessels, through which free antigen as well as 
antigen-loaded dendritic cells can migrate to regional lymph nodes [4, 22]. However, although 
mucosal surfaces are the main route for pathogen entry, yet the induction of effective 
(mucosal) immunity elicited by vaccine antigens is a major challenge. Mechanistic studies 
designed to evaluate and define optimal conditions for sublingual or buccal vaccine delivery 
of macromolecules or even particles are still lacking in literature. Ideally, a minimal contact 
time of the dosage form for optimal antigen transport through oral mucosa should be defined. 
Also the question whether solid oral dosage forms would be preferred over liquid formulations 
are not answered. The risk of swallowing and/or salivary wash-out when administering liquid 
formulation to the oral mucosa exists, but liquid administration may also improve antigen 
uptake due to a larger contact area between vaccine and sublingual mucosa. Ideally, a 
head-to-head comparison is made between different oral films and (thermoresponsive) gel 
formulations with distinctive retention times to optimize mucosal contact area and contact 
time for sublingual delivery. Moreover, antigen transport through oral mucosa and uptake 
by immune cells could also be affected by muco-adhesive and penetration-enhancing 
components. The inclusion of such components in oral films might improve antigen delivery 
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via sublingual (or buccal) film application as well. Furthermore, for the induction of evident 
immunity (i.e., systemic and local mucosal immunity) upon vaccination under the tongue, 
inclusion of adjuvants may be required.
Aim of the current study was to evaluate the possibility to make polymer-based oral 
dissolvable films containing trivalent sIPV. In order to facilitate the formulation screening and 
optimization an antigen sparing ring-based film casting method was developed. Maintaining 
the antigenicity of the polio particle during film casting and drying showed to be challenging, 
especially for sIPV type 3. Addition of the excipients sorbitol, MgCl2 and MSG protected the 
antigen during the drying process, irrespective of the film forming component that was used. 
This study yielded oral film formulations containing sIPV while preserving its D-antigenicity 
for 85-100% for type 1, 60-85% for type 2, and 50-75% for type 3. Amongst these sIPV film 
formulations, the sIPV film based on CMC-containing formulations showed highest D-antigen 
recoveries and is most appropriate for further product development in which several aspects 
need to be considered. The product profile of sIPV-containing oral films consisting of 4% 
(w/v) CMC, 10% (w/v) sorbitol, 8.5% (w/v) MgCl2 and 8.5% (w/v) MSG gives a clear indication 
of the attributes, like stability, dissolution, disintegration and water content, that need to be 
evaluated during further development (Table 5). Due to shrinkage of the casting solution 
when using the standard casting method, it was not possible to obtain reproducible oral film 
formulations upon casting on a film casting apparatus. Since scalability of the production 
process is an important issue, further optimization of both formulation (e.g., inclusion of 
surfactant) and production process (e.g., release liner, casting speed) might be desirable. 
Moreover, based on future insights in the contribution of oral films to immunogenicity of 
sublingually administered sIPV, attention should be paid to further optimization of film 
characteristics, including mechanical properties for ease of handling and release kinetics.
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Table 5 Product profile of sIPV-containing orodissolvable film consisting of 4% (w/v) sodium 
carboxymethyl cellulose, 10% sorbitol, 8.5% magnesium chloride and 8.5% (w/v) monosodium 
glutamate cast using the ring-based casting method. Mean values and standard deviation (n=3) are 
shown.
Attributes Product profile (PP) Target1 achieved?












D-antigen recovery 82 ± 6% (type 1)
85 ± 8% (type 2)





100 ± 2 mg
Unknown
Stability Not measured Unknown
Dissolution Not measured Unknown
Disintegration Not measured Unknown
pH 7.0 ± 0.1 Yes
Water content 2 7.1 ± 1.8% Unknown
1 For expected targets see target product profile (TPP) in table 2.
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SUMMARY
Global polio eradication is closer than ever. The endgame strategy of the Global Polio 
Eradication Initiative (GPEI) includes a phased withdrawal of the live attenuated oral poliovirus 
vaccine (OPV) and the worldwide inclusion of the inactivated poliovirus vaccine (IPV) into 
all routine immunization programs [1]. Furthermore, the GPEI is pursuing several priority 
approaches for the development of a new generation of polio vaccines. Ideally, new polio 
vaccines should be administered through alternative (needle-free) delivery routes, provide 
mucosal immunity, be safe to manufacture, have a long shelf-life, be stable outside the 
cold-chain, and be affordable for low-income countries. Live polio vaccines attenuated with 
modern molecular techniques partially fulfill these requirements, but effective inactivated 
polio vaccines may be faster to develop and be more acceptable to the general public.   
The aim of this thesis was to develop improved formulations and novel vaccine delivery 
strategies for polio vaccination using IPV. To improve storage stability of IPV, thermostable 
solid IPV formulations were developed for possible use in developing countries without the 
need of a cold-chain. Moreover, an alternative delivery system (i.e., Bioneedle) and mucosal 
delivery routes (i.e., intranasal and sublingual) were evaluated for use in IPV vaccination. 
Chapter 2 provides the current status of alternative polio vaccine delivery strategies. 
The feasibility of these strategies is given by highlighting challenges, hurdles to overcome, 
and formulation issues relevant for optimal vaccine delivery. Important variables for the 
development of improved IPV are the route of administration, the selection of adjuvants, the 
vaccine formulation, and the use of (non-invasive) delivery methods.
Chapter 3 focuses on the development of a lyophilized IPV formulation with minimal 
loss during the drying process and improved stability when compared with the conventional 
liquid IPV. Extensive excipient screening was combined with a Design of Experiment (DoE) 
approach. Although earlier research revealed that lyophilization of a trivalent IPV while 
conserving its antigenicity is challenging, we developed a formulation that showed minimal 
loss of D-antigen during drying and subsequent storage at higher temperature. This study 
yielded a highly stable lyophilized polio vaccine formulation, which may be distributed without 
the need of a cold-chain.
Further research on lyophilized IPV was conducted and chapter 4 describes a clear 
difference in rat potency between lyophilized IPV and liquid IPV serotype 3 (upon drying 
2 to 3-fold lower than in liquid form), whereas type 1 and 2 had unaffected antigenicity/
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immunogenicity ratios. In addition, an approach to obtain a hexavalent vaccine by 
reconstituting lyophilized IPV with liquid pentavalent vaccine, containing diphtheria toxoid, 
tetanus toxoid, whole cell pertussis, Haemophilius influenza type B and hepatitis B (DTwP-
Hib-HBV), was evaluated. Reconstituting dried IPV in the presence of thimerosal, a compound 
used in production of or added as antimicrobial in certain pentavalent vaccines, resulted in 
a fast temperature dependent loss in IPV antigenicity. Therefore, the use of lyophilized IPV 
as a component in a hexavalent vaccine by mixing licensed pentavalent vaccine, requires 
neutralization of thimerosal, to overcome the detrimental effect on the polio D-antigen. Use of 
a scavenger, like L-cysteine, to bind thimerosal (or mercury containing degradation products 
thereof), resulted in a hexavalent vaccine mixture in which polio D-antigen was more stable 
allowing an on-site mix-and-shoot approach. 
Chapter 5 describes the development of an alternative delivery of a thermostable IPV in 
the solid state. Bioneedles, which are biodegradable mini-implants, are administered without 
the use of needles and syringes. Also, they have the potential to be stored and transported 
outside the cold-chain. Trivalent IPV was formulated in Bioneedles while remaining most of 
the polio D-antigenicity during the lyophilization process (D-antigen recoveries of >90% for 
all serotypes). Accelerated stability testing revealed that IPV in Bioneedles was more resistant 
to elevated temperatures than liquid IPV. in vivo imaging indicated that IPV administered via 
Bioneedles remained at the site of administration as long as subcutaneously injected liquid 
IPV, i.e. 3 days. This demonstrated that Bioneedles are not a controlled release vehicle, but 
dissolve quickly without forming a local depot (at least for IPV and the formulation used). 
Finally, an immunogenicity study showed that IPV-filled Bioneedles were able to induce virus-
neutralizing antibody titers similar to those obtained by liquid intramuscular injection when 
administered in a booster regime, demonstrating the potential of Bioneedles as a syringe-
free alternative delivery technology for polio vaccination.
Because of their large surface area and immunological competence, mucosal tissues 
are attractive administration and target sites for vaccination. An important characteristic of 
mucosal vaccination is its ability to elicit local immune responses, which act against infection 
at the site of pathogen entry. However, mucosal surfaces are endowed with tolerance 
mechanisms to prevent the immune system from overreacting to the many environmental 
antigens they encounter. In chapter 6, the characteristics of and approaches for sublingual 
and buccal vaccine delivery are described and compared with other mucosal vaccine 
delivery routes. Moreover, this review chapter highlights promising developments in the 
search for vaccine formulations, including adjuvants and suitable dosage forms, which are 
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likely critical for designing a successful sublingual or buccal vaccine. Finally, the challenges, 
hurdles to overcome and formulation issues relevant for sublingual or buccal vaccine delivery 
are outlined. 
In chapter 7 the possibilities of polio vaccination via mucosal surfaces using IPV based 
on attenuated Sabin strains was evaluated. Both intranasal and sublingual Sabin IPV 
immunization induced systemic polio-specific serum IgG in mice that were functional as 
measured by poliovirus neutralization. Moreover, mucosal Sabin IPV delivery elicited polio-
specific IgA titers at different mucosal sites (IgA in saliva, fecal extracts and intestinal tissue) 
and IgA-producing B cells in the spleen, where conventional intramuscular vaccination 
was unable to do so. However, it is likely that a mucosal adjuvant is required for sublingual 
immunization. This study indicates that both the intranasal and sublingual routes might be 
valuable approaches for use in routine vaccination or outbreak control in the period after 
complete oral polio vaccine cessation and post-polio eradication. 
Chapter 8 describes the development of Sabin IPV-containing polymer-based oromucosal 
films suitable for sublingual or buccal vaccination. The combination of a Design of Experiment 
(DoE) approach and the evaluation of excipients with already proven stabilizing capacity 
for polio antigens was used to develop oral film formulations while preserving most of its 
D-antigenicity. This study revealed that the combination of sorbitol, magnesium chloride 
and monosodium glutamate has strong stabilizing potential for sIPV-films, even based on 
different film formers, i.e., hydroxypropyl cellulose, sodium alginate or sodium carboxymethyl 
cellulose. Although further optimization is required during future product development 
studies, especially with respect to the mechanical properties of the film formulations, this 
study showed the promise of dried polymer-based sIPV-films that might be suitable for 





The phased withdrawal of OPV is mandatory to achieve global polio eradication, since 
OPV causes poliomyelitis in rare cases. The inclusion of IPV into all routine immunization 
programs will spur the need for better and more affordable IPV, because current manufacturing 
capacity and relatively high manufacturing costs prevent this. Ideally, a new generation of IPV 
should be easy and safe to administer, provide mucosal immunity, be safe to manufacture, 
have a long shelf-life, be stable outside the cold-chain, and be affordable for low-income 
countries. Alternative delivery strategies using improved formulations may fulfill at least 
some of these preferred vaccine characteristics. The relevance of this ideal target product 
profile also depends on the polio status worldwide (i.e., current situation with both OPV and 
IPV in use, after complete OPV cessation, post-eradication, or eventually, without routine 
polio vaccination), but also on the aim, i.e., for use in routine immunization programs or as 
outbreak control to interrupt transmission (chapter 2). 
Thermostable IPV
Most vaccines, polio vaccines included, currently require storage and transport in 
refrigerators or freezers as exposure to higher temperatures may result in loss of the vaccines 
potency [2]. Unreliable access to electricity is a challenge that limits vaccine coverage in low 
and middle-income countries or may lead to administration of vaccines partially deteriorated 
due to storage and transport at too high temperatures. Replacement of existing vaccines with 
thermostable vaccines can relieve bottlenecks in vaccine supply chains and thus increase 
vaccine availability [3]. The economic impact of thermostable vaccines is immense. When 
vaccines no longer require cold storage, or could be kept out of the cold-chain long enough 
for their transport to remote areas, logistic costs will decrease. The cold-chain contributes 
about 20% of total system costs of vaccination, whereas vaccine wastage, at least partially 
caused by inappropriate storage and transport, add another ~20% to system costs [4]. 
Therefore, substantial reduction occurs in medical costs and diminished productivity 
losses as more vaccines reach the target population [5]. Many attempts have been made 
to develop thermostable formulations for antigens, including influenza [6-8], rotavirus [9], 
human papillomavirus [10, 11] and polio (chapter 3, 4 and 5). The question is which of these 
formulations may ultimately reach the market, since the development of thermostable vaccines 
brings several technological and regulatory challenges. Investments needed to tackle these 
hurdles may finally be worthwhile, since cost savings could compensate even for doubling or 
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even tripling the price charged for thermostable formulations of vaccines [5].
This thesis describes the development of IPV formulations with improved thermostability 
by converting the vaccine into the dry state. Lyophilization of Salk IPV in the presence of 
excipients sorbitol, magnesium chloride and monosodium glutamate resulted in a dried IPV 
formulation stable at temperatures up to 37°C for several weeks, whereas the conventional 
liquid IPV formulation showed significant loss in antigenicity when stored above ambient 
temperatures (chapter 3 and 4). However, the drying procedure might have a detrimental effect 
on the immunogenicity of the type 3 polio particle as revealed by a 2- to 3-fold lower rat 
potency as anticipated based on the measured antigenicity (chapter 4). This phenomenon 
(the loss of correlation between antigenicity and immunogenicity) was also seen in studies 
using solid IPV formulations administered via alternative delivery technologies, like Bioneedles 
(chapter 5) and dissolvable microneedles [12].
Stabilizing IPV, whether based on Salk or Sabin strains, by converting it into the solid 
state is very challenging with type 3 being the most vulnerable serotype for both Salk IPV and 
Sabin IPV. A formulation comprising sorbitol, monosodium glutamate and magnesium chloride 
protects the polio antigen from dehydration stress, even using different drying methods, like 
lyophilization (chapter 3, 4 and 5), vacuum drying [13] or air drying (chapter 8). A head-to-head 
comparison of the thermostability profiles of both (wildtype) Salk IPV and Sabin IPV is lacking 
in literature, so it remains speculative what the dissimilarities are between those polio particles. 
It would be interesting to investigate the impact of extensive thermostability testing, but also of 
different drying techniques on the integrity of Salk IPV versus Sabin IPV. A complicating matter 
in the assessment of their antigenic and immunogenic properties is the fact that the D-antigen 
is not well defined. The D-antigen ELISA can be used as in vitro alternative for the in vivo rat 
potency test for release of polio containing vaccines according to the European Pharmacopoeia 
monograph [14]. However, the set-up of the ELISA is crucial and should therefore be 
standardized among all polio vaccine manufacturers and research groups [15]. Moreover, a 
standardized in vitro measurement of the D-antigen, the calibration free concentration assay, 
which combines quantity and quality, may be suitable [16]. Biosensor analysis allows also a 
more extensive antigenic characterization by assessing different antigenic sites, a so-called 
antigenic fingerprint [16]. Furthermore, biophysical techniques might give a more clear view of 
the structural stability of IPV [17] and mechanisms involved in degradation or destabilization of 
(s)IPVs. With a combination of certain techniques, like field flow fractionation - multi-laser light 
scattering (FFF-MALS), circular dichroism (CD) and fluorescence spectroscopy, both particle 
size and (secondary and tertiary) structural integrity may be characterized.
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Alternative delivery of polio vaccines
Different alternative administration methods and routes for polio vaccines have been 
developed and evaluated over the years (chapter 2). One of these delivery technologies 
are Bioneedles, which are hollow mini-implants from biodegradable polymers that can be 
filled with antigen followed by a lyophilization process. Bioneedles have the potential to 
avoid the cold-chain and they are administered without the use of needles and syringes. 
The feasibility of Bioneedles as vaccine delivery system has been shown preclinically with 
different antigens, including alum-adjuvanted tetanus toxoid [18], LpxL1-adjuvanted hepatitis 
B surface antigen [19], CAF01-adjuvated tuberculosis vaccine [20], and influenza vaccines 
[6]. In chapter 5 of this thesis, Bioneedles were filled with a trivalent IPV-formulation, 
containing excipients that were able to protect the polio antigen from degradation during 
lyophilization as evaluated earlier using glass vials (chapter 3 and 4). Lyophilized IPV, also 
when formulated in Bioneedles, was more resistant to elevated temperatures than liquid 
IPV. Moreover, IPV-filled Bioneedles were able to induce virus-neutralizing antibody titers 
similar to those obtained by liquid intramuscular injection when administered in a booster 
regime. Although this thesis demonstrated the preclinical proof of concept of Bioneedles 
for IPV, several steps should be taken in the further development of this alternative delivery 
system for polio vaccination, including toxicity and dose finding studies. Besides, safety 
concerns with respect to cross-contamination need to be addressed in the development of 
the applicator used for the administration. Thermostable vaccines formulated in Bioneedles 
might be very useful in lower- and middle-income countries, where the logistics for vaccine 
storage and transport under refrigerated conditions (cold-chain) are very limited or at least 
unreliable, interrupting the vaccine supply chain [3, 21-23]. Additionally, when an appropriate 
applicator for Bioneedle administration is developed, vaccine-filled Bioneedles may be 
quickly administered during mass vaccination campaigns. A phase 1 clinical study in healthy 
volunteers showed already that solid Bioneedles without any antigen were well tolerated 
[6]. Further (pre)clinical studies, using an approved administration device, should prove the 
practical use, safety and efficacy of Bioneedles for human vaccination.
The Global Polio Eradication Initiative (GPEI) is pursuing several priority approaches for 
the development of a new generation of IPV. To this extent, Intravacc has developed a new 
polio vaccine based on attenuated Sabin polio viruses, Sabin IPV, that is being transferred to 
local vaccine manufacturers to support post-eradication goals in terms of biosafety and IPV 
availability [24-27]. 
Important variables for the development of improved IPV are the route of administration, 
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the selection of adjuvants, vaccine formulations, and the use of (non-invasive) delivery 
methods [28]. Besides the use of Bioneedles for alternative IPV delivery, this thesis explored 
the possibilities of polio vaccination via mucosal surfaces using Sabin IPV (chapter 7). 
Mucosal vaccine delivery has the benefits of needle-free vaccination, like the relatively easy 
administration (which may avoid the need of trained personnel), eliminating the risk of needle-
stick injuries or reuse of needles, and minimal generation of waste [29, 30]. Moreover, mucosal 
immunization has the potential to evoke strong mucosal immunity at the virus entry site. As 
we know from OPV, polio-specific mucosal immunity in the gut is a powerful mechanism for 
protection and interruption of polio transmission [31, 32].  In contrast to OPV delivered via the 
oral route, mucosal polio vaccination based on IPV might require the inclusion of an adjuvant 
to elicit appropriate immunity against polio, which was confirmed by the preclinical study in 
mice described in chapter 7. Both intranasal  and sublingual (under the tongue) vaccination 
using Sabin IPV plus cholera toxin (CT) as strong mucosal adjuvant were able to significantly 
enhance functional systemic immunity as well as polio-specific IgA titers in mucosal samples 
compared to immune responses obtained after Sabin IPV vaccination without adjuvant 
(chapter 7). Although CT and the Escherichia coli-derived heat-labile toxin (LT) are well-
known as potent mucosal adjuvants, these immune-potentiating components are not desired 
for further clinical testing as they are associated with adverse effects in humans. Concerns 
have been raised after an unwanted association between temporary facial nerve paralysis 
(Bell’s palsy) and the intranasally administered inactivated influenza vaccine containing a 
detoxified mutant of LT (Nasalflu) [33]. Due to the possible neuronal binding capacity of CT 
or LT(-derived) molecules, resulting in migration to and accumulation in the central nerve 
system, nasal administration of certain toxin-based adjuvants is undesirable [34]. Therefore, 
the further development of a mucosal (Sabin) IPV should include the search for a safe mucosal 
adjuvant with strong immune potentiating capacity. Since in literature the mucosal route is 
minimally addressed for IPV yet, current experience is limited to the use of a double mutant 
of LT (dmLT) in combination with the sublingual route [35]. Other adjuvants that have shown 
their potential for (Sabin) IPV via the parenteral route could also be evaluated for mucosal 
vaccination, these include the LPS-derivate PagL [36], alphavirus-based GVI3000 [16], 
CAF01 [37], chitosan [38], CpG oligodeoxynucleotides [39] or vitamin D [40]. However, for a 
fast track to market, adjuvants with a proved safety record in humans might be preferred over 
components with immune potentiating capacity or delivery systems that are not licensed for 
other vaccines or even have been tested in clinical trials yet. With this point of view, CAF01 
(phase I) [41], flagellin (phase II) [42], saponins (phase II) [43], CpG oligonucleotides (phase III) 
[44], or poly(I:C) (phase III) [45] might be worthwhile to test in combination with IPV delivered 
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via mucosal routes. Furthermore, the toxin-based dmLT (NCT02052934) and B subunit of 
CT (NCT00820144) have found to be safe in clinical phase I trials when administered via the 
sublingual route. 
The sublingual route, vaccination under the tongue, has gained increased attention in 
recent years. In this thesis, the characteristics of and approaches for sublingual (and buccal) 
vaccine delivery are described and compared with other mucosal vaccine delivery sites 
(chapter 6). Besides the attractive features of mucosal vaccine delivery in general, which 
are mentioned above, sublingual vaccination may circumvent the safety issues that are 
associated with nasal vaccines. Possible deposition of vaccine components to the olfactory 
bulbs and nerves, which can cause Bell’s palsy, might be avoided by sublingual administration 
[46-48]. For successful vaccination via the sublingual route, the main challenges are to 
overcome the mucosal barrier, improve tissue penetration, and increase vaccine potency. 
To reach immune competent cells, vaccine antigens have to overcome enzymatic and pH 
induced degradation, entrapment in the oral mucosa, and wash-out by salivary flow. The 
development of innovative oral dosage forms might be beneficial to improve antigen delivery 
into the sublingual tissue, and to facilitate access to resident antigen presenting cells. 
Chapter 8 of this thesis describes the development of polymer-based oral films containing 
Sabin IPV. The development of alternative delivery technologies using (trivalent) IPV in a dried 
form is challenging, due to the vulnerability of the polio antigen during the drying procedure 
and a possibly altered polio type 3 particle with reduced potency [12, 13, 49-51]. However, 
optimization of an IPV-containing oral film formulation should not only focus on maintaining 
the vaccine’s potency, but also achieve optimal (mechanical) film properties. The design of 
films and the subsequent properties may influence the ease of handling and enhance antigen 
transport through the oral mucosa and uptake by immune cells. Unfortunately, mechanistic 
studies designed to evaluate and define optimal conditions for sublingual (or buccal) vaccine 
delivery of macromolecules or even particles are lacking in literature. Ideally, these studies 
should define a minimal contact time of the dosage form for optimal antigen uptake. Moreover, 
even the question whether solid oral dosage forms would be preferred over liquid or gel-like 
formulations should be answered. The risk of swallowing and salivary wash-out exist, but 
liquid administration may also improve antigen uptake due to a larger contact area between 
vaccine formulation and the sublingual mucosa. Thermoresponsive gels, which are aqueous 
solutions at room temperature that transform into gels when at body temperature on mucosal 
surfaces, might therefore be a good alternative in between liquid and solid dosage forms. The 
proof of concept of sublingual delivery of thermoresponsive gels containing IPV plus dmLT 
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as adjuvant in mice was described by White et al. [35]. However, this and our preclinical work 
on sublingual administration of IPV in mice revealed the poor immunogenicity of IPV when 
delivered via this relatively novel vaccination route.
Besides the sublingual immunotherapy products on the market, which are aimed at 
immune regulation instead of activation of the adaptive immune system, no sublingual 
(preventive) vaccine has been licensed to date. This may indicate the difficulty of this 
theoretically attractive immunization route. Nevertheless, the preclinical proof of concept of 
the sublingual route for vaccination against infectious diseases has been proven for several 
antigens (chapter 6). Live attenuated viruses and vector-based vaccines showed promising 
results in several rodent models as well as in non-human primates. In contrast, vaccines 
based whole inactivated or subunit pathogens might require adjuvant, which was also 
confirmed by this thesis by testing the sublingual route for Sabin IPV (chapter 7). Repeated 
boost immunization schedules might be essential for the induction of protective immune 
responses upon sublingual vaccine delivery. Besides homologous prime-boost strategies, 
using the same formulation and immunization route both for prime and booster vaccination, 
an increasing amount of research focuses on heterologous prime-boost approaches. 
Certain vaccination strategies, using different routes, different vaccine antigens, different 
vaccine concepts (e.g., live-inactivated or DNA-protein), or a combination thereof, are being 
investigated and some of them are also tested in combination with the sublingual route [52-
55].  
The real potential of sublingual vaccination still has to be proven in clinical studies. Recent 
findings of a head-to-head comparison of sublingually with intranasally applied live attenuated 
influenza vaccine (FluMist) indicate the promise of sublingual vaccination, although this 
may require live vaccine antigens or strong adjuvants. Clinical trials with enterotoxins, e.g., 
dmLT and CT-B subunit, via the sublingual route are underway. These clinical studies should 
provide insight in the general applicability of the sublingual route for vaccine delivery as well 
as the requirement and role of adjuvants, the potential and need of formulation strategies, as 
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The cessation of OPV and inclusion of IPV into all global routine immunization programs 
may create a market for non-invasive delivery of polio vaccines. However, it remains unclear 
how large this market will be, since IPV demand in the post-eradication era is uncertain. A new 
generation of IPV should not only be affordable and safe to produce, but preferably should 
also induce mucosal immunity, remain stable at unrefrigerated conditions, and be easy to 
administer. This is also important with regard to stockpiling and outbreak management in 
the period after complete OPV withdrawal and post-polio eradication. Since more research 
groups have access to (Sabin) IPV via support from nongovernmental organizations 
(e.g., BMGF, WHO) and/or (new) Sabin IPV producers, more efforts to develop alternative 
administration technologies for IPV are expected in the coming years.
Furthermore, it is expected that other novel approaches, like the heterologous prime-boost 
schedules, will get more attention for polio vaccination upcoming years. IPV boosts mucosal 
immunity in recipients who have received OPV earlier [56, 57]. Furthermore, heterologous 
prime-boost approaches using a combination of parenteral and mucosal administration 
can significantly increase mucosal responses [53, 55, 58, 59]. Further (pre)clinical studies, 
whether based on homologous or heterologous prime-boost regimes, should include proper 
readout of mucosal immunity using modern techniques. The readout of mucosal immunity 
should not only be restricted to the detection of secretory IgA at mucosal sites, but those 
secretions (e.g., saliva, feces) and lavages (e.g., bronchoalveolar, intestinal) need also be 
used to investigate whether the antibodies are functional with respect to neutralizing the 
poliovirus. Besides the assessment of secretory IgA at mucosal sites, more and more 
attention is given to the duration as well as memory of mucosal immune responses. Until now 
preclinical vaccination studies on alternative delivery strategies lack the mucosal readout 
based on profiles of homing receptors. Measurement of circulating antibody-producing B 
cells expressing the mucosal integrin α4β7 might facilitate detection of mucosal secretory 
IgA responses at an early stage and could act as surrogate of mucosal immunity upon polio 
vaccination [60, 61]. 
In-depth knowledge on immune activation after immunization via sublingual mucosa is 
still lacking. Reports on systematic mechanistic studies for sublingual vaccination are limited. 
Systems biology approaches and other innovative strategies can provide comprehensive 
insights into immunity elicited by vaccine candidates delivered via mucosal routes, as well as 
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the kinetics of provoked immune responses [62]. Unfortunately, to get mechanistic knowledge 
on the oral mucosa as vaccine delivery route, researchers are still dependent on animal models, 
which are often not predictive for humans. The development of in vitro models for sublingual 
tissue and resembling immune cells might facilitate the screening of new vaccine candidates 
and adjuvants suitable for sublingual delivery and development of oral dosage forms [63-
65]. Inherent to the status of development still many challenges will have to be addressed 
before good models are present. Better knowledge of the human mucosal immune system, 
especially during early life, is needed to ascertain the usefulness of alternative immunization 
routes, like the sublingual route. The mucosal immune system is highly compartmentalized 
and the limited understanding of molecular and cellular mechanisms that induce antigen-
specific IgA antibodies has hampered the development of safe mucosal vaccines capable to 
promote IgA production at distant mucosal sites [48]. Nevertheless, in vitro models combined 
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with systematic in vivo studies may generate new insights, such as the role and potential 
impact of mucosal surface characteristics, penetration of antigens, presence of receptors 
and immune cells and identification of the best inductive sublingual immune cells.
This thesis describes the development of improved formulations and alternative delivery 
strategies for polio vaccination. Solid dosage forms that have improved thermostability, like 
biodegradable Bioneedles comprising lyophilized IPV or polymer-based oral films, would 
be favorable to reach remote areas in developing countries for which proper logistics are 
not available. Replacing the currently used polio vaccines with a thermostable vaccine may 
yield significant cost savings, even when the premium price is up to three times the price 
of the current non-thermostable vaccine [5]. However, one of the main challenges for future 
introduction of IPV formulations administered via other routes than the subcutaneous route is 
the acceptance by the final stakeholders, which include governmental organizations shaping 
their immunization programs, global vaccine procurement organizations (e.g., UNICEF), but 
also key opinion leaders, vaccine producers and vaccine recipients. The feasibility of (multiple) 
fractional doses of IPV using needle-free injector devices have already been demonstrated in 
several clinical trials and, as endorsed by WHO that started stockpiling PharmaJet Tropis®, 
this concept remains an option for outbreak control or can extend coverage if vaccine supplies 
are limited [66-69]. Ongoing and newly initiated research on innovative delivery methods for 
polio vaccination will teach us what the viability is of these approaches.
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Poliomyelitis, ook wel polio genoemd, is een ernstige en besmettelijke infectieziekte 
die veroorzaakt wordt door het poliovirus. Nadat het poliovirus het lichaam, meestal via 
de mond, is binnengedrongen, zal het zich in de darmen vermenigvuldigen. Het virus kan 
van mens op mens worden overgedragen via de ontlasting van besmette personen. In veel 
gevallen veroorzaakt infectie met het poliovirus helemaal geen of slechts milde (griepachtige) 
symptomen. Echter, in minder dan 1% van de gevallen zal het poliovirus doordringen tot 
het centraal zenuwstelsel (het ruggenmerg of de hersenstam) waardoor spierverlammingen 
op kunnen treden. De verlammingen treden meestal op aan de benen of armen, omdat 
het virus de zenuwen beschadigt die de bewegingen van deze lichaamsdelen aansturen. 
Omdat de zenuwen van slik- en ademhalingsspieren meestal worden aangetast, overlijdt 
ongeveer 5 tot 10% van de polio patiënten met verlammingsverschijnselenOverige patiënten 
houden blijvende verlammingen of herstellen, na intensieve fysiotherapie, maar gedeeltelijk. 
Bovendien krijgt ongeveer 40% van de patiënten die een poliovirus infectie hebben 
doorgemaakt zelfs na tientallen jaren opnieuw te maken met spierzwakte, pijn in spieren en 
gewrichten, hevige vermoeidheid en vermindering van spierweefsel. Dit wordt het ‘post-polio 
syndroom’ genoemd.
Besmette personen scheiden het poliovirus gedurende enkele weken uit waardoor het zich 
snel kan verspreiden in de populatie, met name in ontwikkelingsgebieden waar de hygiëne en 
sanitaire voorzieningen slecht zijn. Vooral jonge kinderen die nog onvoldoende ‘toilet-training’ 
hebben gehad zijn een directe bron van besmetting die kan leiden tot een polio uitbraak. Er 
bestaat geen medicijn om polio patiënten te genezen. Wel kan polio voorkomen worden met 
behulp van vaccinatie. Wanneer voldoende kinderen zijn gevaccineerd tegen polio, zal het 
virus zich niet verder kunnen verspreiden onder de bevolking en zal het verdwijnen omdat de 
mens de enige natuurlijke gastheer is voor poliovirus. 
Polio vaccinatie
Er bestaan twee vaccins tegen polio. Het eerste poliovaccin werd in de jaren ’50  ontwikkeld 
door Jonas Salk. Dit is het ‘geïnactiveerde poliovirus vaccin’, vaak afgekort als IPV (vanuit 
het Engelse ‘inactivated poliovirus vaccine’), bestaat uit met formaldehyde geïnactiveerd 
(gedood) poliovirus. Er bestaan  drie serotypes die zodanig van elkaar verschillen dat alle drie 




spier en biedt bescherming door in het bloed antistoffen op te wekken die specifiek gericht 
zijn tegen de drie types van het poliovirus. Hoewel het vaccin goed werkt en veilig is, was 
het moeilijk om er voldoende van te produceren. In de jaren ’60 ontwikkelde Albert Sabin het 
orale poliovirus vaccin, afgekort als OPV, dat bestaat uit levend verzwakte poliovirus (Sabin) 
stammen. Omdat het verzwakte vaccin zich vermenigvuldigt na toediening kan met een 
lagere dosis dan het geïnactiveerde vaccin worden volstaan. Een ander belangrijk voordeel 
van dit oraal (via de mond) toegediende vaccin is dat het niet alleen in het bloed antistoffen 
opwekt, maar ook in de darmen waar het poliovirus het lichaam binnendringt bij een infectie. 
Daarbij kan in gebieden in de wereld waar de hygiëne en sanitaire voorzieningen slecht zijn, 
vaccinatie met OPV resulteren in passieve vaccinatie van personen die zelf niet gevaccineerd 
zijn. Bij een polio uitbraak kan door middel van OPV vaccinatie de overdracht van persoon 
op persoon in korte tijd gestopt worden waardoor verdere verspreiding van het (wildtype) 
poliovirus binnen de hele gemeenschap tegengegaan wordt. 
IPV is zeer veilig. Echter, OPV veroorzaakt in extreem zeldzame gevallen (2 tot 4 keer 
op een miljoen gevaccineerden) verlammingsverschijnselen. Daarnaast komt het binnen 
een gemeenschap waarin de vaccinatiegraad laag is (zeldzaam) voor dat het verzwakte 
vaccinvirus blijft circuleren en kan veranderen in een vorm die wel polio veroorzaakt. Deze 
vaccin-afkomstige poliovirussen kunnen dus leiden tot nieuwe polio-uitbraken. Een belangrijk 
voordeel van OPV is dat het vaccin goedkoper is te produceren en beter betaalbaar is voor 
landen met lage en middeninkomens. Omdat IPV geen levend vaccin is, heeft het de risico’s 
Tabel 1 De voor- en nadelen van de verschillende polio vaccins: het levend verzwakte oraal toegediende 
polio vaccin (OPV) en het geïnactiveerde polio vaccin (IPV).
Oraal polio vaccine (OPV) Inactief polio vaccine (IPV)
Voordelen + Goedkoop 
   (betaalbaar voor ontwikkelingslanden)
+ Makkelijke toediening
   (druppelen op tong, soms op suikerklontje)
+ Lokale bescherming (in de darm)
   (na natuurlijke polio infectie zal het lichaam 
direct een beschermende reactie geven en het 
virus opruimen)  
+ Effectief
   (biedt langdurige bescherming)
+ Veilig 
   (vaccin kan geen polio veroorzaken)
+ Redelijk stabiel
   (vaccin wordt bij 2-8°C bewaard en 
verzonden)
+ Zeer effectief 
   (slechts 1 of 2 vaccinaties nodig om 
langdurige bescherming te bieden)
Nadelen - Risico op poliomyelitis 
   (vaccinvirus kan soms muteren naar een vorm 
die verlammingsverschijnselen kan veroorzaken)
- Risico op nieuwe polio uitbraak
   (vaccinatie kan leiden tot hercirculatie van 
terug gemuteerd poliovirus)
- Zeer gevoelig voor hogere temperaturen
   (vaccin wordt in vriezer bewaard en 
getransporteerd)
- Duur
   (ruim vijf keer duurder dan OPV, tot voor kort 
voornamelijk gebruikt in Westerse landen)
- Geen lokale bescherming
   (lichaam kan poliovirus niet direct in de darm 
opruimen. Geïnfecteerde persoon wordt niet 
ziek, maar kan het virus wel verspreiden)
- Getraind personeel nodig voor toediening
- Risico op hergebruik van naalden
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op polio symptomen en ontstaan van nieuwe uitbraken niet. Echter, dit vaccin is ruim vijf keer 
duurder dan OPV. Daarbij brengt de toediening door middel van injectie in de spier waarbij 
gebruikt wordt gemaakt van spuit en naald, andere nadelen met zich mee. Vaccinaties zullen 
gegeven moeten worden door getraind personeel  en er zijn steriele injectiematerialen en 
procedures nodig om hergebruik van naalden en ongelukken met naalden (prikincidenten) te 
voorkomen. In tabel 1 staan de voor- en nadelen van zowel OPV als IPV opgesomd. 
Polio de wereld uit
In 1988 werd het Global Polio Eradication Initiative (GPEI), oftewel de wereldwijde 
publiek-private samenwerking van nationale overheden en partijen zoals o.a. de 
wereldgezondheidsorganisatie (WHO), UNICEF en de Bill & Melinda Gates Foundation, 
opgericht. Dit initiatief is in het leven geroepen met als doel om polio wereldwijd uit te roeien. 
Het aantal poliogevallen is sindsdien met meer dan 99.9% afgenomen. In de late jaren ’80 
veroorzaakte poliovirus verlammingen bij meer dan 1000 kinderen per dag. In 2017 was 
Figuur 1 Geografsche weergave van alle poliogevallen die werden gemeld in het jaar 2017. De blauwe 
bolletjes geven de meldingen van wildtype poliovirus en de oranje bolletjes de gevallen van vaccin-




dat afgenomen tot 22 poliogevallen van het wildtype poliovirus en 91 vaccin-gerelateerde 
poliogevallen (zie figuur 1). Er zijn nog drie landen waarin poliovirus voorkomt: Afghanistan, 
Nigeria en Pakistan. 
Twee van de drie wildtype poliovirussen zijn inmiddels wereldwijd uitgeroeid. De laatste 
melding van polio type 2 dateert van 1999 en de meest recente melding van wildtype 
poliovirus type 3 werd gedaan in November 2012 (zie tabel 2). Echter, het blijkt een grote 
uitdaging te zijn om echt alle polio infecties te stoppen en het poliovirus volledig de wereld 
uit te helpen, onder andere door conflictgebieden, politieke instabiliteit, zeer moeilijk te 
bereiken populaties, en soms gebrekkige infrastructuur. Daarom is er in 2013 een uitgebreid 
strategisch eindplan gelanceerd waarin verschillende stappen staan beschreven om polio 
dan echt de wereld uit te helpen en hoe de wereld vervolgens polio-vrij kan blijven. Allereerst 
moet de verspreiding van het wildtype poliovirus zo snel mogelijk gestopt worden, maar 
moeten nieuwe polio uitbraken als gevolg van vaccin-afkomstige poliovirusssen ook 
worden tegengegaan. Belangrijke maatregelen die in gang gezet zijn, zijn het versterken van 
poliovaccinatieprogramma’s wereldwijd én het gefaseerd terugtrekken van het gebruik van 
OPV voor routine vaccinaties. Er wordt nu alleen nog maar gevaccineerd met een bivalent 
OPV, met daarin alleen de verzwakte poliovirus stammen van type 1 en type 3. Immers, 
poliovirus type 2 is al sinds 1999 de wereld uit en alle meldingen van polio type 2 infecties 
worden sindsdien veroorzaakt door het vaccinvirus (OPV type 2). Daarom zijn alle landen 
die voorheen trivalent OPV (met type 1, 2 en 3) gebruikten in hun vaccinatie programma’s 
overgestapt op bivalent OPV om zo het risico op hercirculatie van polio type 2 te verkleinen. 
Daarbij wordt in deze landen tenminste 1 dosis trivalent IPV gegeven om de kinderen wel 
bescherming te geven tegen het type 2 poliovirus. Zeker in gebieden waar het risico op polio 
infectie nog aanwezig is. Al deze maatregelen resulteren in de huidige situatie waarin de 
uitroeiing van het poliovirus zijn voltooiing nadert. 
Een ander doel van het ‘strategische eindplan’ richt zich op hoe de verschillende regio’s in 
de wereld polio-vrij kunnen blijven en hoe alle voorraden van het poliovirus en de poliovaccins 
vervolgens veilig bewaard moeten worden na uitroeiing van het poliovirus. 
Hoewel er al vele successen zijn geboekt, blijken sommige doelen van het eindplan tot op 
heden niet haalbaar binnen de gestelde termijnen. Hieraan liggen zowel externe (bv. groeiende 
conflictgebieden) als interne factoren (bv. beperkte beschikbaarheid van IPV, onvoldoende 
toezicht). Nu het poliovirus alleen nog maar voorkomt in een zeer beperkt aantal gebieden 
in de wereld, zal de uitroeiing van polio afhankelijk zijn van de inzet van vaccinatieteams die 
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ervoor moeten zorgen dat ieder kind in hoog-risico gebieden gevaccineerd wordt. Zelfs de 
kinderen die in extreem afgelegen en moeilijk bereikbare gebieden wonen, of op de vlucht 
zijn. 
Nieuwe generatie poliovaccins
Zoals hierboven beschreven is de uitroeiing van polio aanstaande. Juist nu is er grote 
behoefte aan nieuwe en verbeterde poliovaccins. Idealiter kan een nieuwe generatie 
poliovaccins de voordelen van de huidige vaccins (IPV en OPV) combineren; is het 
eenvoudig (naaldvrij) toe te dienen, biedt het lokale bescherming (in de darm), is het veilig 
om te produceren, lang houdbaar en betaalbaar voor lage inkomenslanden? Daarbij zou een 
poliovaccin dat buiten de koelkast of vriezer bewaard en vervoerd kan worden van grote 
waarde zijn. Door verschillende onderzoeksgroepen in de wereld wordt er gewerkt aan de 
Tabel 1 Overzicht van wereldwijd alle polio gevallen van de afgelopen jaren (2012-2018). Zowel 
meldingen van wildtype poliovirus als hercirculatie van poliovirus afkomstig van het vaccinvirus (OPV) 
zijn weergegeven.




Type 1 217 160 340 74 37 22 14
Type 2 0 0 0 0 0 0 0
Type 3 21 0 0 0 0 0 0
Niet-endemische 
landen
Type 1 6 256 19 0 0 0 0
Type 2 0 0 0 0 0 0 0




Type 1 0 0 0 0 0 0 0
Type 2 33 55 52 3 2 0 5
Type 3 0 0 0 0 0 0 0
Niet-endemische 
landen
Type 1 0 0 1 20 3 0 4
Type 2 35 10 3 9 0 96 14
Type 3 3 1 0 0 0 0 3





ontwikkeling van alternatieve manieren om poliovaccins toe te dienen. Naaldvrije vaccinatie 
strategieën hebben als groot voordeel dat er geen risico bestaat op hergebruik van naalden en 
prikincidenten. In hoofdstuk 2 wordt een overzicht gegeven van de verschillende alternatieve 
toedieningsroutes die momenteel voor polio in verschillende stadia van ontwikkeling zijn. 
Met name de toediening via de huid (dermaal) is voor poliovaccins uitgebreid onderzocht, 
omdat het idee is dat via dermale vaccinatie met een lagere dosis vergelijkbare bescherming 
verkregen wordt in vergelijking tot de conventionele toediening via naaldinjectie (in de spier). 
In dit hoofdstuk staat ook beschreven waar de moeilijkheden liggen om goede nieuwe 
vaccinformuleringen te ontwikkelingen die, idealiter, ook eenvoudig zijn toe te dienen.
Thermostabiele vaccins
De meeste vaccins, en poliovaccins zijn geen uitzondering, moeten gekoeld of soms zelfs 
ingevroren bewaard en vervoerd worden, omdat blootstelling aan hogere temperaturen de 
effectiviteit van het vaccin kan aantasten. Echter is in lage- en midden inkomens landen de 
beschikbaarheid van elektriciteit niet vanzelfsprekend, waardoor het niet eenvoudig is om 
de zogenoemde ‘cold-chain’ (koude keten), ofwel onafgebroken gekoelde condities tijdens 
opslag en vervoer van vaccins, in stand te houden. Het is niet zeldzaam dat partijen vaccins 
weggegooid moeten worden omdat ze niet onder de juiste condities bewaard zijn. Dit komt 
de beschikbaarheid van vaccins uiteraard niet ten goede. De vervanging van bestaande 
vaccins door verbeterde (thermostabiele) vaccinformuleringen die buiten de koeling bewaard 
kunnen worden zouden vaccin bevoorrading kunnen vereenvoudigen en de wereldwijde 
beschikbaarheid van vaccins sterk verbeteren.
Een veelgebruikte manier om de stabiliteit van vaccins te verbeteren is door het te 
drogen tot een vaste stof. In hoofdstuk 3 staat de ontwikkeling van een gevriesdroogde IPV 
formulering beschreven. Het is een uitdaging gebleken om IPV te vriesdrogen met behoud 
van effectiviteit van het vaccin. Na een uitgebreide screening van allerlei suikers, zouten en 
aminozuren werden uiteindelijk een aantal stoffen geselecteerd die in staat waren het IPV 
te stabiliseren tijdens het droogproces. Door vervolgens gebruik te maken van statistische 
modellen (een ‘Design of Experiment’ benadering) is een optimale formulering ontwikkeld 
waarbij het IPV gevriesdroogd kan worden met minimaal verlies tijdens het droogproces 
en verbeterde thermostabiliteit in vergelijking tot het huidige vloeibare IPV. Deze verbeterde 
vaccin formulering kan mogelijk buiten de ‘koude keten’ vervoerd worden en dus bijdragen 
aan de beschikbaarheid van IPV in moeilijk bereikbare gebieden. 
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In hoofdstuk 4 staat het vervolgonderzoek van het gevriesdroogde IPV beschreven. 
Hieruit blijkt dat er een duidelijk verschil bestaat tussen de effectiviteit van het gevriesdroogde 
type 3 vaccin (2 tot 3 keer minder immunogeen getest in een diermodel) en het vloeibare 
vaccin, waar voor type 1 en type 2 geen verschillen zijn waargenomen tussen het vloeibare 
en gevriesdroogde vaccin. Mogelijk is het type 3 poliovirusdeeltje tijdens het drogen toch 
iets aangetast. Dit effect is kennelijk alleen aantoonbaar in proefdieren en niet in de in vitro 
test. De oorzaak van dit verschil is momenteel niet bekend. Daarnaast is er gekeken naar de 
mogelijkheid om een hexavalent vaccin (6 vaccins in 1) te ontwikkelen door een al bestaand 
vloeibaar pentavalent vaccin tegen difterie, (a-cellulair) kinkhoest, tetanus, Heamophilius 
influenza type B en hepatitis B (DaKT-Hib-HepB, 5 vaccins in 1) samen te voegen met het 
gevriesdroogde IPV. De aanwezigheid van thiomersal, een antimicrobieel middel, in het 
bestaande pentavalent DaKT-Hib-HepB vaccin zorgt er echter voor dat het poliovaccin 
binnen een dag afneemt in werkzaamheid. Buiten de koelkast (bij kamertemperatuur (25°C) 
of lichaamstemperatuur (37°C)) is dit afbraakproces zelfs al na enkele uren zichtbaar. In 
hoofdstuk 4 is aangetoond dat het schadelijke effect van thiomersal op het poliovaccin 
grotendeels ongedaan gemaakt kan worden door cysteïne toe te voegen. Cysteïne is een 
natuurlijk voorkomend aminozuur en is door een specifieke functionele groep (thiol, SH-
groep) in het molecuul in staat om de thiomersal weg te vangen door hieraan te binden. Het 
is daardoor mogelijk om een 6-in-1 vaccin te verkrijgen door gevriesdroogd IPV op te lossen 
met een bestaand 5-in-1 combinatievaccin, een zogenoemd mix-and-shoot oplossing. 
Bionaalden
Zoals benoemd wordt het vloeibare IPV normaliter toegediend door middel van 
intramusculaire injectie (in de spier) met spuit en naald. Deze conventionele manier van 
toediening heeft enkele nadelen, zoals het risico op prikongelukken waardoor kans bestaat 
op besmettingen met bijvoorbeeld hepatitis B. Daarbij is het afvoeren van naaldafval een 
ingewikkeld en prijzig proces waarbij hergebruik van naalden niet uitgesloten wordt, met 
name in ontwikkelingslanden. De vraag naar alternatieven voor naalden wordt echter ook 
steeds groter in westerse landen door de angst en stress die kan ontstaan bij kinderen 
die gevaccineerd worden (en hun ouders). Dit is nadelig voor de acceptatie van vaccins. 
In hoofdstuk 5 staat de ontwikkeling van een alternatieve toediening voor IPV beschreven 
waarbij gebruik werd gemaakt van Bionaalden. Dit zijn holle mini-implantaten gemaakt van 
een biologisch afbreekbaar zetmeel, die gevuld kunnen worden met een vaccin waarna 




toegediend (idealiter onder hoge druk met een applicator), zal de Bionaald oplossen en het 
vaccin vrijkomen in het lichaam. De vriesdroogformulering die werd ontwikkeld in hoofdstuk 
2 is hier toegepast in het Bionaald-concept, een alternatieve toedieningsvorm waarbij geen 
spuiten met naalden nodig zijn. Daarnaast hebben Bionaalden als belangrijk voordeel dat 
ze mogelijk buiten de koude keten bewaard en vervoerd kunnen worden. Het IPV in de 
Bionaalden bleek beter bestand te zijn tegen hogere temperaturen dan het conventionele 
vloeibare IPV. Een studie in ratten liet zien dat na twee vaccinaties, de IPV-Bionaalden 
vergelijkbare bescherming opwekten in vergelijking tot het vloeibare vaccin. We hebben 
hierbij de potentie van Bionaalden als alternatieve poliovaccinatie methode laten zien waarbij 
met name de thermostabiliteit van IPV-Bionaalden van grote waarde kan zijn in lage- en 
middeninkomens landen.
Mucosale vaccinatie: via de neus en onder de tong
Door de grote oppervlaktes en immunologische eigenschappen zijn de slijmvliezen, ook 
wel mucosa genoemd, interessante routes voor vaccintoediening. Een van de belangrijkste 
eigenschappen is dat mucosale vaccinatie niet alleen bescherming geeft in het bloed, maar 
daarnaast ook lokale immuunreacties kan opwekken op slijmvliezen elders in het lichaam, 
daar waar ziekteverwekkers, zoals virussen en bacteriën, het lichaam binnen kunnen 
dringen. In hoofdstuk 6 staan de mogelijkheden van vaccinatie via slijmvliezen in de mond 
beschreven: buccale (binnenkant wang) en sublinguale (onder de tong) vaccinatie. De laatste 
jaren is er in toenemende mate onderzoek gedaan naar sublinguale toediening van vaccins. 
Hoofdstuk 6 geeft een overzicht van de resultaten die hierover gepubliceerd zijn en beschrijft 
wat de moeilijkheden zijn die moeten worden onderzocht voordat er succesvolle sublinguale 
vaccins op de markt zullen verschijnen. De toevoeging van een adjuvant, een stof die het 
immuunsysteem stimuleert, aan het vaccin lijkt voor vaccinatie onder de tong onvermijdelijk. 
Het immuunsysteem in de mondholte wordt namelijk voortdurend uitgedaagd om wel of 
niet te reageren op van alles wat er in de mond terecht komt. Er heeft zich daarom een 
tolerantie mechanisme ontwikkeld waardoor het immuunsysteem niet alles als indringer 
detecteert en dus niet overal meer op reageert. Bovendien zijn de slijmvliezen juist bedoeld 
om indringers niet tot het lichaam door te laten dringen. Bij vaccinatie willen we juist wel dat 
er een immuunreactie plaatsvindt en vandaar dat er manieren moeten worden gezocht om 
het tolerantiemechanisme te omzeilen en het vaccin op de juiste plek zijn werk te laten doen. 
Speciale toedieningsvormen en formuleringen, zoals orale films of gels die na toediening 
blijven plakken aan de orale mucosa, kunnen mogelijk bijdragen om het gewenste effect te 
bereiken na vaccinatie via de mondholte. 
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In hoofdstuk 7 is onderzocht of IPV-toediening via mucosale routes potentie heeft om 
als nieuwe generatie poliovaccins te dienen. Zowel poliovaccinatie via de neus (intranasaal) 
als onder de tong (sublinguaal) zijn onderzocht door muizen via deze routes te vaccineren 
met IPV en de opgewekte immuunreacties te meten in zowel het bloed als ook in mucosale 
afscheidingen. Zowel intranasale als sublinguale IPV vaccinatie bleken in staat om in het 
bloed poliovirus-neutraliserende antistoffen op te wekken. Daarnaast werden er ook 
mucosale antistoffen tegen polio gemeten in het speeksel, de ontlasting (feces) en de 
darmen, terwijl conventionele toediening via injectie in de spier dat niet doet. Uit deze studie 
blijkt ook dat voor sublinguale IPV vaccinatie de toevoeging van een adjuvant nodig is om het 
immuunsysteem voldoende te stimuleren. Zowel de intranasale als sublinguale route lijken 
waardevolle poliovaccinatie strategieën om te gebruiken in vaccinatieprogramma’s of om 
een onverwachte polio-uitbraak snel te kunnen stoppen in de periode waarin OPV niet meer 
gebruikt wordt. 
Zoals hierboven beschreven, kunnen nieuwe vaccinformuleringen mogelijk zorgen voor 
een optimale opname van het vaccin door de orale mucosa en de gewenste immuunreactie 
daaropvolgend. In hoofdstuk 8 staat de ontwikkeling van gedroogde orale films voor 
sublinguale of buccale poliovaccinatie beschreven. Net als in hoofdstuk 2 bleek het 
wederom een uitdaging om het IPV te drogen, nu in films, met behoud van de werkzaamheid 
van het vaccin. De combinatie van sorbitol, magnesium chloride en glutamaat, die tijdens 
vriesdrogen in staat was het vaccin te stabiliseren, was ook nu succesvol bij de ontwikkeling 
van een filmformulering. Een andere uitdaging was om de gewenste eigenschappen van de 
film te behouden tijdens het drogen; een film die makkelijk toe te dienen is moet bijvoorbeeld 
flexibel zijn, makkelijk vast te houden zijn en niet te plakkerig (mogen niet blijven plakken aan 
je hand, wel aan de mucosa). De studie die in hoofdstuk 8 beschreven staat laat zien dat 
het mogelijk is om een filmformulering te ontwikkeling met behoud van de antigene structuur 
(de structuur die door antistoffen wordt herkend) van het poliovaccin. Hoewel optimalisatie 
nodig is tijdens verdere productontwikkeling, waarbij met name gekeken moet worden naar 
de gewenste eigenschappen van de filmformulering, lijken orale films potentie te hebben 





Het gefaseerd terugdringen van OPV en includeren van IPV in alle routine 
vaccinatieprogramma’s over de gehele wereld, creëert een markt voor poliovaccins die worden 
toegediend via alternatieve routes. Een nieuwe generatie IPV moet niet alleen betaalbaar 
en veilig zijn, maar idealiter ook lokale mucosale immuunreacties opwekken, stabiel blijven 
buiten de koude keten, en makkelijk toe te dienen zijn. Dit is ook belangrijk met het oog op de 
periode waarin poliovaccins langere tijd opgeslagen moeten worden om plotseling massaal 
ingezet te worden bij een uitbraak (eventueel na mogelijke bioterroristische aanslag) nadat 
polio de wereld uit is. 
Dit proefschrift beschrijft de ontwikkeling van verschillende verbeterde formuleringen en 
alternatieve toedieningsstrategieën voor poliovaccinatie. Gedroogde vaccinformuleringen zijn 
beter bestand tegen hogere temperaturen en kunnen mogelijk buiten de koelkast bewaard en 
vervoerd worden. Bionaalden met daarin gevriesdroogd IPV of gedroogde filmformuleringen 
zouden gebruikt kunnen worden om afgelegen gebieden in ontwikkelingslanden te bereiken 
waar dat met de reguliere logistiek onmogelijk is. Het vervangen van de huidige poliovaccins 
door thermostabiele IPV formuleringen zouden enorme kostenbesparingen opleveren, zelfs 
wanneer de initiële vaccinprijs tot drie keer hoger is dan de huidige vaccins. 
Toekomstige (klinische) studies waarbij innovatieve toedieningsvormen voor 
poliovaccinatie verder onderzocht moeten worden zullen ons leren wat de haalbaarheid is 
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